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Understanding  the  mechanisms  that  control  T  cell  function  and  differentiation  is  
crucial  to  develop  new  strategies  to  modulate  immune  function  and  prevent  
autoimmune  and  inflammatory  disease.    The  balance  between  effector  (Teff;  Th1,  Th2  
and  Th17)  and  regulatory  (Treg)  T  cells  is  critical  to  provide  an  appropriate,  but  not  
excessive,  immune  response  and  therapies  to  induce  Treg  or  inhibit  Teff  are  likely  
promising  treatment  strategies.    It  has  recently  become  clear  that  T  cell  metabolism  is  
important  in  both  T  cell  activation  and  differentiation.    T  cells  undergo  a  metabolic  
reprogramming  upon  activation  and  not  all  differentiated  T  cell  subsets  utilize  the  same  
metabolic  fuels  or  programs.      
These  metabolic  differences  are  not  trivial,  as  T  cell  metabolism  is  tightly  
regulated  and  dysregulation  can  lead  to  cell  death  or  reduced  immunity.    An  
understanding  of  the  metabolic  differences  between  Teff  and  Treg  may  lead  to  a  new  
direction  for  treating  inflammatory  diseases  by  modulating  the  Teff:Treg  balance  
through  metabolic  inhibition.    Previous  studies  have  shown  that  Teff  express  higher  
levels  of  the  glucose  transporter  Glut1  than  Treg,  however  the  role  of  Glut1,  and  
importantly,  the  cell-­‐‑intrinsic  role  of  glucose  metabolism  in  T  cell  differentiation  and  
inflammation  was  not  previously  examined.    The  work  presented  here  examines  the  role  
of  Glut1  in  T  cell  differentiation.    We  show  that  effector  CD4  T  cells  were  dependent  on  
    
v  
Glut1  for  proliferation  and  function  both  in  vitro  and  in  vivo.    In  contrast,  Treg  were  
Glut1-­‐‑independent  and  capable  of  suppressing  colitis  in  the  absence  of  Glut1  expression.        
Additionally,  previous  studies  have  shown  broad  metabolic  differences  between  
Teff  and  Treg,  however  the  specific  metabolic  profiles  of  Teff  and  Treg  are  poorly  
understood.    Here,  Teff  and  Treg  metabolism  is  examined  to  test  if  dependence  on  
distinct  metabolic  pathways  will  allow  selective  targeting  of  different  T  cell  populations.    
We  show  that  pyruvate  dehydrogenase  kinase  1  (PDHK1)  is  differentially  expressed  in  
the  T  cell  subsets  and  inhibition  of  PDHK1  selectively  suppresses  Th17  and  promotes  
Treg  differentiation  and  function.    Because  Teff  and  Treg  have  distinct  metabolic  
profiles,  we  hypothesized  that  the  Treg-­‐‑specific  transcription  factor  FoxP3  may  drive  the  
Treg  oxidative  metabolic  program.    We  therefore  examined  the  role  of  FoxP3  in  T  cell  
metabolism  and  determined  that  FoxP3  promotes  glucose  and  lipid  oxidation  and  
suppresses  glycolytic  metabolism.    Importantly,  we  show  that  promoting  glycolysis  with  
transgenic  expression  of  Glut1  inhibits  Treg  suppressive  capacity.    Together,  this  data  
suggests  that  FoxP3  drives  an  oxidative  metabolic  program  that  is  critical  to  Treg  
function.    Overall,  this  work  examines  the  metabolic  phenotypes  and  regulation  of  Teff  
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1. Introduction  
CD4  T  cells  are  a  major  component  of  the  adaptive  immune  system.    They  direct  
the  immune  response  and  provide  protection  against  foreign  pathogens.    Upon  
activation,  CD4  T  cells  can  differentiate  into  a  variety  of  effector  cells,  including  Th1,  Th2  
and  Th17.    These  effector  T  cells  coordinate  the  immune  system  depending  on  the  type  
of  response  needed  for  a  given  pathogen.    This  involves  diverse  functions  including  
activating  B  cells,  recruiting  neutrophils  and  eosinophils,  and  directing  macrophage  
differentiation  (reviewed  in  Zhu  et  al.,  2010).    CD4  T  cells  can  also  differentiate  into  
regulatory  T  cells,  which  are  important  in  immune  tolerance  and  protection  against  
autoimmunity.    Together,  effector  and  regulatory  T  cells  balance  each  other  to  ensure  an  
appropriate  but  not  excessive  immune  response.      
Critical  to  the  immune  response  is  the  ability  of  T  cells  to  rapidly  proliferate  
upon  T  cell  receptor  (TCR)  engagement  and  subsequent  T  cell  activation.    As  each  T  cell  
is  specific  for  any  given  antigen,  rapid  proliferation  is  necessary  to  mount  an  
appropriate  immune  response  (Moon  et  al.,  2007).    T  cell  activation  creates  a  significant  
metabolic  demand,  as  a  T  cell  needs  to  generate  sufficient  energy  and  biosynthetic  
precursors  to  clonally  expand.    Among  these  is  a  metabolic  reprogramming  from  an  
energy-­‐‑efficient  oxidative  metabolic  state  to  a  highly  glycolytic  metabolism  likely  to  
support  increased  protein  and  lipid  synthesis,  cell  growth  and  effector  functions  
(Frauwirth  et  al.,  2004;  Fox  et  al.,  2005).    
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It  is  now  becoming  apparent  that  T  cell  metabolism  can  have  an  enormous  
impact  on  T  cell  activation  and  differentiation  (reviewed  in  MacIver  et  al.,  2013).    Specific  
metabolic  pathways  support  particular  cellular  functions  and  therefore  naïve,  effector,  
regulatory  and  memory  T  cells  have  distinct  metabolic  requirements.    Importantly,  these  
metabolic  differences  may  provide  an  opportunity  to  modulate  the  balance  between  the  
CD4  subsets,  particularly  effector  and  regulatory  T  cells.    Therefore,  targeting  CD4  T  cell  
metabolism  may  provide  new  directions  to  modulate  the  immune  response  and  treat  
autoimmune  or  inflammatory  conditions.  
  
1.1 CD4 T cell development 
CD4  T  cells  are  a  type  of  lymphocytes  that  play  a  critical  role  in  the  adaptive  
immune  system.    CD4  T  cells  develop  in  the  thymus  and  are  pluripotent,  having  the  
ability  to  differentiate  into  distinct  subtypes  depending  on  the  cytokine  environment  
during  T  cell  activation.    Depending  on  the  type  of  immune  response  needed,  CD4  T  
cells  can  then  go  on  to  activate  B  cells,  cytotoxic  CD8  T  cells,  macrophages  or  other  cell  
types  and  direct  the  immune  response  appropriately.  
T  cell  development  is  initiated  when  lymphoid  progenitor  cells  arise  in  the  bone  
marrow  and  then  migrate  to  the  thymus,  an  organ  in  the  chest  cavity  located  near  the  
heart.    At  this  point,  the  precursor  T  cells  lack  expression  of  both  CD4  and  CD8  co-­‐‑
receptors  and  are  known  as  double-­‐‑negative  (DN)  T  cells.    During  the  four  DN  stages  of  
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T  cell  development,  each  identified  by  the  expression  of  specific  surface  activation  
markers  such  as  CD44  and  CD25,  αβ-­‐‑T  cells  rearrange  the  genes  encoding  the  T  cell  
receptor  (TCR),  eventually  ending  up  with  a  mature  αβ  antigen  receptor  (Godfrey  et  al.,  
1993).    The  transition  from  DN3  to  DN4,  in  particular,  involves  rapid  cell  proliferation  as  
the  selected  cells  expand  in  number  (Shortman  et  al.,  1990).    A  subset  of  thymocytes  also  
goes  on  to  become  natural  regulatory  T  cells  (nTreg,  described  below).    After  the  DN  
stage,  TCR-­‐‑expressing  thymocytes  begin  to  express  both  CD4  and  CD8  co-­‐‑receptors,  
becoming  double-­‐‑positive  (DP)  thymocytes.      
DP  thymocytes  continue  to  rearrange  the  TCR  and  those  that  can  interact  with  
the  major  histocompatibility  complex  (MHC)-­‐‑antigen  structures  expressed  by  thymic  
epithelial  cells  receive  signals  required  to  maintain  their  viability.    Those  thymocytes  
with  TCR  that  cannot  interact  with  the  MHC:peptide  complexes  eventually  die  of  
neglect  (Robey  et  al.,  1994).    This  process  is  known  as  positive  selection,  and  is  necessary  
to  generate  T  cells  that  will  be  able  to  recognize  MHC  antigen  presentation.    However,  
some  of  the  T  cells  that  survive  positive  selection  are  able  to  bind  to  self-­‐‑antigen-­‐‑MHC  
complexes;  these  cells  have  the  capacity  to  cause  autoimmune  disease  in  the  periphery.    
Therefore,  a  second  process  known  as  negative  selection  occurs.    The  thymocytes  that  
bind  strongly  to  self-­‐‑antigen-­‐‑MHC  complexes  receive  signals  that  promote  their  
apoptosis.    At  this  stage,  about  3%  of  all  DP  thymocytes  are  selected  to  become  single  
positive  (SP)  cells,  expressing  either  CD4  or  CD8  alone  (Germain,  2002).    At  this  point,  
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there  is  a  second  wave  of  thymocyte  proliferation  to  expand  the  SP  thymocyte  numbers  
(Shortman  et  al.,  1990).    SP  cells  then  exit  the  thymus  and  enter  the  periphery  as  mature  
naïve  T  cells,  waiting  for  the  proper  signals  to  activate  and  differentiate.      
  
1.2 CD4 T cell activation 
After  a  naïve  CD4  T  cell  enters  the  periphery,  it  may  encounter  an  MHC  class  II  
antigen  presenting  cell  (APC)  presenting  antigen  that  is  recognized  by  its  TCR.    If  this  
binding  occurs  along  with  a  secondary  co-­‐‑stimulatory  signal,  such  as  CD28  binding  to  
B7.1  or  B7.2  on  the  APC,  the  T  cell  will  then  undergo  rapid  expansion  and  activation  
(June  et  al.,  1987).    T  cell  activation  is  accompanied  by  changes  in  gene  expression,  
signaling  pathways,  proliferation,  cytoskeleton  rearrangements  and  metabolism.    A  
series  of  tyrosine  kinases,  adaptor  proteins  and  small  GTPases  direct  the  intracellular  
signaling  pathways  that  initiate  early  T  cell  activation  (Koretzky  et  al.,  2003).    Along  with  
other  changes,  calcium  release  from  the  endoplasmic  reticulum  activates  
calcium/calmodulin-­‐‑dependent  kinases  (CamK)  and  calcineurin,  which  in  turn  activates  
mitogen-­‐‑activating  kinases  (MAPK)  and  nuclear  factor  of  activated  transcription  factors  
(NFAT),  among  others  (reviewed  in  Smith-­‐‑Garvin  et  al.,  2009).    
Additionally,  an  important  aspect  of  T  cell  stimulation  is  the  co-­‐‑stimulation  of  
other  cell  surface  receptors.    Indeed,  activation  of  the  TCR  without  co-­‐‑stimulation  leads  
to  T  cell  anergy,  in  which  T  cells  are  functionally  inactivated  (Schwartz,  2003).    One  of  
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these  co-­‐‑stimulatory  receptors  is  the  molecule  CD28.    CD28  activates  the  phosphatidyl-­‐‑
inositol-­‐‑3-­‐‑kinase  (PI3K)/Akt  pathway,  thereby  promoting  cell  growth,  metabolic  changes  
and  cytokine  production  (Lenschow  et  al.,  1996).    Together,  these  and  additional  
signaling  pathways  lead  to  the  increased  cell  growth,  proliferation,  cytokine  production  
and  cytoskeletal  changes  that  are  characteristic  of  T  cell  activation.  
      
1.3 CD4 T cell differentiation 
Depending  on  the  cytokine  environment  at  the  time  of  T  cell  activation,  a  CD4  T  
cell  can  differentiate  into  a  number  of  fates,  including  but  not  limited  to  Th1,  Th2,  Th17  
and  Treg  (Fig  1.1).    Th1,  Th2  and  Th17  are  known  as  effector  T  cells  (Teff).    These  
subtypes  each  play  a  unique  role  in  the  immune  system,  coordinating  the  immune  
response  depending  the  immune  threat  at  hand.    Regulatory  T  cells  (Treg)  instead  
function  to  actively  suppress  Teff  proliferation  to  prevent  excessive  inflammation  or  
autoimmunity.    Therefore,  a  balance  between  each  of  these  subtypes  is  important  to  
provide  appropriate  immune  protection  without  autoimmunity  or  immune  suppression.                
  
1.3.1 Th1 cells 
Th1  cells  were  one  of  the  first  T  cell  subsets  to  be  described  and  they  function  to  
facilitate  the  immune  response  against  intracellular  pathogens  by  activating  
macrophages  and  other  phagocytes.    Th1  cells  were  initially  characterized  as  a  type  of  
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immune  cell  that  produce  the  cytokines  IL-­‐‑2  and  interferon  gamma  (IFNγ)  upon  
activation  (Mosmann  et  al.,  1986).    Several  years  later,  Hsieh  et  al.  reported  that  Th1  cells  
could  be  generated  in  vitro  by  culturing  naïve  T  cells  with  IL-­‐‑12  produced  by  Listeria-­‐‑
induced  macrophages  (Hsieh  et  al.,  1993).    It  was  later  found  that  IL-­‐‑12  functions  by  
activating  the  signal  transducer  and  activator  of  transcription  4  (Stat4)  signaling  
pathway,  which  leads  to  the  expression  of  the  Th1-­‐‑specific  transcription  factor  T-­‐‑box  
transcription  factor  TBX21  (T-­‐‑bet)  (Szabo  et  al.,  2000).      
T-­‐‑bet  expression  plays  a  central  role  in  the  differentiation  of  Th1  cells,  activating  
the  expression  of  IFNγ  and  actively  repressing  the  Th2  differentiation  pathway  (Hwang  
et  al.,  2005).    Confirming  the  importance  of  this  signaling  pathway  to  Th1  differentiation,  
mice  lacking  either  IL-­‐‑12,  Stat4  or  T-­‐‑bet  cannot  mount  a  Th1-­‐‑driven  immune  response  
(reviewed  in  Gately  et  al.,  1998).    Additionally,  T-­‐‑bet  knockout  mice  spontaneously  
develop  an  asthma  disorder,  likely  because  of  an  abundance  of  Th2  in  the  absence  of  Th1  
cells  (Finotto  et  al.,  2002).    In  addition  to  T-­‐‑bet,  the  cytokine  IL-­‐‑2  was  found  to  be  critical  
to  Th1  differentiation  and  the  induction  of  IFNγ  (Liao  et  al.,  2011).    Th1  cells  are  also  
involved  in  autoimmune  disease  and  have  been  implicated  in  the  pathogenesis  of  
inflammatory  bowel  disease  (IBD),  arthritis  and  type  1  diabetes,  among  others  
(Lazarevic  et  al.,  2011).      
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1.3.2 Th2 cells 
Along  with  the  discovery  of  Th1  cells,  Mosmann  and  Coffman  also  described  a  
second  population  of  T  cells,  Th2  cells.    Whereas  Th1  cells  produce  the  cytokines  IL-­‐‑2  
and  IFNγ,  Th2  were  found  to  produce  IL-­‐‑4,  IL-­‐‑5  and  IL-­‐‑13  (Mosmann  et  al.,  1989).    Th2  
cells  were  also  found  to  play  a  distinct  role  from  Th1  in  the  immune  response,  being  
responsible  for  antibody  responses  and  immunity  to  extracellular  pathogens.    The  
cytokines  IL-­‐‑4  and  IL-­‐‑5,  in  particular,  activate  and  recruit  B  cells  and  eosinophils  to  drive  
the  extracellular  immune  response.    Naïve  T  cells  differentiate  into  Th2  cells  in  the  
presence  of  TCR  stimulation  and  the  cytokine  IL-­‐‑4  (Le  Gros  et  al.,  1990).    IL-­‐‑4  functions  
to  activate  the  Stat6  signaling  pathway  and  subsequently  the  transcription  factor  GATA-­‐‑
binding  protein  3  (GATA-­‐‑3)  (Zheng  et  al.,  1997).      
GATA-­‐‑3  was  originally  described  as  a  transcription  factor  involved  with  T  cell  
development  and  is  required  for  the  transition  from  DP  to  SP  thymocytes  (Pai  et  al.,  
2003).    However,  GATA-­‐‑3  was  later  found  to  be  involved  specifically  with  Th2  
differentiation,  both  by  activating  the  expression  of  IL-­‐‑4  and  suppressing  the  expression  
of  the  Th1  cytokine  IFNγ.    Indeed,  T  cell  specific  GATA-­‐‑3  knockout  mice  show  a  
decreased  ability  to  generate  Th2  cells,  instead  producing  IFNγ  even  in  the  presence  of  
IL-­‐‑4  (Zhu  et  al.,  2004).    In  addition  to  their  role  in  the  immune  system,  Th2  are  also  
involved  with  the  induction  of  allergy  and  asthma  responses  mediated  through  their  
activation  of  B  cells,  mast  cells  and  basophils  (reviewed  in  Hammad  et  al.,  2006).      
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1.3.3 Th17 cells 
After  the  discovery  of  Th1  and  Th2  cells,  immunologists  spent  the  next  thirty  
years  with  the  notion  that  no  other  effector  T  cell  subset  existed.    However,  as  a  better  
understanding  of  immune  pathology  emerged,  it  was  clear  that  the  Th1/Th2  hypothesis  
needed  to  be  revised.    One  of  the  first  signs  that  another  T  cell  subset  existed  was  data  
generated  in  the  mouse  model  experimental  autoimmune  encephalomyelitis  (EAE).      
EAE  is  a  mouse  model  of  neuroinflammation  and  multiple  sclerosis.    EAE  was  proposed  
to  be  mediated  by  Th1  cells,  and  would  therefore  be  predicted  to  worsen  with  increased  
IFNγ  expression.    However,  treatment  of  mice  with  IFNγ  protected  from  EAE,  and  
instead  IFNγ  knockout  mice  had  more  severe  EAE  than  wild  type  mice  (Voorthuis  et  al.,  
1990).      
Data  soon  emerged  that  both  IL-­‐‑6  and  IL-­‐‑17  knockout  mice  showed  resistance  to  
EAE  (Samoilova  et  al.,  1998;  Komiyama  et  al.,  2006).    This  led  to  the  discovery  of  Th17  
cells  as  a  new  class  of  effector  T  cells.    Th17  were  later  shown  to  be  induced  by  TCR  
stimulation  in  the  presence  of  both  IL-­‐‑6  and  transforming  growth  factor  beta  (TGFβ)  
(Veldhoen  et  al.,  2006;  Bettelli  et  al.,  2006;  Mangan  et  al.,  2006).    Th17  cells  produce  the  
cytokine  IL-­‐‑17  as  well  as  IL-­‐‑22  and  IL-­‐‑23.    IL-­‐‑17  can  induce  the  expression  of  other  
inflammatory  cytokines  as  well  as  activate  neutrophils.    Similarly  to  Th2,  Th17  cells  are  
involved  in  the  immune  response  against  fungi  and  extracellular  bacteria,  but  
importantly  are  specifically  involved  in  mucosal  immunity.    Interestingly,  Th17  may  be  
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important  in  the  regulation  of  the  resident  gut  microbiota  and  distinguish  between  
“good”  and  “bad”  bacteria  (Weaver  and  Hatton,  2009).    Th17  cells  also  contribute  to  
many  different  autoimmune  diseases,  including  those  that  were  once  thought  caused  
exclusively  by  Th1  cells  including  IBD,  EAE  and  psoriasis  (Zheng  et  al.,  2007;  reviewed  
in  Steinman  2007).  
RAR-­‐‑related  orphan  receptor  gamma  (RORγt)  was  determined  to  be  the  master  
regulator  of  Th17  cells  when  RORγt  knockout  mice  were  shown  to  have  decreased  IL-­‐‑17  
production  and  importantly  were  resistant  to  the  induction  of  EAE  (Ivanov  et  al.,  2006).      
The  Stat3  signaling  pathway  was  also  found  to  be  critical  in  Th17  cells,  as  deletion  of  
Stat3  led  to  the  loss  of  IL-­‐‑17  and  IL-­‐‑23  producing  cells  (Harris  et  al.,  2007).    When  both  
TGFβ  and  IL-­‐‑6  are  present,  Stat3  activation  leads  to  Th17  differentiation  and  RORγt  
expression.      
  
1.3.4 Regulatory T cells 
Regulatory  T  cells  (Treg)  play  an  important  role  in  maintaining  immune  
tolerance.    They  have  the  ability  to  suppress  the  activation  or  proliferation  of  other  T  
cells,  thereby  preventing  an  excessive  immune  response  or  autoimmunity.    Treg  that  
develop  naturally  in  the  thymus  together  with  normal  T  cell  development  are  called  
natural  Treg  (nTreg)  (Hsieh  et  al.,  2004).    However,  naïve  peripheral  T  cells  can  also  
differentiate  into  “inducible”  Treg  (iTreg).    Both  nTreg  and  iTreg  are  characterized  by  
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the  expression  of  the  surface  marker  CD25,  the  alpha  chain  of  the  IL-­‐‑2  receptor,  as  well  
as  the  transcription  factor  Forkhead  Box  3  (FoxP3)  (Fontenot  et  al.,  2003;  Hori  et  al.,  2003).    
Although  activated  T  cells  express  a  transient  level  of  CD25,  Treg  have  a  higher  
expression  level  and  it  is  expressed  constitutively.    The  importance  of  Treg  becomes  
clear  in  mice  with  a  loss-­‐‑of-­‐‑function  mutation  in  FoxP3;  the  mice  develop  a  fatal  
autoimmune  disease  and  die  within  a  month  (Brunkow  et  al.,  2001).    Similarly,  humans  
with  mutations  in  the  FoxP3  gene  have  a  disorder  called  immunodysregulation  
polyendocrinopathy  enteropathy  X-­‐‑linked  syndrome  (IPEX)  and  many  do  not  live  past  
the  age  of  two  due  to  extensive  multi-­‐‑organ  autoimmune  disease  and  eventual  organ  
failure  (Bennett,  et  al.  2001).      
Treg  exert  their  suppressive  function  by  both  cell-­‐‑to-­‐‑cell  contact  and  cytokine-­‐‑
mediated  methods.    Treg  were  shown  to  inhibit  the  TCR-­‐‑induced  proliferation  and  IL-­‐‑2  
expression  of  Teff  during  cell-­‐‑to-­‐‑cell  contact  (Thornton  et  al.,  1998).    Treg  also  express  the  
inhibitory  surface  marker  Cytotoxic  T-­‐‑Lymphocyte  Antigen  4  (CTLA-­‐‑4)  that  may  
contribute  to  Teff  suppression  (Takahashi  et  al.,  2000).    Treg  secrete  several  cytokines  
including  TGFβ  and  IL-­‐‑10.    TGFβ  is  also  critical  in  the  differentiation  of  naïve  T  cells  into  
iTreg  (Chen  et  al.,  2003).    IL-­‐‑10  production  has  been  shown  to  be  essential  in  the  control  
of  colitis,  as  IL-­‐‑10  deficient  Treg  were  unable  to  prevent  colitis  in  a  mouse  model  
(Asseman  et  al.,  1999).      
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Recent  literature  has  suggested  that  Treg  may  also  suppress  effector  T  cells  by  
metabolic  interference.    Adenosine  is  a  critical  component  of  both  adenosine  
triphosophate  (ATP)  and  the  signaling  molecule  cyclic  adenosine  monophosphate  
(cAMP).    FoxP3  drives  the  expression  of  CD39,  an  enzyme  that  degrades  ATP  to  AMP  
and  suppresses  Teff  through  activation  of  the  adenosine  receptor  2A  (Deaglio  et  al.,  
2007).    A  second  group  showed  that  Treg  could  transfer  cAMP  into  Teff  through  gap  
junctions  as  an  additional  suppressive  mechanism  (Bopp  et  al.,  2007).    Additionally,  Treg  
expression  of  CTLA-­‐‑4  triggers  a  signaling  response  in  dendritic  cells  upon  binding  to  
CD80  that  inhibits  glutathione  (GSH)  synthesis.    This  decrease  in  GSH  limits  cysteine  
availability  and  inhibits  Teff  activation  and  proliferation  (Yan  et  al.,  2010).    Treg  also  
directly  compete  with  Teff  for  cysteine  uptake  in  vitro  (Yan  et  al.,  2010).        
Treg  also  have  distinct  intracellular  signaling  events  from  Teff.    In  particular,  
while  all  T  cells  respond  to  the  cytokine  IL-­‐‑2,  it  has  a  unique  signaling  pathway  in  Treg.    
In  effector  T  cells,  IL-­‐‑2  binds  to  the  high-­‐‑affinity  IL-­‐‑2  receptor  and  activates  the  
JAK/STAT,  MAPK  and  PI3K/Akt/mammalian  target  of  rapamycin  (mTor)  pathways  
during  T  cell  activation.    However,  the  PI3K/Akt/mTOR  pathway  is  not  activated  in  Treg  
(Bensinger  et  al.,  2004;  Zeiser  et  al.,  2008).    This  is  in  part  due  to  negative  regulation  of  the  
PI3K  pathway  through  phosphatase  and  tensin  homolog  deleted  on  chromosome  10  
(PTEN).    While  PTEN  is  downregulated  upon  Teff  activation,  PTEN  expression  remains  
high  in  Treg.    The  suppression  of  PI3K/Akt/mTOR  signaling  is  also  important  clinically,  
  12  
as  the  mTOR  inhibitor  rapamycin  was  found  to  expand  Treg  in  vitro  and  is  used  to  
prevent  graft-­‐‑vs-­‐‑host  disease  (GvHD)  in  human  patients  (Battaglia  et  al.,  2006;  Blazar  et  
al.,  1997).        
  
1.4 Memory T cells 
Following  pathogen  clearance,  the  majority  of  T  cells  undergo  apoptosis  while  a  
small  percentage  remain  as  memory  T  cells.    These  persisting  antigen-­‐‑specific  T  cells  are  
maintained  indefinitely  and  have  the  ability  to  rapidly  respond  to  subsequent  pathogen  
challenge  (Badovinac  et  al.,  2002).    The  memory  T  cell  pool  remains  relatively  constant  in  
size  and  is  maintained  by  IL-­‐‑7-­‐‑  and  IL-­‐‑15-­‐‑driven  homeostatic  proliferation  (Surh  et  al.,  
2006).    There  are  both  CD4  and  CD8  memory  T  cells,  although  memory  CD8  T  cells  have  
been  studied  more  extensively.    Memory  CD8  T  cells  are  typically  divided  into  two  
categories  based  on  the  expression  of  specific  homing  receptors  and  surface  markers.    
Central  memory  T  cells  are  defined  as  CD62L+CCR7+  and  they  localize  to  lymphoid  
tissues  while  effector  memory  T  cells  are  CD62L-­‐‑CCR7-­‐‑  and  persist  in  peripheral  tissues  
(Woodland  and  Kohlmeier,  2009).    Upon  rechallenge,  both  types  of  memory  T  cells  
produce  inflammatory  cytokines  including  IFNγ  and  TNF  while  effector  memory  T  cells  
also  produce  high  levels  of  perforin  and  granzyme  B  to  kill  infected  cells.    Memory  CD4  
cells  have  been  examined  in  the  context  of  influenza  A  infection  and  found  to  promote  
the  B  cell  and  cytotoxic  CD8  T  cell  responses  in  addition  to  having  direct  cytotoxic  
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effects    (McKinstry  et  al.,  2012).    Overall,  memory  T  cells  are  an  important  part  of  the  




Figure  1.1:  CD4  T  cell  subsets  
Naïve  T  cells  are  pluripotent  and  have  the  ability  to  differentiate  into  Teff  (Th1,  Th2  and  
Th17)  or  Treg  depending  on   the  cytokine  environment  at   the   time  of  TCR  stimulation.    
Each   T   cell   subset   has   a   unique   transcription   factor   (Th1,   T-­‐‑bet;   Th2,   GATA-­‐‑3;   Th17,  






















1.5 Glucose Metabolism 
Many  different  types  of  organisms  use  glucose  as  a  main  source  of  fuel.    Glucose  
is  particularly  important  in  the  mammalian  brain,  where  it  is  used  as  the  primary  energy  
source  during  normal  conditions.    For  this  reason,  if  blood  glucose  levels  drop  too  low,  it  
is  a  dangerous  and  potentially  fatal  condition  if  not  immediately  corrected  (Cryer  et  al.,  
2007).    At  the  same  time,  excessive  glucose  levels  such  as  those  that  occur  in  the  context  
of  diabetes  can  result  in  peripheral  vascular  disease,  renal  failure  and  blindness  
(reviewed  in  Kaiser  et  al.,  2003).    The  liver  plays  a  critical  role  in  whole  body  glucose  
homeostasis  and  is  one  of  the  main  glycogen  stores  (McGarry  et  al.,  1987).    The  
regulation  of  plasma  glucose  levels  is  in  part  driven  by  changes  to  the  levels  of  the  
hormones  insulin  and  glucagon,  which  influence  glucose  metabolism  in  the  liver  and  
skeletal  muscle.    The  tight  regulation  of  glucose  homeostasis  is  critical  to  maintain  
glucose  levels  at  the  appropriate  level  for  normal  bodily  functions.      
While  glucose  is  important  to  an  organism  as  a  whole,  glucose  metabolism  on  a  
cellular  level  may  be  equally  as  important.    T  cells,  in  particular,  require  large  amounts  
of  glucose  upon  activation  to  provide  energy  for  rapid  growth  and  proliferation  (Fox  et  
al.,  2005).    Glucose  needs  to  first  be  imported  into  the  cell  where  it  can  then  be  used  to  
generate  ATP  energy  or  for  other  purposes  such  as  protein  glycosylation,  conversion  
into  lipids  for  building  membranes,  or  for  nucleotide  biosynthesis.    Cellular  control  of  
glucose  metabolism  occurs  at  both  the  level  of  glucose  import,  as  well  as  the  regulation  
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of  glycolytic  enzymes  through  signaling  pathways  that  direct  glucose  towards  different  
fates.        
  
1.5.1 Glucose Transport: Glut1 
For  glucose  to  be  metabolized  intercellularly,  it  first  needs  to  be  taken  up  into  the  
cell  (Fig  1.2,  1).    As  the  lipid  membrane  is  not  permeable  to  glucose,  it  is  transported  
across  the  membrane  by  carrier  proteins  called  glucose  transporters.    There  are  both  
sodium-­‐‑coupled  and  sodium-­‐‑independent  glucose  transport  mechanisms  to  bring  
glucose  into  the  cell.    The  sodium-­‐‑coupled  transporters  comprise  a  family  of  sodium  
dependent  glucose  transporters  (SGLT)  and  are  primarily  located  in  the  intestines  and  
renal  system  (Wright  et  al.,  2001).      The  SGLTs  co-­‐‑transport  sodium  and  glucose,  and  
contribute  to  the  reabsorption  of  glucose  in  the  renal  system.    The  sodium-­‐‑independent  
carriers  are  members  of  the  facilitative  glucose  transporter  (Glut)  family.    There  are  
fourteen  Glut  transporters,  which  are  expressed  in  a  tissue-­‐‑specific  manner.    All  of  the  
Gluts  are  membrane  proteins  and  share  a  series  of  12  transmembrane  helices  that  are  
typically  heavily  glycosylated  (Mueckler  et  al.,  1985).    With  the  exception  of  Glut5,  which  
transports  fructose,  the  Glut  transporters  regulate  glucose  uptake  and  all  have  different  
binding  affinities  and  Km  values  that  allows  for  specific  glucose  regulation  needs  
depending  on  the  cell  type  or  organ  system  (Douard  et  al.,  2008).      
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Glut1  (gene  name:  SLC2A1)  is  the  most  abundantly  expressed  Glut  transporter  
isoform  and  plays  an  important  role  in  many  tissues,  particularly  the  brain  where  it  
transports  glucose  across  the  blood-­‐‑brain  barrier  (Brockmann  et  al.,  2009).    Glut1  is  also  
expressed  in  activated  lymphocytes,  increasing  drastically  in  expression  level  upon  
stimulation  (Chakrabarti  et  al.,  1994).    In  T  cells,  it  is  highly  regulated;  cytokine  
stimulation  promotes  glucose  uptake  through  Glut1  trafficking.    In  a  related  cytokine-­‐‑
dependent  hematopoietic  cell  line,  cytokine  withdrawal  led  to  Glut1  internalization  and  
upon  cytokine  readdition,  Glut1  was  returned  to  the  surface  (Wieman  et  al.,  2007).    This  
regulation  occurs  through  the  PI3K  pathway,  which  promotes  Glut1  trafficking  to  the  
cell  surface  (Wieman  et  al.,  2007;  Bentley  et  al.,  2003).    Inhibition  of  PI3K  activity  reduced  
surface  Glut1  levels,  while  constitutive  expression  of  active  Akt  was  sufficient  to  
maintain  surface  Glut1  levels  even  in  the  context  of  cytokine  withdrawal.      
  
1.5.2 Aerobic Glycolysis 
After  glucose  gets  transported  into  the  cell,  it  has  three  major  metabolic  fates.    
Glucose  can  be  fully  oxidized  to  carbon  dioxide  and  water,  yielding  ATP  energy  for  the  
cell  (Fig  1.2,  4).    Glucose  can  also  be  shunted  to  the  pentose  phosphate  pathway  (PPP).    
The  PPP  generates  both  nicotinamide  adenine  dinucleotide  phosphate  (NADPH)  and  
ribose-­‐‑5-­‐‑phosphate,  contributing  to  lipid  synthesis  and  nucleotide  synthesis,  
respectively  (Hothersall  et  al.,  1979).    Additionally,  glucose  can  be  reductively  
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metabolized  to  alcohols  or  organic  acids  including  ethanol  and  lactate  through  the  
process  of  fermentation  (Fig  1.2,  3).    Unlike  glucose  oxidation,  fermentation  does  not  
require  oxygen  but  it  is  much  less  efficient  at  ATP  energy  generation.    Indeed,  many  
anaerobic  organisms  obtain  energy  through  this  pathway  when  oxygen  is  lacking  
(Rolland  et  al.,  2002).      
However,  in  1924  Otto  Warburg  found  that  mammalian  cancer  cells  produce  
high  levels  of  lactate  from  glucose  even  in  the  presence  of  oxygen  (Warburg  et  al.,  1956).    
This  has  been  termed  aerobic  glycolysis,  as  glucose  is  converted  to  lactate  even  in  the  
presence  of  sufficient  oxygen  levels  for  glucose  oxidation  through  the  carboxylic  acid  
(TCA)  cycle  and  oxidative  phosphorylation  (OXPHOS).    Shortly  thereafter,  other  groups  
found  that  other  non-­‐‑transformed  cells  also  utilize  aerobic  glycolysis,  particularly  those  
that  are  highly  proliferative  (Wang  et  al.,  1976).    This  includes  proliferating  fibroblasts  
and  both  human  and  mouse  lymphocytes.          
Once  glucose  enters  the  cell,  it  is  immediately  converted  into  glucose-­‐‑6-­‐‑
phosphate  (G6P)  by  the  enzyme  hexokinase  (Hk).  The  phosphorylation  of  glucose  to  
G6P  effectively  traps  glucose  in  the  cytoplasm  of  the  cell,  as  G6P  cannot  be  transported  
back  out  of  the  cell  (Berg  et  al.,  2007).    There  are  several  isoforms  of  hexokinase  (Hk1-­‐‑4)  
with  varying  tissue  specificity  and  affinities  for  glucose.    Hk1-­‐‑3  are  100kD  and  thought  
to  be  due  to  a  gene  duplication  of  a  50kD  ancesteral  Hk  (Bork  et  al.,  1993).    Hk4  is  a  50kD  
protein,  which  is  also  referred  to  as  glucokinase.    Hk1  is  ubiquitously  expressed,  while  
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Hk2  is  found  primarily  in  skeletal  muscle  and  adipose  tissue,  both  insulin  sensitive  
tissues  (reviewed  in  Wilson  et  al.,  2003;  Postic  et  al.,  1994).    Wilson  et  al.  propose  that  the  
specific  response  of  Hk2  to  G6P  and  inorganic  phosphate  (Pi)  suggest  that  it  plays  a  
more  anabolic  role  by  providing  G6P  to  PPP  (Wilson  et  al.,  1995).    Data  suggest  that  Hk1  
and  2  are  associated  with  the  mitochondria,  both  having  a  hydrophobic  N-­‐‑terminal  
mitochondrial  signaling  sequence  (Sui  and  Wilson,  1997).    In  contrast,  Hk3  does  not  
contain  this  signaling  sequence.    After  24  hours  of  activation,  T  cells  express  Hk1,  2  and  
3  with  Hk2  being  the  predominant  isoform  (Wang  et  al.,  2011).      
After  glucose  is  converted  to  G6P  by  Hk,  another  enzyme  called  
phosphofructokinase  (PFK1)  commits  it  to  the  glycolytic  pathway.    PFK1  is  regulated  
allosterically  through  ATP  and  citrate  inhibition.    Glucose  is  then  further  metabolized  by  
other  glycolytic  enzymes  to  the  final  product  of  pyruvate.    Overall,  glycolysis  generates  
2  ATP  molecules  per  molecule  of  glucose  as  well  as  reducing  agents  in  the  form  of  
nicotinamide  adenine  dinucleotide  (NADH)  (Berg  et  al.,  2007).    Pyruvate  can  then  either  
be  transported  across  the  mitochondrial  membrane  and  converted  to  acetyl  CoA  or  
converted  to  lactate  in  the  cytoplasm.      
The  conversion  of  pyruvate  to  lactate  is  performed  by  an  enzyme  called  lactate  
dehydrogenase  (LDH)  and  this  consumes  NADH  and  recycles  NAD+.    This  recycling  is  
important,  as  cytosolic  NAD+  is  limiting  and  it  is  important  for  the  cell  to  maintain  a  
specific  NAD+/NADH  ratio  (reviewed  in  Lunt  et  al.  2011).    Although  aerobic  glycolysis  is  
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much  less  efficient  at  ATP  generation  than  glucose  oxidation,  it  may  be  that  the  
glycolytic  flux  in  rapidly  proliferating  cells  exceeds  the  capacity  of  pyruvate  
dehydrogenase  (PDH)  and  other  enzymes  in  the  glucose  oxidation  pathway  (Curi  et  al.,  
1988).    Therefore,  glucose  would  be  converted  to  lactate  and  allow  NAD+  regeneration.      
Another  function  of  aerobic  glycolysis  in  proliferating  cells  may  be  to  contribute  
to  the  generation  of  biosynthetic  precursors  to  support  cell  growth.    Cell  growth  and  
proliferation  requires  the  doubling  of  all  cellular  contents,  including  nucleotides,  
proteins  and  lipids;  all  of  which  can  be  generated  from  glucose  (Berg  et  al.,  2007).    
Indeed,  Newsholme  et  al.  has  suggested  that  lymphocytes  perform  glycolysis  at  a  high  
rate  to  allow  for  glycolytic  intermediates  to  be  shunted  off  towards  biosynthetic  
pathways  that  allow  for  rapid  cell  growth  and  division  (Newsholme  et  al.,  1985a).    
However,  the  reasons  why  highly  proliferative  cells  utilize  aerobic  glycolysis  rather  than  
OXPHOS  are  still  under  active  investigation.              
  
1.5.3 Pyruvate Dehydrogenase Kinase 
The  pyruvate  dehydrogenase  complex  (PDH)  converts  pyruvate  to  acetyl  CoA  in  
the  committal  step  of  glucose  oxidation.    PDH  is  comprised  of  three  subunits,  pyruvate  
dehydrogenase,  dihydrolipoyl  transacetylase  (DLAT)  and  dihydrolipoyl  dehydrogenase  
(DLD).    Pyruvate  dehydrogenase  uses  the  cofactor  thiamine  pyrophosphate  (TPP,  
vitamin  B1)  to  decarboxylate  pyruvate.    DLAT  and  DLD  subsequently  add  coenzyme  A  
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and  reduce  NAD+  to  NADH  (reviewed  in  Patel  and  Korotchkina,  2006).    Because  PDH  
sits  at  the  branch  point  between  the  conversion  of  pyruvate  to  lactate  or  oxidation  to  
carbon  dioxide,  it  is  highly  regulated.      
PDH  is  regulated  allosterically  by  its  end  products  acetyl  CoA,  NADH  and  ATP,  
all  of  which  lead  to  its  inhibition.    Additionally,  the  activity  of  PDH  can  be  acutely  
regulated  by  the  phosphorylation  and  dephosphorylation  of  three  specific  sites  on  the  
alpha  subunit:  Ser-­‐‑203,  Ser-­‐‑264  and  Ser-­‐‑271  (Korotchkina  et  al.,  2001).      Phosphorylation  
of  PDH  is  inhibitory  to  the  complex  while  the  active  form  is  dephosphorylated.    PDH  is  
specifically  phosphorylated  by  the  pyruvate  dehydrogenase  kinase  (PDHK)  family  of  
enzymes.    There  are  four  PDHK  isoforms  (PDHK1-­‐‑4)  that  have  varying  specificity  for  
the  three  PDH  phosphorylation  sites.    Only  PDHK1  is  able  to  efficiently  phosphorylate  
all  three  sites  (Korotchkina  et  al.,  2001).  Additionally,  there  are  two  specific  pyruvate  
dehydrogenase  phosphatases  (PDP1  and  PDP2)  that  dephosphorylate  the  same  three  
phosphorylation  sites  (Teague  et  al.,  1982).  
In  addition  to  phospho-­‐‑site  specificity,  the  four  PDHK  isoforms  also  differ  in  
tissue  distribution.    PDHK1  is  found  primarily  in  the  heart  with  lower  levels  in  the  liver  
and  spleen,  while  PDHK3  is  highly  expressed  in  the  testis  and  also  found  in  the  lung,  
brain  and  spleen.    PDHK4  is  expressed  in  the  skeletal  muscle  and  heart  while  PDHK2  is  
fairly  ubiquitously  expressed  (Bowker-­‐‑Kinley  et  al.,  1998).    PDHK1  itself  is  allosterically  
regulated;  inhibited  by  ADP  and  pyruvate  and  activated  by  NADH  and  acetyl  CoA  
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(Roche  et  al.,  2001).    Overall,  PDH  is  an  important  and  highly  regulated  step  linking  
glycolysis  to  both  oxidative  phosphorylation  and  fatty  acid  synthesis.  
Recently,  a  role  for  PDHK  has  been  described  in  the  cancer  field.    Many  cancer  
cells,  like  T  cells,  undergo  a  metabolic  transition  from  an  oxidative  metabolism  to  using  
glycolysis  as  a  primary  energy  source  (Gatenby  et  al.,  2004;  Vander  Heiden  et  al.,  2009).    
A  150  dalton  compound  called  dichloroacetate  (DCA)  was  found  to  inhibit  all  four  of  the  
PDHK  isoforms  in  a  dose-­‐‑dependent  manner  (Stacpoole,  1989).    DCA  has  been  shown  to  
promote  cancer  cell  apoptosis  in  vitro  and  decreased  tumor  growth  in  mouse  models  
(Bonnet  et  al.,  2007;  Sun  et  al.,  2010).    DCA  is  currently  in  clinical  trials  for  several  
different  types  of  cancer,  however,  at  this  time  there  is  limited  efficacy  data  and  this  
continues  to  be  an  active  area  of  investigation  (Sutendra  et  al.,  2013;  Garon  et  al.,  2014).    
In  humans,  DCA  appears  to  have  no  significant  toxicity  other  than  reversible  peripheral  
neuropathy  at  high  doses,  although  more  studies  are  needed  (Michelakis  et  al.,  2010;  
Dunbar  et  al.,  2013).  Additionally,  PDH  activity  has  been  linked  to  oncogene-­‐‑induced  
senescence  and  Kaplon  et  al.  showed  that  PDK1  depletion  is  toxic  to  melanoma  cells    
(Kaplon  et  al.,  2013).    These  data  suggest  that  targeting  PDHK  is  potentially  an  exciting  
metabolic  therapeutic  strategy  for  a  variety  of  diseases.            
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1.5.4 Glucose and Lipid Oxidation 
After  glucose  is  taken  up  into  the  cell,  it  can  be  ultimately  oxidized  to  carbon  
dioxide  and  water  or  converted  to  lactate.    Under  standard  oxygen  conditions,  glucose  is  
typically  converted  to  pyruvate,  which  is  transported  into  the  mitochondria  for  further  
breakdown  in  the  TCA  cycle  (Fig  1.2,  5).    Pyruvate  is  first  converted  to  acetyl  CoA  by  
PDH,  as  described  above.    Acetyl  CoA  enters  the  TCA  cycle  and  combines  with  the  four-­‐‑
carbon  oxaloacetate  (OAA)  into  the  organic  acid  citrate.    The  TCA  cycle  consists  of  nine  
reactions,  which  ultimately  remove  two  carbons  in  the  form  of  CO2  and  recycle  OAA.    
The  catabolism  of  acetyl  CoA  yields  both  carbon  dioxide  and  electrons,  which  are  
donated  to  the  electron  carriers  NAD+  and  flavin  adenine  dinucleotide  (FAD+)  to  make  
NADH  and  FADH2,  respectively.    Additionally,  a  guanine  triphosphate  (GTP)  is  
generated  by  substrate  level  phosphorylation.    Overall,  six  CO2  molecules,  8  NADH  and  
2  FADH2  are  generated  per  glucose  in  the  TCA  cycle  (Lodish  et  al.,  2000).  
ATP  generation  is  coupled  to  the  re-­‐‑oxidation  of  NADH  and  FADH2,  which  
donate  electrons  to  the  electron  transporter  chain  (ETC).    This  process  requires  oxygen  
as  the  final  electron  acceptor.    The  movement  of  electrons  is  coupled  with  the  transfer  of  
protons  from  the  inner  mitochondrial  membrane  to  the  intermembrane  space,  setting  up  
an  electrochemical  gradient.    This  gradient  is  then  utilized  by  F0F1  ATP  synthase  to  
generate  ATP  (Mitchell  et  al.,  1961).    Protons  pass  through  the  F0  subunit,  following  their  
concentration  gradient  and  the  energy  released  is  used  to  convert  ADP  and  inorganic  
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phosphate  to  ATP  in  the  F1  subunit.    Therefore,  glucose  is  fully  oxidized  in  the  TCA  
cycle  to  CO2  and  the  remaining  electrons  are  put  onto  electron  carriers  and  are  donated  
to  the  electron  transport  chain  to  ultimately  generate  ATP  energy  for  the  cell.  
Similarly  to  glucose  oxidation,  lipid  oxidation  also  involves  the  generation  of  
NADH  and  FADH2  electron  carriers  as  well  as  acetyl  CoA  molecules  that  enter  the  TCA  
cycle  (Fig  1.2,  6).    Long-­‐‑chain  fatty  acids  enter  the  mitochondria  through  a  carrier  
system,  the  carnitine  shuttle,  while  short-­‐‑chain  fatty  acids  can  enter  the  mitochondria  
through  diffusion.    Even-­‐‑numbered  fatty  acids  are  fully  oxidized  to  acetyl  CoA  through  
a  series  of  dehydrogenation  and  oxidization  steps.    Odd-­‐‑numbered  fatty  acids  yield  
acetyl  CoA  molecules  plus  propionyl  CoA,  which  is  ultimately  converted  to  succinyl  
CoA  (Lodish  et  al.,  2000)  and  enters  the  TCA  cycle.                
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Figure  1.2:  Metabolic  pathways  and  fates  of  glucose  and  lipids  
Glucose   enters   the   cell   via   glucose   transporters   such   as   Glut1   (1).      Glucose   is   then  
converted   into   pyruvate   in   the   glycolytic   pathway   (2).      Pyruvate   can   be   converted   to  
either   lactate   via   lactate   dehydrogenase   (LDH,   3)   or   to   acetyl   CoA   by   pyruvate  
dehydrogenase   (PDH,   4).      PDH   is   in   part   regulated   by   a   group   of   kinases   called   the  
pyruvate  dehydrogenase  kinases  (PDHK).  Acetyl  CoA  generated  from  either  glucose  or  
lipids   is   then   oxidized   in   the   carboxylic   acid   (TCA)   cycle   (5).      In   contrast   to   glucose,  
lipids  enter   the  cell  via  diffusion   through   the   lipid  bilayer  and  undergo  beta-­‐‑oxidation  
(β-­‐‑Ox,  6)  where  they  are  broken  down  to  acetyl  CoA  and  then  are  further  oxidized  in  the  
TCA  cycle  similarly  to  glucose.    The  electrons  removed  during  the  TCA  cycle  are  placed  
on  electron  carriers  and  shuttled   to   the  electron   transport   chain   (ET).     The  ET  chain   is  

























T  cells  are  critically  important  to  provide  protection  against  foreign  pathogens.    T  
cell  activation  leads  to  an  extremely  high  rate  of  growth  and  proliferation,  which  is  
necessary  to  provide  sufficient  immune  protection.    To  fuel  this  proliferative  demand,  T  
cell  metabolism  is  reprogrammed  to  provide  the  necessary  energy  and  biosynthetic  
precursors  to  support  growth  and  effector  function.    Furthermore,  naïve,  effector,  
regulatory  and  memory  T  cells  have  distinct  roles  in  the  immune  system  and  with  those  
different  functions  comes  unique  metabolic  requirements  (Fig  1.3,  reviewed  in  Gerriets  
et  al.,  2012).    Therefore,  lymphocyte  metabolism  is  intimately  linked  to  immune  function  
and  an  understanding  of  these  metabolic  differences  and  requirements  may  provide  
new  opportunities  to  treat  autoimmune  and  inflammatory  diseases.    
  
1.6.1 Naïve T cell metabolism 
After  positive  and  negative  selection  in  the  thymus,  naïve  T  cells  enter  the  
periphery  and  migrate  between  the  spleen,  lymph  nodes  and  peripheral  lymphoid  
organs.    Naïve  T  cells  require  only  low  levels  of  metabolic  fuels  to  provide  energy  for  
basal  functions,  including  migration,  homeostatic  proliferation  and  immunosurveillance.    
To  perform  these  functions,  naïve  T  cells  utilize  a  variety  of  fuels  including  glucose,  
glutamine  and  fatty  acids  (Jones  et  al.,  2007).    Importantly,  they  oxidize  these  fuels  in  the  
mitochondria  and  produce  very  little  lactate  (Ardawi  et  al.,  1984).      
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Naïve  T  cells  rely  on  extrinsic  signals,  such  as  IL-­‐‑7,  to  maintain  their  survival  and  
metabolic  phenotype  (Rathmell  et  al.,  2001).    Cells  deprived  of  IL-­‐‑7  are  unable  to  
maintain  cell  size  or  glucose  uptake  and  will  upregulate  pro-­‐‑apoptotic  Bcl-­‐‑2  family  
member  proteins  and  undergo  apoptosis  (Coloff  et  al.,  2011;  Rathmell  et  al.,  2000).    The  
IL-­‐‑7  receptor  regulates  glucose  uptake  in  part  through  PI3K/Akt/mTor  pathway  
regulation  of  Glut1  trafficking  to  the  cell  surface.    This  may  allow  naïve  T  cells  to  
maintain  survival  via  upregulation  of  glucose  uptake  and  glycolysis  (Wofford  et  al.,  
2008).    Indeed,  conditional  deletion  of  the  IL-­‐‑7  receptor  in  T  cells  leads  to  an  inability  to  
maintain  glycolysis  and  leads  to  subsequent  cell  death  (Jacobs  et  al.,  2010).    This  
metabolic  role  of  IL-­‐‑7  is  important  to  maintain  homeostasis  of  T  cell  numbers  without  
promoting  autoimmune  disease  or  immune  suppression.      
  
1.6.2 Metabolic reprogramming in T cell activation 
After  antigen  presented  by  a  stimulated  antigen-­‐‑presenting  cell  (APC)  is  
recognized  by  a  T  cell  along  with  appropriate  co-­‐‑stimulatory  conditions,  the  T  cell  will  
become  activated.    Along  with  activation  comes  an  enormous  demand  for  rapid  growth  
and  proliferation  to  drive  the  immune  response  (Moon  et  al.,  2007).    To  fuel  this  demand,  
T  cells  have  significantly  increased  metabolic  requirements  necessary  to  support  cell  
growth  and  proliferation.    T  cell  metabolism  shifts  from  an  oxidative,  catabolic  state  to  
an  anabolic  state,  as  the  proliferating  T  cell  needs  cellular  building  blocks  including  
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protein,  nucleic  acids  as  well  as  lipids  for  building  new  membranes.    This  metabolic  shift  
is  reminiscent  of  many  cancer  cells,  with  a  high  rate  of  aerobic  glycolysis  and  involves  a  
drastic  increase  in  glucose  uptake  and  glycolysis  as  well  as  glutamine  metabolism  
(Macintyre  and  Rathmell,  2013).    In  addition  to  metabolic  reprogramming  towards  
aerobic  glycolysis,  Chang  et  al.  has  also  shown  that  oxidative  phosphorylation  is  
important  for  early  T  cell  activation,  as  oligomycin  treatment  to  inhibit  ATP  synthase  
blocked  the  expression  of  surface  activation  markers  and  prevented  T  cell  proliferation  
following  activation  (Chang  et  al.,  2013).      
The  metabolic  reprogramming  that  occurs  upon  T  cell  activation  was  originally  
described  over  thirty  years  ago  in  rat  lymphocytes.    Newsholme  et  al.  showed  that  in  
concanavalin  A  (ConA)  stimulated  lymphocytes,  carbon  dioxide  produced  after  the  
metabolism  of  glucose  was  far  less  than  expected  given  the  high  rate  of  glucose  uptake  
(Newsholme  et  al.,  1985b).    Instead,  lymphocytes  only  partially  oxidize  glucose  and  
glutamine,  instead  converting  glucose  to  lactate  and  glutamine  to  either  glutamate  or  
other  amino  acids.    Glutamine  was  also  found  to  be  essential  for  lymphocyte  
proliferation,  as  replacement  of  glutamine  with  other  amino  acids  did  not  rescue  
thymidine  incorporation  into  DNA  (Ardawi  and  Newsholme,  1983).    Further  work  
suggested  that  both  glycolysis  and  glutaminolysis  function  at  a  high  rate  in  order  to  
allow  the  use  of  metabolic  intermediates  for  biosynthesis  of  macromolecules  
(Newsholme  et  al.,  1985a).    Importantly,  these  studies  used  ConA,  a  lectin  that  functions  
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as  a  mitogen,  to  activate  lymphocytes  and  therefore  it  will  be  important  to  confirm  these  
studies  with  physiological  T  cell  stimulation.      
These  changes  in  metabolism  are  coordinated  by  various  signaling  events  after  T  
cell  stimulation.    Co-­‐‑stimulation  through  CD28  activates  the  phosphatidyl-­‐‑inositol-­‐‑3-­‐‑
kinase  (PI3K)/Akt/mTORC  pathway  to  promote  both  Glut1  expression  and  trafficking  to  
the  surface  (Jacobs  et  al.,  2008).    The  PI3K/Akt/mTORC  pathway  also  activates  lipid  
synthesis  through  sterol  regulatory  element-­‐‑binding  protein  1  (SREBP1)  (Duvel  et  al.,  
2010).  In  addition,  c-­‐‑Myc  is  important  to  promote  genes  associated  with  both  glucose  
and  glutamine  metabolism  early  on  in  T  cell  activation  (Wang  et  al.,  2011).  Consequently,  
c-­‐‑Myc  knockout  T  cells  cannot  upregulate  glycolytic  and  glutaminolytic  genes  and  fail  to  
activate.    In  addition  to  c-­‐‑Myc,  the  nuclear  hormone  receptor  estrogen-­‐‑related  receptor  
alpha  (ERRα)  has  been  shown  to  be  important  for  T  cell  activation  as  well  as  
differentiation.    ERRα  was  initially  described  as  a  transcriptional  regulator  of  
mitochondrial  biogenesis  and  oxidation  that  is  important  to  regulate  cell  energy  balance  
(Sladek  et  al.,  1997).    ERRα  expression  is  induced  upon  T  cell  activation  and  was  shown  
to  direct  gene  expression  regulated  to  both  glucose  and  mitochondrial  metabolism,  
promoting  T  cell  growth  and  proliferation  (Michalek  et  al.,  2011b).    T  cells  deficient  in  
ERRα  had  decreased  cytokine  production,  proliferation  and  glucose  metabolism  
(Michalek  et  al.,  2011b).    Together,  these  signaling  pathways  coordinate  cell  metabolism  
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to  balance  energy  generation  and  biosynthesis  for  maximal  T  cell  growth  and  
proliferation  rates.      
While  glucose  and  glutamine  utilization  increase  upon  activation,  fatty  acid  
oxidation  is  downregulated,  likely  because  lipids  are  necessary  to  provide  building  
blocks  for  new  membranes.    In  hematopoietic  cells,  fatty  acid  oxidation  is  regulated  in  
part  through  the  PI3K/Akt/mTOR  pathway,  which  can  suppress  the  expression  of  
carnitine  palmitoyltransferase  Ia  (CPT1α),  the  rate-­‐‑limiting  step  of  long-­‐‑chain  fatty  acid  
oxidation  (Deberardinis  et  al.,  2006).    In  addition,  CPT1α  is  likely  allosterically  inhibited  
by  malonyl  CoA,  the  end  product  of  fatty  acid  synthesis,  although  this  has  not  been  
shown  in  lymphocytes  (McGarry  et  al.,  1977).          
This  switch  in  fuel  usage  during  T  cell  activation  is  critical  to  support  both  
growth  and  proliferation.    Glucose  starvation  or  limitation  can  inhibit  T  cell  proliferation  
as  well  as  cytokine  production  (Cham  et  al.,  2005;  Jacobs  et  al.,  2008;  Zheng  et  al.  2009).    
This  occurs  even  in  the  presence  of  other  fuel  sources,  suggesting  that  glucose  is  
required  for  T  cell  activation  and  function  (Jacobs  et  al.,  2008).    Together,  these  data  
indicate  that  glucose  and  glutamine  metabolism  is  a  critical  and  necessary  aspect  of  T  
cell  activation.      
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1.6.3 Effector and Regulatory T cell metabolism 
Along  with  TCR  engagement  and  co-­‐‑stimulation,  the  cytokine  environment  
promotes  CD4  T  cells  to  undergo  differentiation  into  effector  T  cells  (Teff;  Th1,  Th2,  
Th17)  or  inducible  regulatory  T  cells  (Treg).    Each  of  these  subsets  has  a  unique  role  to  
promote  or  suppress  immunity.    Along  with  unique  immunological  roles,  recent  data  
suggests  that  the  CD4  T  cell  subsets  may  have  specific  metabolic  requirements  and  
programs.    Metabolic  differences  between  the  subsets  could  potentially  provide  a  way  to  
regulate  the  immune  response  in  the  context  of  an  autoimmune  or  inflammatory  
disorder.  
Like  activated  T  cells,  effector  T  cells  rely  on  glucose  to  support  the  bioenergetics  
needs  of  rapid  growth  and  proliferation.    Effector  T  cells  express  high  levels  of  Glut1  
and  have  high  rates  of  glucose  uptake  and  glycolysis  (Michalek  et  al.,  2011a;  Shi  et  al.,  
2011).    In  contrast,  Treg  have  lower  rates  of  glucose  uptake  and  glycolysis  and  a  lower  
expression  of  Glut1,  albeit  higher  than  naïve  T  cells.    In  vitro,  Teff  are  much  more  
sensitive  to  2-­‐‑deoxyglucose  (2DG)  treatment  to  inhibit  glycolysis,  suggesting  that  there  
may  be  differences  in  glucose  utilization  between  Teff  and  Treg  (Shi  et  al.,  2011).    
Instead,  we  have  found  that  Treg  have  a  higher  rate  of  lipid  oxidation  than  Teff  
(Michalek  et  al.,  2011a).    Furthermore,  the  addition  of  exogenous  fatty  acids  promotes  
Treg  formation  but  inhibits  Teff.    This  suggests  that  Treg  have  more  fuel  flexibility  and  
in  the  presence  of  glycolytic  inhibitors,  are  able  to  rely  on  lipid  oxidation.  
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The  PI3K/Akt/mTOR  pathway  also  plays  an  important  metabolic  role  in  the  T  
cell  subsets.    This  pathway  both  promotes  Teff  by  upregulating  glucose  metabolism  and  
inhibits  Treg  generation.    T  cell  specific  mTOR  knockout  cells  fail  to  become  effector  T  
cells  even  when  differentiated  in  vitro  with  the  appropriate  cytokines  (Delgoffe  et  al.,  
2009).    Instead,  the  T  cells  become  FoxP3+  Treg.    In  addition,  the  mTOR  inhibitor  
rapamycin  promotes  the  generation  of  Treg  both  in  vitro  and  in  vivo  (Battaglia  et  al.,  
2005),  although  the  role  of  rapamycin  is  complex.    There  are  two  mTOR  complexes,  
mTORC1  and  mTORC2;  mTORC1  is  regulated  by  PI3K  while  mTORC2  promotes  Akt  
and  other  related  kinases  (Chi,  2012).    Interestingly,  these  two  mTOR  complexes  have  
differential  roles  in  effector  T  cell  differentiation.    Ras  homolog  enriched  in  brain  (Rheb)  
knockout  T  cells  lack  mTORC1  activity  and  can  differentiate  into  Th2  but  not  Th1  or  
Th17  (Delgoffe  et  al.,  2011).    Alternatively,  T  cells  lacking  mTORC2  activity  have  the  
ability  to  become  Th1  and  Th17  but  not  Th2.    Therefore,  the  mTOR  signaling  pathway  
has  an  important  and  complex  role  in  T  cell  differentiation  and  it  will  be  important  to  
see  how  alterations  in  these  pathways  lead  to  changes  in  T  cell  metabolism.      
In  addition  to  the  PI3K/Akt/mTOR  signaling  pathway,  the  opposing  AMP-­‐‑
activated  kinase  (AMPK)  may  play  a  role  in  T  cell  differentiation.    Treg  have  been  
shown  to  have  a  higher  expression  of  phospho-­‐‑AMPK  than  Teff  (Michalek  et  al.,  2011b).    
AMPK  senses  metabolic  stress  and  is  allosterically  activated  by  AMP  and  inhibited  by  
ATP.    When  activated,  AMPK  increases  catabolic  processes  including  glucose  uptake  
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and  fatty  acid  oxidation,  although  this  has  not  been  shown  in  T  cells  (Mihaylova  and  
Shaw,  2011).    Treatment  of  mice  with  metformin,  which  leads  to  AMPK  activation,  can  
also  induce  Treg  in  vivo  (Michalek  et  al.,  2011b).    AMPK  signaling  opposes  the  mTOR  
pathway,  as  AMPK  inhibits  mTORC1  by  the  phosphorylation  of  tuberous  scloreosis  2  
protein  (TSC2)  and  subsequent  inhibition  of  Rheb  (Chi,  2012).    Therefore,  the  
AMPK/mTOR  signaling  pathways  appear  to  coordinate  opposing  metabolic  programs  in  
Teff  and  Treg.      
In  addition  to  the  PI3K/Akt/mTOR  signaling  pathway,  the  transcription  factor  
hypoxia  inducible  factor  1  alpha  (HIF1α)  plays  a  role  in  T  cell  differentiation.    Although  
HIF1α  has  been  shown  to  be  dispensable  in  early  T  cell  activation,  it  is  selectively  
expressed  in  Th17  and  important  to  upregulate  glucose  metabolism  (Wang  et  al.,  2011;  
Shi  et  al.,  2011).    This  was  shown  to  be  dependent  on  mTOR  signaling.    HIF1α  also  
modulates  the  balance  between  Th17  and  Treg,  as  a  T  cell  specific  HIF1α  knockout  
promotes  Treg  generation  and  inhibits  IL-­‐‑17  production  in  vitro  and  protects  against  
EAE  in  vivo  (Dang  et  al.,  2011).    In  this  setting,  HIF1α  acts  to  directly  increase  the  activity  
of  RORγt,  the  master  regulator  of  Th17  and  can  also  bind  to  FoxP3  and  lead  to  its  
degradation  (Dang  et  al.,  2011).    Therefore,  HIF1α  likely  has  both  metabolic  and  non-­‐‑
metabolic  roles  to  control  T  cell  differentiation.      
Complicating  the  understanding  of  Treg  metabolism  is  recent  data  with  the  
PDHK1  inhibitor  DCA.    As  described  above,  DCA  inhibits  PDHK1,  which  in  turn  
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activates  PDH  to  drive  glucose  oxidation  and  subsequently  reduce  lactate  production.      
Treatment  of  T  cells  with  DCA  promotes  the  generation  of  Treg  (Ostroukhova  et  al.,  
2012).    In  vivo  DCA  treatment  inhibits  airway  inflammation  and  collagen-­‐‑induced  
arthritis  in  mice  (Bian  et  al.,  2009).    Although  these  studies  did  not  examine  T  cell  
metabolism  in  detail,  this  role  of  DCA  suggests  that  glucose  oxidation  may  be  favorable  
for  Treg.  However,  the  role  and  requirement  of  mitochondrial  oxidation  of  fuel  for  Treg  
differentiation  or  function  is  not  yet  understood.      
  
1.6.4 Memory T cell metabolism 
At  the  end  of  an  immune  response  and  pathogen  clearance,  TCR  stimulation  
decreases  and  the  majority  of  effector  T  cells  die  of  apoptosis;  however  a  few  antigen-­‐‑
specific  T  cells  persist  as  memory  cells.    Memory  T  cells  are  important  to  confer  
protection  to  pathogens  that  were  previously  seen  by  the  immune  system  and  upon  
secondary  challenge  with  the  same  pathogen  can  given  an  enhanced  and  efficient  
response  (reviewed  in  D’Cruz  et  al.,  2009).    Memory  cells  therefore  may  require  a  unique  
metabolic  program  that  allows  for  both  long-­‐‑lived  quiescence  as  well  as  have  the  ability  
to  rapidly  respond  to  secondary  infections.    While  memory  CD4  T  cell  metabolism  has  
not  been  extensively  studied,  recent  studies  have  examined  memory  CD8  T  cell  
metabolism.        
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The  first  evidence  that  memory  T  cells  may  utilize  a  unique  metabolic  program  
was  when  TNF  receptor  associated  factor  6  (TRAF6)  knockout  T  cells  were  shown  to  
have  defects  in  the  transition  between  effector  and  memory  phenotypes.    TRAF6-­‐‑
deficient  T  cells  were  shown  to  have  defects  in  fatty  acid  metabolism  that  could  be  
rescued  with  metformin  treatment  (Pearce  et  al.,  2009).    Subsequently,  the  same  group  
showed  that  a  cytokine  important  for  T  cell  memory,  IL-­‐‑15,  promotes  the  expression  of  
CPT1α  and  therefore  lipid  oxidation  (van  der  Windt  et  al.,  2012).    In  addition,  when  
CPT1α  was  retrovirally  expressed  in  T  cells,  it  increased  the  recall  response  of  CD8  T  
cells  in  vivo,  suggesting  that  memory  T  cells  require  fatty  acid  oxidation  to  rapidly  
proliferate  upon  restimulation  (van  der  Windt  et  al.,  2012;  van  der  Windt  et  al.,  2013).      
Similarly  to  Treg,  CD8  memory  T  cells  were  also  found  to  have  high  levels  of  
AMPK  activity,  as  measured  by  AMPK  phosphorylation.    Additionally,  treatment  of  T  
cells  with  metformin  in  vivo  promoted  CD8  memory  T  cell  accumulation  (Pearce  et  al.,  
2009).    At  the  same  time,  Araki  et  al.  showed  that  mTOR  is  an  important  regulatory  of  
CD8  memory  T  cells,  as  rapamycin  treatment  to  inhibit  mTOR  leads  to  increased  
memory  formation  and  enhanced  the  effector  to  memory  transition  (Araki  et  al.,  2009).      
Therefore,  promoting  oxidative  metabolism  appears  to  be  critical  for  memory  T  cell  
formation  to  allow  recall  responses.  
In  addition  to  the  transition  between  glycolytic  effector  and  quiescent  memory  
cells,  memory  CD8  T  cells  need  to  be  able  to  rapidly  respond  to  secondary  infection.    
  35  
Van  der  Windt  et  al.  showed  that  in  vitro  memory  T  cells  have  higher  spare  respiratory  
capacity  (SRC),  which  is  a  measurement  of  the  reserve  capacity  of  the  cell  to  increase  
oxygen  consumption  (Van  der  Windt  et  al.,  2012;  Gubser  et  al.,  2013).    Memory  CD8  T  
cells  were  also  shown  to  have  more  mitochondrial  biomass  than  effector  or  naïve  T  cells.    
Together,  this  suggests  that  while  memory  T  cells  have  a  quiescent  catabolic  metabolism,  
they  have  the  capacity  to  greatly  increase  their  respiratory  rate  and  energy  production  as  





Figure  1.3:  Distinct  metabolic  programs  in  the  T  cell  subsets  
As  each  of   the  T  cell  subsets  has  a  unique  role   in   the   immune  system,  different  
types   of   T   cells   have  unique  metabolic   programs   and   requirements.      (a)  Naïve  
CD4   T   cells   transition   from   an   oxidative   catabolic   metabolism   to   an   anabolic  
glycolytic   metabolism.   Depending   on   the   cytokine   environment   during   T   cell  
activation,   the  T   cell   can   then  either  differentiate   into   effector  T   cells   (Th1,  Th2  
and  Th17)  with  a  glycolytic  phenotype  or  regulatory  T  cells  (Treg)  that  maintain  
and  oxidative  metabolism.      (b)  Similarly   to  CD4  T  cells,  naïve  CD8  T  cells  start  
out   in   a   quiescent   oxidative   state   and   transition   to   effector  CD8  T   cells,  which  
utilize   aerobic   glycolysis.      At   the   end   of   the   immune   response,   CD8   T   cells  
transition  back  to  an  oxidative  metabolism  to  allow  for  the  survival  of  long-­‐‑lived  









































1.7 Metabolism in autoimmunity and inflammatory disease 
The  studies  on  T  cell  metabolism  have  largely  come  from  in  vitro  experiments  
with  culture  media  and  supraphysiological  T  cell  stimulation.    Recent  data  have  
emerged,  however,  suggesting  that  this  metabolic  reprogramming  is  necessary  to  
effector  T  cell  function  in  vivo.    For  example,  treatment  of  mice  with  2-­‐‑deoxyglucose  to  
inhibit  hexokinase  and  glycolysis  alleviates  EAE  (Shi  et  al.,  2011).    Inhibition  of  PDK1  
with  DCA  treatment  has  also  been  shown  to  inhibit  airway  inflammation  and  collagen-­‐‑
induced  arthritis  in  mice  (Ostroukhova  et  al.,  2011;  Bian  et  al.,  2009).    In  addition,  T  cells  
isolated  from  human  asthma  patients  and  treated  with  DCA  had  decreased  proliferation  
and  inflammatory  cytokine  production  compared  to  vehicle  (Ostroukhova  et  al.,  2011).    
Increased  glucose  metabolism  has  also  been  linked  to  autoimmune  disease  in  Glut1  
transgenic  mice  (Jacobs  et  al.,  2008).    The  increased  expression  of  Glut1  in  the  T  cells  of  
these  mice  leads  to  increased  rates  of  glucose  uptake  and  glycolysis  upon  T  cell  
activation.    Aged  Glut1  transgenic  mice  accumulated  activated  T  cells  in  the  spleen  and  
lymph  nodes  and  have  anti-­‐‑dsDNA  antibodies  and  other  signs  of  autoimmunity  (Jacobs  
et  al.,  2008;  Michalek  et  al.,  2011b).      
While  much  of  the  previous  focus  has  been  on  glucose  metabolism  and  aerobic  
glycolysis,  mitochondrial  dysfunction  has  also  been  associated  with  inflammatory  
disease,  especially  in  the  context  of  chronically  activated  T  cells.    For  example,  
chronically  stimulated  T  cells  in  the  setting  of  graft-­‐‑vs-­‐‑host  disease  (GvHD)  increase  
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both  glycolysis  and  OXPHOS  compared  to  normal  T  cells  in  response  to  alloantigen  
(Gatza  et  al.,  2011).    Wahl  et  al.  also  found  that  autoreactive  splenocytes  in  mice  with  
systemic  lupus  erythematosus  (SLE)  preferentially  oxidize  glucose  rather  than  convert  it  
to  lactate  in  vivo  (Wahl  et  al.,  2010).    Similarly,  T  cells  from  human  lupus  patients  have  
increased  mitochondrial  mass  and  membrane  potential  compared  to  control  T  cells  
(Gergely  et  al.,  2002).    These  mitochondrial  alterations  may  be  used  to  specifically  target  
autoreactive  or  chronically  stimulated  T  cells.    To  this  end,  Gatza  et  al.  showed  that  the  
treatment  of  T  cells  with  the  compound  Bz-­‐‑423,  which  inhibits  F1F0-­‐‑ATPase  activity,  
decreased  the  viability  of  alloreactive  but  not  healthy  T  cells  (Gatza  et  al.,  2011).    
Treatment  of  mice  with  Bz-­‐‑423  in  the  context  of  GvHD  also  improved  the  survival  and  
clinical  scores  of  the  mice  compared  to  vehicle  control.    This  data  suggests  that  targeting  
oxidative  metabolism  may  be  useful  in  certain  contexts  including  alloreactive  and  
chronically  stimulated  T  cells.  
In  addition  to  cellular  metabolism,  the  overall  metabolic  status  of  an  organism  
may  influence  T  cell  function.    Malnutrition  has  long  been  associated  with  
immunosuppression,  while  obesity  is  classically  associated  with  inflammation  (Shears,  
1991;  Gregor  et  al.,  2011).    Furthermore,  the  adipokine  leptin  is  important  to  regulate  
energy  intake  and  expenditure  and  has  recently  been  shown  to  play  a  role  in  immune  
homeostasis.  Leptin  itself  can  function  as  a  proinflammatory  cytokine  (Procaccini  et  al.,  
2012).    Further,  both  leptin-­‐‑deficient  humans  and  mice  have  immune  defects  in
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reduced  T  cell  numbers,  decreased  Th1  and  increased  Th2  cells  (Mattioli  et  al.,  2005).    
Fasting-­‐‑induced  hypoleptinema  in  mice  also  led  to  reduced  cytokine  production  and  
decreased  glucose  uptake  and  glycolysis  in  T  cells  (Saucillo  et  al.,  2013).    This  was  likely  
because  leptin  plays  an  important  role  to  increase  Glut1  and  glucose  metabolism.    Leptin  
has  also  been  shown  to  decrease  Treg  proliferation,  likely  through  activation  of  the  
mTOR  signaling  pathway  (Procaccini  et  al.,  2010).    Therefore,  leptin  and  other  metabolic  
regulators  can  also  contribute  to  T  cell  metabolism  and  differentiation.      
  
1.8 Questions to be addressed 
The  metabolic  reprogramming  that  occurs  upon  T  cell  activation  has  been  well  
described  (MacIver  et  al.,  2013;  Gerriets  et  al.,  2012).    Additionally,  recent  literature  
suggests  that  Treg  utilize  a  distinct  metabolic  program  from  Teff  (Michalek  et  al.,  2011a;  
Shi  et  al.,  2011).    The  metabolic  manipulations  used  in  these  studies  have  pointed  to  
metabolic  differences  between  Teff  and  Treg,  however  the  metabolic  programs  
underlying  each  individual  subset,  Th1,  Th2,  Th17  and  Treg,  are  unclear.    Previous  
studies  also  use  pharmacological  agents  to  examine  T  cell  metabolism,  including  2-­‐‑
deoxyglucose  and  etomoxir,  which  inhibit  glycolysis  and  fatty  acid  oxidation  
respectively.      
The  use  of  pharmacological  agents  complicates  the  interpretation  of  in  vivo  T  cell  
data,  as  these  inhibitors  can  affect  all  cell  types,  including  antigen-­‐‑presenting  cells  and  
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non-­‐‑immune  cells  which  may  contribute  indirectly  to  T  cell  function.    In  addition,  
pharmacological  approaches  can  have  off-­‐‑target  effects.    Therefore,  it  is  necessary  to  use  
a  genetic  approach  in  which  metabolism  can  be  altered  specifically  and  intrinsically  to  
the  T  cell  to  examine  the  affect  of  metabolic  manipulation  on  T  cell  differentiation  and  
function.    Additionally,  a  more  detailed  understanding  of  these  metabolic  programs  
may  provide  a  way  to  specifically  modulate  the  immune  system  to  favor  one  T  cell  
subset  over  another.    This  would  be  useful  in  the  context  of  autoimmune  disorders.    
Currently,  many  autoimmune  therapies  affect  all  lymphocytes,  leading  to  general  
immune  suppression.    Modulation  of  the  balance  between  Th17  and  Treg,  specifically,  
would  be  advantageous  in  autoimmunity  without  causing  unwanted  side  effects  from  
general  immune  suppression.  
Therefore,  the  work  here  examines  a  genetic  approach  of  metabolic  inhibition  
through  Glut1  deletion.    As  described  above,  Glut1  is  one  of  the  major  glucose  
transporters  in  T  cells  and  is  important  to  control  the  rate  of  glucose  uptake  and  
glycolysis  upon  T  cell  activation  (Jacobs  et  al.,  2008;  Michalek  et  al.,  2011a).    Previous  
work  has  shown  that  effector  T  cells  (Th1,  Th2  and  Th17)  express  much  higher  levels  of  
Glut1  than  Treg,  however  the  role  of  Glut1,  and  importantly,  the  cell-­‐‑intrinsic  role  of  
glucose  metabolism  in  T  cell  differentiation  and  inflammation  was  not  directly  tested  
(Michalek  et  al.,  2011a).      
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Additionally,  previous  literature  has  shown  broad  metabolic  differences  between  
Teff  and  Treg,  however  the  metabolic  phenotypes  of  both  Teff  and  Treg  are  poorly  
understood.    Here,  Teff  and  Treg  metabolism  is  explored  to  determine  the  metabolic  
programs  underlying  each  of  the  T  cell  subsets  and  test  if  dependence  on  distinct  
metabolic  pathways  will  allow  selective  targeting  of  different  T  cell  populations.    A  
question  that  arises  from  differences  in  T  cell  metabolic  profiles  is  how  and  why  this  
occurs.    What  accounts  for  differences  in  fuel  utilization  and  metabolic  pathways?    
Particularly,  Treg  seem  to  not  rely  on  glucose  but  instead  have  fuel  flexibility  and  
remain  more  oxidative  than  Teff.    Because  the  transcription  factor  FoxP3  drives  the  Treg  
program,  the  role  of  FoxP3  in  metabolism  is  also  examined  to  determine  if  FoxP3  drives  
the  Treg  metabolic  program.    Overall,  the  work  presented  here  examines  the  metabolic  
programs  and  regulation  of  the  CD4  T  cell  subsets  and  potential  metabolic  targets  that  
could  be  used  to  treat  autoimmune  and  inflammatory  conditions.        
    
     
  42  
2. Materials and Methods 
  
2.1 Mice 
Six  to  eight  week  old  C57BL/6J  mice  from  Jackson  Laboratory  were  used  for  all  
experiments  unless  otherwise  indicated.    Glut1fl  animals  were  crossed  to  mice  expressing  
Cre  recombinase  under  the  control  of  the  p56Lck,  CD4  or  UbiCreER  promoters  (Jackson  
Laboratory)  and  have  been  described  previously  (Young  et  al.,  2011).    Mice  expressing  
endogenous  levels  of  myc-­‐‑epitope  tagged  Glut1  (Glut1myc)  have  also  been  described  
(Michalek  et  al.,  2011a).    All  procedures  were  performed  under  Duke  University  Medical  
Center  IACUC-­‐‑approved  protocols.  
    
2.2 T cell isolation and differentiation 
Naïve  CD4+CD25-­‐‑  T  cells  were  isolated  ex  vivo  and  T  helper  cell  subsets  were  
generated  as  described  previously  (Michalek  et  al.,  2011a).    Briefly,  CD4+CD25-­‐‑  T  cells  
were  cultured  on  irradiated  splenic  feeder  cells  (300  Gy)  with  2.5µμg/mL  of  anti-­‐‑CD3  
antibody  at  a  ratio  of  5:1  in  RPMI  supplemented  with  10%  FBS,  sodium  pyruvate,  
penicillin/streptomycin,  HEPES  and  beta-­‐‑mercaptoethanol.    The  following  cytokines  
were  added  to  each  subset:  Th1,  10ng/mL  IL-­‐‑12  (R&D  Systems),  10µμg/mL  anti-­‐‑IL-­‐‑4  
(eBioscience,  clone  11B11),  1µμg/mL  anti-­‐‑IFNγ  (eBioscience);  Th2,  1000U/mL  recombinant  
IL-­‐‑4  (R&D  Systems),  10µμg/mL  anti-­‐‑IL-­‐‑12  (eBioscience),  10µμg/mL  anti-­‐‑IFNγ;  Th17,  
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20ng/mL  IL-­‐‑6  (R&D  Systems),  2.5ng/mL  TGFβ  (R&D  Systems),  10µμg/mL  anti-­‐‑IFNγ;  
Treg,  3ng/mL  TGFβ.    On  day  3  post  stimulation,  cells  were  split  1:2  and  re-­‐‑plated  with  
IL-­‐‑2  alone  for  an  additional  2  days.  In  some  experiments,  cells  were  treated  with  5nM  
rotenone,  500µμM  2-­‐‑deoxyglucose,  10mM  dichloroacetate  or  labeled  with  CellTrace  
Violet  (Invitrogen)  per  manufacturer’s  instructions.  
  
2.3 Metabolic assays 
Glycolysis  and  glucose  uptake  assays  using  3H-­‐‑glucose  or  3H-­‐‑2-­‐‑deoxyglucose  
have  been  described  previously  (Plas  et  al.,  2001;  Wieman  et  al.,  2007).  Glutamine  
oxidation,  pentose  phosphate  pathway  (PPP)  flux  and  glucose  oxidation  were  
determined  by  the  rate  of  14CO2  release  from  U-­‐‑14C-­‐‑glutamine,  1-­‐‑14C-­‐‑glucose  and  6-­‐‑14C-­‐‑
glucose  as  described  (Wang  et  al.,  2011).    All  values  were  normalized  to  cell  number.    
OCR  and  ECAR  were  measured  with  an  XF24  extracellular  flux  analyzer  (Seahorse  
Bioscience)  as  described  (Wu  et  al.,  2007).    Suspension  cells  were  attached  to  culture  
plates  using  Cell-­‐‑Tak  (BDBioscience).  OCR  and  ECAR  were  measured  in  unbuffered  
RPMI  (Sigma-­‐‑Aldrich)  supplemented  with  10mM  D-­‐‑glucose  (Sigma-­‐‑Aldrich),  10mM  L-­‐‑
glutamine,  and  10mM  sodium  pyruvate,  as  indicated.  OCR  and  ECAR  values  were  
normalized  to  cell  number.    For  certain  experiments,  ECAR  was  measured  over  time  
following  injection  of  10mM  D-­‐‑glucose,  oligomycin  and  2DG.  Glycolytic  capacity  is  
defined  as  the  difference  between  the  ECAR  following  the  injection  of  oligomycin  and  
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basal  ECAR.    Spare  respiratory  capacity  is  defined  as  the  percent  increase  in  OCR  
between  the  initial  basal  readings  and  the  injection  of  FCCP.      Lactate  production  was  
measured  by  colorimetric  assay.  
  
2.4 Flow cytometry 
Murine  T  cells  were  labeled  with  anti-­‐‑mouse  CD4-­‐‑allophycocyanin  (APC),  CD4-­‐‑  
fluorescein  isothiocyanate  (FITC),  CD4-­‐‑eFluor  450,  CD25-­‐‑phycoerythrin  (PE),  CD8  PE-­‐‑
Cy5.5,  CD44-­‐‑Violet  Blue,  CD71-­‐‑APC,  CD98-­‐‑PE  or  Thy1.2-­‐‑FITC  (all  eBioscience).  
Exofacially  tagged  Glut1myc  was  stained  with  mouse  anti-­‐‑myc  (Millipore)  followed  by  rat  
anti-­‐‑mouse  IgG-­‐‑PE  (eBioscience).  To  measure  intracellular  cytokines,  cells  were  
unstimulated  or  stimulated  for  5h  with  PMA  (50ng/ml;  Sigma-­‐‑Aldrich)  and  ionomycin  
(750ng/ml;  Calbiochem)  in  the  presence  of  GolgiStop  (IL-­‐‑4,  IL-­‐‑17)  or  GolgiPlug  (IFNγ,  
IL-­‐‑17,  IL-­‐‑2),  permeabilized  with  Cytofix/Cytoperm  Plus  (BDBiosciences),  and  then  
stained  with  IFNγ-­‐‑APC,  IL-­‐‑2-­‐‑PE,  IL-­‐‑17-­‐‑PE,  or  IL-­‐‑4-­‐‑APC  (all  eBioscience).  FoxP3  staining  
was  performed  using  FoxP3-­‐‑PE  in  combination  with  Regulatory  T  cell  staining  kit  #1  
(eBioscience).    Intracellular  mouse  and  human  Glut1  staining  was  performed  by  fixing  
cells  in  1%  paraformaldehyde,  permeabilizing  with  methanol  and  then  staining  with  
rabbit  anti-­‐‑Glut1  (Abcam)  followed  by  rat  anti-­‐‑rabbit  IgG-­‐‑PE  or  rat  anti-­‐‑rabbit  IgG-­‐‑APC  
(eBioscience).  Cell  proliferation  was  assayed  by  flow  cytometry  of  carboxyfluorescein  
succinimidyl  ester  (5µμM  CFSE;  Molecular  Probes)  labeled  cells.  Cell  viability  was  
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determined  flow  cytometrically  by  propidium  iodide  exclusion  (1µμg/ml  PI;  Invitrogen).  
Data  were  acquired  on  a  MacsQuant  cytometer  (Miltenyi  Biotec)  and  analyzed  with  
FlowJo  software  (TreeStar).  
  
2.5 Treg suppression assay 
Treg  cells  were  differentiated  as  described  above  and  cultured  at  ratios  of  1:1,  1:2,  
1:4  or  1:8  with  CFSE  labeled  CD4+CD25-­‐‑  T  cells  on  plates  coated  with  5µμg/ml  of  anti-­‐‑CD3  
and  anti-­‐‑CD28  (eBioscience).  Treg  suppression  of  CD4  T  cell  proliferation  was  
determined  72h  post  stimulation  by  CFSE  dilution  of  target  population.  
  
2.6 Glucose transporter family expression 
RNA  was  isolated  from  snap-­‐‑frozen  cell  pellets  using  RNAeasy  Plus  Mini  kit  
(Qiagen).    Glucose  transporter  absolute  copy  number  was  determined  as  described  
(Rudolph  et  al.,  2011).  Briefly,  total  RNA  was  converted  to  cDNA  using  the  Verso  cDNA  
synthesis  kit  with  blended  oligo  dT  and  random  hexamer  primers  (Thermofisher).    
qPCR  was  performed  using  Absolute  Fast  qPCR  Mix-­‐‑lox  Rox  (ThermoFisher).    Probe  
sets  (Applied  Biosystems)  and  amplicon  sizes  are  given  in  Supplementary  Table  1.  Data  
were  collected  with  the  7500  fast  thermocycler  (Applied  Biosystems),  and  the  Ct  value  
for  unknowns  were  fitted  to  each  target  regression  curve  to  quantify  transcript  copy  
number  for  that  target.  
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2.7 Semi quantitative real time PCR 
RNA  was  extracted  from  cells  with  the  RNeasy  RNA  purification  minikit  
(Qiagen).  Reverse-­‐‑transcription  PCR  was  performed  with  iScript  cDNA  synthesis  kit  
(Biorad).  Real-­‐‑time  PCR  was  performed  with  iQSYBR  Green  detection  chemistry  
(Biorad)  using  an  iCycler  (BioRad).  Relative  mRNA  levels  were  normalized  to  18S  RNA  
content.  Primers  used:  18S  (Fwd:5’GTAACCCGTTGAACCCCATT3’  




Immunoblotting  was  performed  as  described  previously  (Jacobs  et  al.,  2008).  
Blots  were  probed  for  CPT1α  (Proteintech  group,  15184-­‐‑1-­‐‑AP),  Glut1  (abcam,  ab115730)  
or  β-­‐‑actin  (Sigma,  A5441),  followed  by  mouse-­‐‑  or  rabbit-­‐‑conjugated  horseradish  
peroxidase  (HRP)  (Cell  Signaling  Technology).  HRP-­‐‑conjugated  antibodies  were  
detected  by  enhanced  chemiluminescence  detection  (Thermofisher).  Alternatively,  
primary  antibodies  were  followed  by  fluorescently  labeled  anti-­‐‑mouse  or  rabbit  
antibodies  (LiCor)  and  imaged  using  the  Odyssey  infrared  imaging  system  (LiCor).    This  
included  the  following  antibodies:  Glut1  (ab652,  Abcam),  Glut3  (Millipore),  Glut6  
(Osenses),  Glut8  (Millipore),  Glut9  (Thermo-­‐‑Fisher  Scientific),  Hk1  (Millipore),  Hk2  
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(Millipore),  Hk3  (Abcam),  Hk4  (Abcam),  OXPHOS  antibody  cocktail  (Abcam),  CPT1α,  
cytochrome  C  (BD  Biosciences),  Actin  (Abcam).        
 
2.9 FoxP3-ER cell lines 
FL5.12  cells  were  infected  with  control  or  FoxP3-­‐‑ER  expressing  lentivirus  and  
selected  with  NGFR.    The  FoxP3-­‐‑ER-­‐‑NGFR  construct  has  been  previously  published  
(Allan  et  al.,  2008).    Three  clones  of  each  were  selected  based  on  equivalent  NGFR  
expression.    To  activate  FoxP3-­‐‑ER,  100nM  4-­‐‑hydroxtamoxifen  (4-­‐‑OHT)  was  added  36  
hours  prior  to  experimental  procedures.  
  
2.10 Retroviral FoxP3 expression 
CD4+CD25-­‐‑  primary  T  cells  were  isolated  and  activated  with  3ng/mL  PMA  and  
1µμM  ionomycin  overnight.    Cells  were  then  infected  with  FoxP3-­‐‑NGFR  or  NGFR  control  
retrovirus  along  with  8µμg/mL  polybrene  and  centrifuged  for  90  min  at  2500rpm.    Cells  
were  rested  for  5h  and  then  plated  with  fresh  media  and  10U/mL  IL-­‐‑2  for  72h.    FoxP3-­‐‑
NGFR  or  NGFR  control  cells  were  positively  selected  with  PE  magnetic  beads  following  
NGFR-­‐‑PE  labeling  (≥90%  purity,  Miltenyi  Biotec).      
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2.11 T cell transfer model of colitis 
Splenic  CD4  T  cells  were  isolated  as  described  above,  and  naïve  effector  
(CD4+CD25−CD45RBhi)  and  regulatory  (CD4+CD25+CD45RBlo)  T  cells  were  sorted  
(FACSvantage,  BDBioscience).  Naïve  effector  T  cells  from  were  injected  i.p.  into  6-­‐‑8  
week  old  C57BL/6  RAG1−/−  recipients  (4x105  cells/mouse).  Treg  cells  (2x105  cells/mouse)  
were  co-­‐‑injected  as  indicated.    Alternatively,  Treg  were  injected  21  days  later  after  
disease  initiation  where  indicated.    Because  the  mice  were  H.  pylori  negative,  and  colitis  
does  not  occur  spontaneously  in  this  setting,  disease  was  initiated  two  weeks  following  
T  cell  injection  with  200ppm  piroxicam  (Sigma-­‐‑Aldrich)  in  powdered  rodent  chow  for  5  
days  to  enhance  mucosal  exposure  to  enteric  bacteria  and  induce  colitis  (Hale  et  al.,  
2005).    In  certain  cases,  mice  were  then  injected  i.p  with  4mg/kg/day  of  tamoxifen  
(Sigma-­‐‑Aldrich)  dissolved  in  corn  oil  (Sigma-­‐‑Aldrich)  for  4  days  to  induce  Glut1fl  
deletion  and  monitored  three  times  weekly.  For  analysis  the  colon  was  divided  into  5  
segments  representing  the  cecum,  and  proximal,  mid-­‐‑,  distal,  and  terminal  
colon/rectum.  Tissues  were  fixed  and  a  board-­‐‑certified  pathologist  blindly  scored  the  
severity  of  colonic  inflammation  in  hematoxylin  and  eosin-­‐‑stained  sections  as  described  
(Hale  et  al.,  2005).  
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2.12 Ova Immunization Model 
Ovalbumin  (Ova)-­‐‑specific  OT-­‐‑II  T  cell  receptor  (TCR)  Thy1.2  transgenic  control  
(CD4CreGlut+/+)  or  knockout  (CD4CreGlut1fl/fl)  CD4  T  cells  were  labeled  with  CTV  and  
adoptively  transferred  into  wild  type  Thy1.1  hosts.  One  day  later,  mice  were  immunized  
with  i.p.  Ova  in  Complete  Adjuvant  (Sigma).  Three  days  after  immunization,  
lymphocytes  were  isolated  and  proliferation  was  assessed  by  CTV  dilution  of  Thy1.2  
labeled  cells.  
  
2.13 PCR arrays 
RNA  was  isolated  from  naïve,  Th1,  Th2,  Th17  or  Treg  cells  using  RNeasy  Plus  
Mini  kit  (Qiagen)  following  the  manufacturers'ʹ  instructions.    1  µμg  total  RNA  was  
subjected  to  single-­‐‑strand  cDNA  synthesis  using  the  RT2  first  strand  kit  (Qiagen).    The  
cDNA  was  used  in  mitochondrial  energy  metabolism  and  glucose  metabolism  
SuperArray  RT2  Profiler  PCR  arrays  were  used  according  to  the  manufacturer’s  
instructions  and  assayed  on  a  ViiA  7  (Applied  Biosystems).  Data  was  analyzed  using  the  
RT2  Profiler  program  supplied  by  Qiagen  and  normalized  to  the  housekeeping  genes  
TATA  box  binding  protein  and  Beta-­‐‑glucuronidase  as  determined  by  GeNorm  in  
accordance  with  the  MIQE  Guidelines.      
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2.14 Human T cell isolation and siRNA 
Peripheral  blood  mononuclear  cells  (PBMC)  were  isolated  from  healthy,  
anonymized  donors  by  density  gradient  centrifugation.  T  cells  were  isolated  by  
magnetic  bead  negative  selection  (≥90%  purity;  Miltenyi  Biotec)  and  cultured  in  RPMI  
1640  (MediaTech)  supplemented  with  10%  FBS  (Gemini  Bio-­‐‑Products),  L-­‐‑glutamine  
(Gibco),  penicillin-­‐‑streptomycin  (Gibco),  and  50µμM  β-­‐‑mercaptoethanol  (β-­‐‑ME)  (Sigma-­‐‑
Aldrich).    Human  siRNA  pools  (Dharmacon:  FoxP3  or  scrambled  pool)  were  transiently  
transfected  by  nucleofection  (Amaxa;  Human  T  cell  Nucleofector  kit  program  U14;  
Lonza)  and  cells  were  rested  4-­‐‑6h  before  stimulation.  Where  indicated  cells  were  
activated  on  plates  coated  with  5µμg/ml  anti-­‐‑CD3  (clone  UCHT1)  and  5µμg/ml  anti-­‐‑CD28  
(eBioscience)  and  stimulated  in  the  presence  of  20ng/ml  IL-­‐‑2  (Novartis).  
  
2.15 Lentiviral PDHK1 shRNA 
PDHK1  shRNA  expressing  and  control  lentiviruses  were  purchased  from  Sigma.    
CD4  T  cells  were  isolated  and  differentiated  as  described  above  and  infected  with  
PDHK1  shRNA  or  control  lentivirus  after  24  hours.    Polybrene  was  added  to  facilitate  
the  infection  and  the  cells  were  centrifuged  for  90  min  at  2500rpm.    After  2  days,  the  cells  
were  split  1:2  and  treated  with  2µμg/mL  puromycin  for  2  days  to  select  for  infected  cells.      
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2.16 Experimental autoimmune encephalomyelitis (EAE) 
EAE  was  induced  as  previously  described  (Michalek  et  al.,  2011b).    Briefly,  
wildtype  mice  were  injected  with  100  ng  MOG  peptide  mixed  with  Complete  Freund'ʹs  
Adjuvant  and  Mycobacterium  tuberculosis  followed  by  1  µμg/mL  pertussis  toxin  
administered  by  i.p  injection  on  days  0  and  2.    DCA  (2g/L)  was  given  to  the  mice  in  their  
drinking  water  where  indicated.    Clinical  signs  of  EAE  were  assessed  according  to  the  
following  score:  0,  no  signs  of  disease;  1,  loss  of  tone  in  the  tail;  2,  hindlimb  paresis;  3,  
hindlimb  paralysis;  4,  tetraplegia.  
  
2.17 Statistical analysis 
Statistical  analyses  were  performed  with  Prism  software  (GraphPad)  using  the  
nonparametric  Mann  Whitney  test.  The  Wilcoxon  signed-­‐‑rank  test  was  used  for  paired  
samples.  Longitudinal  data  was  analyzed  by  two-­‐‑way  ANOVA  followed  by  Tukey’s  
test.  Statistically  significant  results  are  indicated  (*  p  <  0.05)  and  n.s.  indicates  select  non-­‐‑
significant  data.  
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3. The Glucose Transporter Glut1 is Essential for 
Activation and Effector, but Not Regulatory, CD4 T Cell 
Metabolism and Inflammation 
  
3.1 Introduction 
T  cell  activation  initiates  a  transition  from  quiescence  to  rapid  cell  growth,  
proliferation,  and  differentiation  into  functional  subsets  to  drive  or  suppress  the  
immune  response  (Zhu  et  al.,  2010).  Effector  CD4  T  cells  (Teff;  including  Th1,  Th2,  and  
Th17)  promote  immunity  and  are  enriched  in  inflammatory  diseases.  Regulatory  CD4  T  
cells  (Treg),  in  contrast,  suppress  immunity  and  are  decreased  in  number  or  function  in  
these  settings  (Zhu  et  al.,  2010).  Importantly,  the  transition  from  quiescence  to  rapid  
growth  and  proliferation  increases  energetic  and  biosynthetic  demands.  Activated  T  
cells  thus  upregulate  nutrient  uptake  and  metabolic  rates  (MacIver  et  al.,  2013),  resulting  
in  a  significant  elevation  of  glucose  and  amino  acid  transport  (Frauwirth  et  al.,  2002;  
Sinclair  et  al.,  2013;  Wang  et  al.,  2011)  that  may  provide  new  directions  to  modulate  
immunity.    T  cell  metabolism  has  been  shown  in  distinct  settings  to  require  lipid  
synthesis  (Kidani  et  al.,  2013)  or  oxidation  (Byersdorfer  et  al.,  2013;  Gatza  et  al.,  2011),  
mitochondrial  reactive  oxygen  species  (Sena  et  al.,  2013),  and  amino  acid  uptake  (Sinclair  
et  al.,  2013).  However,  the  in  vivo  mechanism  and  roles  of  increased  glucose  uptake  and  
metabolism  in  T  cell-­‐‑mediated  inflammatory  diseases  remain  uncertain.  
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It  is  now  evident  that  metabolic  reprogramming  is  shaped  to  support  specific  cell  
functions  (MacIver  et  al.,  2013).  In  vitro  generated  Teff  strongly  induce  glycolysis  and  
decrease  lipid  oxidation  (Michalek  et  al.,  2011a;  Shi  et  al.,  2011;  Wang  et  al.,  2011).  In  
contrast,  in  vitro  induced  Treg  and  memory  CD8  T  cells  utilize  lipid  oxidation  as  a  
primary  metabolic  pathway  (Michalek  et  al.,  2011a;  Pearce  et  al.,  2009;  Shi  et  al.,  2011).  
These  metabolic  programs  provide  distinct  metabolites  (MacIver  et  al.,  2013),  signaling  
through  the  mTORC1  pathway  (Sinclair  et  al.,  2013),  and  cytokine  production  (Cham  
and  Gajewski,  2005;  Chang  et  al.,  2013).  Importantly,  induced  Teff  and  Treg  may  be  
differentially  sensitive  to  glycolytic  inhibition,  as  in  vitro  glucose  limitation  or  2DG  
treatment  suppressed  Th17  but  not  Treg  cells  (Michalek  et  al.,  2011a;  Shi  et  al.,  2011).  
Because  these  pharmacologic  approaches  result  in  broad  non-­‐‑specific  effects  that  impact  
all  cells,  mechanistic  insight  has  been  limited.  A  genetic  approach  is  needed  to  establish  
the  cell-­‐‑intrinsic  roles  of  glucose  metabolism  in  T  cell  activation  and  regulation  of  
inflammation.  
Glucose  uptake  provides  a  key  metabolic  control  point  through  the  Glut  family  
of  facilitative  glucose  transporters.  The  fourteen  Glut  family  members  are  differentially  
regulated  and  possess  distinct  substrates  and  biological  properties  (Thorens  and  
Mueckler,  2010).  The  array  of  Glut  transporters  utilized  by  T  cells  in  activation  and  
differentiation  has  not  yet  been  defined.  In  vitro  stimulated  murine  and  human  T  cells  
express  high  levels  of  Glut1  (Slc2a1)  (Frauwirth  et  al.,  2002;  Jacobs  et  al.,  2008)  and  Teff  
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cells  maintain  higher  levels  of  Glut1  than  Treg  (Michalek  et  al.,  2011a).  Glut1  can  
promote  Teff,  as  transgenic  Glut1  overexpression  selectively  increased  Teff  frequency  
and  led  to  inflammatory  disease  (Jacobs  et  al.,  2008;  Michalek  et  al.,  2011a).  
Here  we  examine  the  Glut  transporter  family  to  directly  test  the  role  and  
mechanisms  that  control  T  cell  glucose  uptake  and  metabolism  in  activation  and  in  
inflammatory  disease.  Although  T  cells  expressed  four  distinct  glucose  transporter  
isoforms,  genetic  targeting  showed  a  selective  role  for  Glut1  in  proliferative  thymocytes  
and  Teff  cells.  While  resting  murine  and  human  T  cells  were  independent  of  Glut1,  Teff  
required  Glut1  for  efficient  expansion  and  specification  in  vivo.  In  contrast,  both  natural  
and  induced  Treg  were  independent  of  Glut1.  As  a  result,  Glut1-­‐‑deficient  Teff  were  
unable  to  effectively  induce  either  Graft-­‐‑vs-­‐‑Host  Disease  (GvHD)  or  colitis,  while  Treg  
could  protect  against  colitis  independent  of  Glut1.  Thus,  Glut1  has  a  selective  cell-­‐‑
intrinsic  function  in  T  cell  metabolic  reprogramming  to  drive  glycolysis  of  Teff  for  
growth,  expansion,  and  inflammatory  disease.  
  
3.2 Results 
3.2.1 T cells express a subset of dynamically regulated Glut family 
transporters 
The  mechanism  of  glucose  uptake  and  role  of  Glut  family  glucose  transporters  in  
activation-­‐‑induced  glucose  uptake  in  T  cells  has  not  been  directly  established.  The  
absolute  expression  of  each  Glut  family  member  was,  therefore,  mRNA  transcript  copy  
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number  was  quantified  in  resting  and  activated  murine  T  cells  (Fig.  3.1A).  Of  the  
thirteen  glucose  transporter  family  members  measured,  only  Glut  1,  3,  6,  and  8  were  
detected.  Slc2a1  (Glut1)  and  Slc2a3  (Glut3)  mRNA  were  equally  expressed  in  resting  
CD4  T  cells.  Following  activation,  Slc2a1  (Glut1)  was  induced  or  sustained,  while  Slc2a3  
(Glut3)  mRNA  became  less  prominent.  Slc2a6  (Glut6)  was  also  induced  with  activation,  
but  remained  at  lower  copy  number  than  Slc2a1  (Glut1).  Glut  family  member  expression  
was  also  measured  in  induced  Th1,  Th2,  Th17,  and  Treg  (Fig.  3.1B).  Again,  Gluts  1,  3,  6,  
and  8  were  the  only  detectable  Glut  transporters,  and  while  each  T  cell  subset  had  a  
distinct  transporter  profile,  Glut1  was  found  in  the  highest  copy  number  in  each  case.  Of  
note,  differentiated  cells  expressed  Glut3  more  similarly  to  Glut1.  
In  addition  to  mRNA  levels,  the  trafficking  of  Glut1  to  the  cell  surface  is  also  
highly  regulated  (Edinger  and  Thompson,  2002;  Wieman  et  al.,  2007).  Glut1  protein  
levels  and  trafficking  were  therefore  examined  during  T  cell  activation.  Because  
available  antibodies  react  poorly  with  the  extracellular  domains  of  Glut1,  Glut1myc  
knock-­‐‑in  mice  were  used  to  measure  cell  surface  Glut1  in  T  cell  development  and  
activation.  In  this  model  a  tandem-­‐‑Myc  tag  was  knocked  into  exon  3  of  Slc2a1,  which  
encodes  the  large  exofacial  loop  of  Glut1,  enabling  sensitive  and  specific  flow  cytometric  
measurement  of  endogenous  cell  surface  Glut1  using  antibodies  against  the  Myc  epitope  
(Michalek  et  al.,  2011a).  
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Increased  total  intracellular  expression  of  Glut1myc  was  detected  within  two  
hours  of  CD3  and  CD28  stimulation.  Cell  surface  levels  of  Glut1myc  increased  more  
slowly,  but  elevated  Glut1myc  surface  expression  were  measurable  within  four  hours  of  
stimulation  and  maximal  after  24  hours  (Fig.  3.1C).  Consistent  with  previous  data  
implicating  the  PI3K-­‐‑Akt-­‐‑mTORC1  pathway  in  the  regulation  of  Glut1  expression  and  
trafficking  (Frauwirth  et  al.,  2002;  Wieman  et  al.,  2007),  inhibitors  of  PI3K  (LY294002),  
PI3K/mTOR  kinase  (PP242),  or  mTORC1  (rapamycin)  suppressed  the  induction  of  cell  
surface  Glut1  (Fig.  3.1D).  Glut1  upregulation  and  cell  surface  trafficking  is,  therefore,  an  




Figure  3.1:  Glut1  is  selectively  and  rapidly  increased  in  murine  T  cell  activation.  
  (A,   B)  Glut   family  mRNA   copy   number   in   (A)   naïve   and  CD3/CD28-­‐‑stimulated  CD4  
murine  T  cells,  and  (B)  in  vitro  polarized  CD4  T  cell  subsets.  N.D.:  not  detected.  
(C,  D)  Glut1myc  expression  in  CD3/CD28  stimulated  CD4  Glut1myc  T  cells  (C)  over  time  
and   (D)   with   inhibitors   or   vehicle   control.   Mean   ±   SD   from   3   or   more   independent  












































































N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 



























































N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. N.D. 









24h 8h 4h 2h 1h 15’ 0h 
4.7 3.0 0.9 5.4 25.1 45.9 81.1 
24h 8h 4h 2h 1h 15’ 0h 
total Glut1myc 
9.8 15.0 12.7 43.3 55.2 78.6 89.3 
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3.2.2 Glut1 is required for growth and proliferation of mature T cells 
Based  on  the  dynamic  expression  of  Glut1,  the  specific  role  of  this  transporter  
was  tested  in  T  cell  development  and  activation.  Glut1fl/fl  mice  (Young  et  al.,  2011)  were  
crossed  with  LckCre  transgenic  mice  to  specifically  delete  Glut1  in  early  DN  thymocytes.  
Total  thymocyte  numbers  were  reduced  60-­‐‑70%  in  LckCreGlut1fl/fl  mice  compared  to  
control  animals  (data  not  shown).    To  bypass  potential  developmental  defects,  Glut1fl/fl  
mice  were  crossed  to  CD4Cre  transgenic  mice,  which  delete  loxP  flanked  genes  in  the  
DP  to  SP  transition  following  the  proliferative  DN3-­‐‑DN4  stage  in  thymopoiesis.  
Thymocyte  numbers  and  phenotype  were  normal  in  CD4CreGlut1fl/fl  mice  (data  not  
shown).    Additionally,  resting  peripheral  T  cells  do  not  require  Glut1  for  survival.      
The  decreased  numbers  of  LckCreGlut1fl/fl  thymocytes  after  the  proliferative  
DN3-­‐‑DN4  phase  and  apparent  Glut1-­‐‑independence  of  resting  T  cell  survival  suggested  
that  Glut1  is  selectively  required  to  support  proliferation.  To  test  the  dependence  of  
peripheral  T  cells  on  Glut1  for  activation-­‐‑induced  proliferation,  Ovalbumin  (Ova)-­‐‑
specific  OT-­‐‑II  T  cell  receptor  (TCR)  transgenic  control  or  CD4CreGlut1fl/fl  CD4  T  cells  
were  labeled  with  the  proliferation  dye  CellTrace  Violet  (CTV)  and  adoptively  
transferred  into  Thy1.1  hosts  that  were  then  immunized  with  Ova.  Importantly,  Glut1-­‐‑
deficient  CD4  T  cells  had  reduced  proliferation  (Fig.  3.2A).  We  also  tested  the  ability  of  
Glut1-­‐‑deficient  T  cells  to  undergo  homeostatic  proliferation  after  adoptive  transfer  into  
irradiated  and  lymphopenic  recipients.  Consistent  with  a  need  for  Glut1  to  allow  
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proliferation  in  vivo,  Glut1-­‐‑deficient  CD8  and  CD4  T  cells  underwent  only  limited  
homeostatic  proliferation  (Fig.  3.2B).  
T  cells  were  stimulated  in  vitro  to  examine  mechanisms  that  suppressed  
proliferation  and  accumulation  of  Glut1-­‐‑deficient  T  cells  in  vivo.  Importantly,  in  vitro  
stimulated  Glut1-­‐‑deficient  T  cells  grew  very  poorly,  as  evidenced  by  a  failure  to  increase  
forward  light  scatter  by  flow  cytometry  (Fig.  3.2C).  Further,  activation  sufficient  to  drive  
the  proliferation  of  control  T  cells  failed  to  induce  proliferation  (Fig.  3.2D)  and  instead  
led  to  rapid  induction  of  cell  death  of  many  LckCreGlut1fl/fl  T  cells  (Fig.  3.2E).  Glut1-­‐‑
deficient  T  cells  that  survived  this  initial  period  of  activation  appeared  under  metabolic  
stress  and  had  increased  levels  of  phospho-­‐‑AMPK  (Fig.  3.2F)  and  failed  to  sustain  
activated  mTORC1  signaling,  as  assessed  by  phosphorylation  of  the  downstream  p70  S6  
kinase  target,  small  ribosomal  subunit  S6  (Fig.  3.2G).  The  mTOR  pathway  can  broadly  
regulate  nutrient  uptake  (McCracken  and  Edinger,  2013),  and  the  transferrin  receptor  
(CD71)  and  the  4F2hc  amino  acid  transporter  (CD98)  were  not  efficiently  induced  in  
activated  Glut1-­‐‑deficient  T  cells  (data  not  shown).  Most  signaling  pathways,  however,  
were  unchanged,  as  cMyc  was  induced  and  phospho-­‐‑Akt  and  -­‐‑ERK  were  equivalent  or  
only  modestly  reduced  and  activation  markers  were  normal  in  activated  Glut1-­‐‑deficient  
T  cells  (data  not  shown).  
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Figure  3.2:  Glut1  is  necessary  to  support  activation-­‐‑induced  growth,  
proliferation  and  survival  
(A,   B)   Proliferation   of   CellTrace   Violet   (CTV)   labeled   control   (Glut1fl/fl)   and  
CD4CreGlut1fl/fl   (A)   OT-­‐‑II   transgenic   T   cells   on   day   3   after   adoptive   transfer   ±  
immunization  with  Ovalbumin  or  (B)  T  cells  6  days  after  adoptive  transfer  into  intact  or  
irradiated   recipients   for   homeostatic   proliferation.   (C)   Control   (Glut1fl/fl)   and  
LckCreGlut1fl/fl  T  cells  were  rested  in  IL-­‐‑7  or  CD3/CD28-­‐‑  and  cell  size  (forward  scatter)  of  
viable   cells  was  determined  by   flow   cytometry   after   24h.   (D,  E)  Control   (Glut1fl/+)   and  



































































































stimulated   and   examined   by   flow   cytometry   for   (D)   proliferation   at   72   hours   or   (E)  
viability   over   time.   (F)   Control   (Glut1fl/fl)   and  CD4CreGlut1fl/fl   T   cells  were  CD3/CD28-­‐‑
stimulated  16h  and  analyzed  by  immunoblot.  (G)  Control  (Glut1fl/fl)  and  CD4CreGlut1fl/fl  
T  cells  were  rested  in  IL-­‐‑7  or  CD3/CD28-­‐‑stimulated  for  10h  and  analyzed  by  intracellular  
flow   cytometry   and   immunoblot.   Data   are   representative   of   n=3  mice/group   (A,   B)   a  
minimum  of   (F,  G)   2   or   (C-­‐‑E)   3   experiments.   (E)   Shows  mean   ±   SD   of   3   independent  
experiments.    AN  Macintyre:  C-­‐‑G.  
  
  
3.2.3 Glut1 is necessary to support T cell metabolic reprogramming 
upon activation 
Glucose  uptake  and  glycolysis  were  measured  in  resting  and  activated  T  cells  to  
assess  the  metabolic  role  of  Glut1.  Consistent  with  a  selective  role  in  activation,  resting  
IL-­‐‑7  treated  peripheral  T  cells  did  not  rely  on  Glut1  and  had  similar  rates  of  glucose  
uptake,  glycolysis,  and  lactate  production  regardless  of  Glut1  expression  (Fig.  3.3A,  B,  
C).  However,  while  control  T  cells  rapidly  increased  glucose  metabolism  after  activation,  
stimulated  LckCreGlut1fl/fl  T  cells  maintained  only  a  basal  rate  of  glucose  uptake  and  
greatly  reduced  glycolytic  rate  (Fig.  3.3A,  B).  Likewise,  stimulated  CD4CreGlut1fl/fl  T  
cells  failed  to  increase  lactate  production  when  measured  directly  or  by  extracellular  
acidification  rate  (ECAR)  (Fig.  3.3C,  D).  As  a  consequence,  activated  Glut1-­‐‑deficient  T  
cells  had  reduced  glycolytic  capacity  (Fig.  3.3E)  and  an  elevated  ratio  of  oxygen  
consumption  rate  (OCR)  to  ECAR  (Fig.  3.3F).  Glut1  is,  therefore,  essential  for  rapid  
metabolic  reprogramming  to  aerobic  glycolysis  for  maximal  growth,  survival,  and  
proliferation  of  in  vitro  stimulated  T  cells.  
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Figure  3.3:  Glut1  is  required  for  activation-­‐‑induced  metabolic  reprogramming  
(A,   B)   Control   (Glut1fl/fl)   and   LckCreGlut1fl/fl   T   cells  were   rested   in   IL-­‐‑7   or   CD3/CD28-­‐‑
stimulated  and  (A)  glucose  uptake  or   (B)  glycolytic  rate  was  measured  after  16h.   (C-­‐‑F)  
Control   (Glut1fl/fl)   and   CD4CreGlut1fl/fl   T   cells   were   rested   in   IL-­‐‑7   or   CD3/CD28-­‐‑
stimulated   for   16h.   (C)   Total   lactate   produced   was   measured.   (D)   Extracellular  
acidification   rate   (ECAR)  was  assessed  after   the  addition  of  glucose   (gluc),  oligomycin  
(oligo),  and  2-­‐‑deoxyglucose  (2-­‐‑DG)  at  indicated  times  and  (E)  glycolytic  capacity  and  (F)  
Oxygen  Consumption  Rate  (OCR)/ECAR  ratio  determined.  Mean  ±  SD  (n=4)  are  shown  
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3.2.4 Glut1 is required for Teff, but not nTreg or iTreg, generation  
We  and  others  have  previously  shown  in  vitro  that  murine  Teff  (Th1,  Th2,  and  
Th17)  utilize  a  highly  glycolytic  metabolism  while  Treg  are  primarily  oxidative  and  use  
lipids  as  a  fuel  (Michalek  et  al.,  2011a).    Control  and  Glut1-­‐‑deficient  Teff  and  Treg  were  
therefore  examined  to  test  the  selective  dependence  of  CD4  subsets  on  Glut1.  
Interestingly,  while  overall  peripheral  T  cell  numbers  and  frequency  were  lower  in  the  
spleen  of  LckCreGlut1fl/fl  mice,  the  CD4+  FoxP3+  natural  Treg  (nTreg)  population  was  not  
decreased  and  only  FoxP3  negative  cells  were  reduced  (Fig.  3.4A).  This  selective  loss  of  
FoxP3-­‐‑  cells  led  to  an  increase  in  FoxP3+  nTreg  in  the  peripheral  CD4  T  cell  compartment  
(Fig.  3.4B).  Naïve  CD4  T  cells  can  be  induced  to  differentiate  into  Th1,  Th2,  Th17,  or  Treg  
subsets  in  appropriate  cytokine  conditions  (Zhu  et  al.,  2010).  CD4  T  cells  from  control  
and  CD4CreGlut1fl/fl  mice  were  therefore  activated  in  vitro  under  polarizing  conditions  to  
generate  Teff  and  Treg.  The  addition  of  cytokines  reduced  activation-­‐‑induced  cell  death,  
allowing  generation  of  each  subset.  The  surviving  cells  in  each  case  remained  Glut1-­‐‑
deficient  (Fig.  3.4C).  Importantly,  the  viable  cell  number  in  each  Teff  culture  and  the  
fraction  of  viable  cytokine  producing  cells  in  Th1  and  Th17  cultures  were  reduced  by  
Glut1-­‐‑deficiency  (Fig.  3.4D).  Conversely,  induced  Treg  cultures  were  unaffected  by  
Glut1-­‐‑deletion  and  maintained  normal  cell  numbers,  fraction  positive  for  FoxP3,  and  
ability  to  suppress  Teff  proliferation  (Fig.  3.4D,  E).    
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Figure  3.4:  Glut1  is  required  for  Teff,  but  not  Treg,  generation  or  function  
(D,  E)  Flow  cytometry  of  control  (Glut1fl/fl)  and  LckCreGlut1fl/fl  spleen  for  FoxP3+  CD4  T  
cells.   (D)   Representative   plot   and   (E)   cumulative   data   of   fraction   of   CD4   T   cells  
expressing  FoxP3.  (F-­‐‑H)  Th1,  Th2,  Th17,  and  Treg  were  induced  using  control  (Glut1fl/+,  
Glut1fl/fl)   and   CD4CreGlut1fl/fl   CD4   T   cells   and   analyzed   by   (F)   immunoblot,   (G)   flow  
cytometry   to   determine   the   number   of   live   skewed   cells   and   percentage   of   live   cells  
expressing  subset  markers.  (H)  Treg  function  was  tested  in  an  in  vitro  suppression  assay.  
























































































































































The  normal  number  and  function  of  Glut1-­‐‑deficient  Treg  did  not  appear  due  to  
compensation  by  alternate  glucose  transporters,  as  Gluts  3  and  8  were  unchanged  and  
expressed  at  low  levels  and  Glut6  was  only  modestly  increased  by  Glut1-­‐‑deletion  (Fig.  
3.5).  Rather,  these  data  suggest  that  Teff,  but  not  Treg,  are  Glut1-­‐‑dependent.  
  
  
Figure  3.5:  Glut  transporter  compensation  for  Glut1  loss  in  T  cell  subsets  
CD4  T  cells   from  control   (Glut1fl/+,  Glut1fl/fl)  and  CD4CreGlut1fl/fl  mice  were  collected  ex  
vivo  (naïve),  stimulated  for  24  hours  (24h  CD3/CD28)  or  polarized   in  vitro  for  3  days  to  
generate  Th1,  Th2,  Th17  or  Treg  cells.    Glut  family  mRNA  copy  number  was  measured  
in  naïve,   stimulated  or  differentiated  CD4  T  cells   from  control   (Ctrl)  or  knockout  mice  
(KO).     Data  shown  are  mean  ±  SD  of  pooled  T  cell  mRNA  from  2  mice.     MC  Rudolph  
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3.2.5 Glut1 is required for Teff expansion in colitis 
Colitis  is  driven  by  Th1  and  Th17  Teff  and  suppressed  by  Treg  (Brand,  2009).  The  
requirement  of  Teff  for  Glut1  to  induce  IBD  was  first  tested  using  an  adoptive  transfer  
model  (Mottet  et  al.,  2003)  in  which  sorted  naïve  control  and  CD4CreGlut1fl/fl  T  cells  were  
transferred  into  immunodeficient  Rag1-­‐‑/-­‐‑  recipients.  The  NSAID  piroxicam  was  given  
two  weeks  after  T  cell  transfer  to  induce  gut  damage  and  trigger  disease.  Importantly,  
CD4CreGlut1fl/fl  T  cells  were  unable  to  effectively  promote  IBD  as  indicated  by  weight  
loss  (Fig.  3.6A;  day  0  indicates  the  start  of  piroxicam  treatment),  while  control  T  cells  
induced  significant  weight  loss  over  time.    CD4CreGlut1fl/fl  T  cells  lacked  Glut1  
throughout  the  course  of  the  experiment  (Fig.  3.6B).    Importantly,  both  total  (Fig.  3.6C)  
and  cytokine  producing  (Fig.  3.6D,  E)  T  cell  numbers  were  decreased  by  Glut1-­‐‑
deficiency.  
To  test  if  acute  deletion  of  Glut1  also  affected  IBD,  sorted  naïve  T  cells  or  nTreg  
from  control  or  UbiCreERT2Glut1fl/fl  mice  were  adoptively  transferred  individually  or  in  
combination  into  Rag1-­‐‑/-­‐‑  hosts.  After  two  weeks  to  allow  homeostatic  expansion,  mice  
were  treated  with  piroxicam  to  trigger  IBD  followed  by  tamoxifen  to  activate  CreERT2  
and  delete  Glut1  in  Teff  or  Treg  subsets  in  vivo.  Although  Glut1  deletion  was  
incomplete  (Fig.  3.7A),  UbiCreERT2Glut1fl/fl  T  cells  failed  to  induce  inflammation,  gut  
hyperplasia  or  granuloma,  which  were  observed  with  control  T  cells  (Figs.  3.7B  panels  i  
and  ii).  Broadly  scoring  colitis  including  architectural  distortion,  crypt  abscesses,  
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severity  of  inflammation,  ulceration,  and  percent  of  bowel  affected,  suggested  mice  that  




Figure  3.6:  Glut1  is  required  for  Teff  expansion  and  function  in  colitis  
Naïve   control   (Glut1fl/fl)   or  CD4CreGlut1fl/fl   Teff  were   transferred   into   Rag1-­‐‑/-­‐‑  hosts   and  
colitis  was  triggered  2  weeks  later  via  piroxicam  (Pirox;  day  0  on  start  of  Pirox)  exposure  
and   animal  weights  measured   over   time   (A).      (B)  Glut1   expression   by   immunoblot   of  
CD4  T  cells  isolated  from  the  spleen  and  mesenteric  lymph  nodes  of  control  (Glut1fl/fl)  or  
CD4CreGlut1fl/fl  T  cells  4-­‐‑5  weeks  later.    (C)  The  number  of  CD4  T  cells  or  (D,  E)  IFNγ  or  
































































































Figure  3.7:  T  cell  expression  of  Glut1  is  required  for  severe  colitis  
Rag   1-­‐‑/-­‐‑  mice  were   reconstituted   intraperitoneally   via   injection   of   naïve   effector   Rag1-­‐‑/-­‐‑  
mice   were   injected   with   control   (CreERGlut1+/+,   Glut1fl/fl)   or   CreERGlut1fl/fl   naïve   Teff.  
Colitis  was  triggered  by  piroxicam  exposure  2  weeks  after  T  cell  transfer.  Animals  were  
then   treated  with   tamoxifen   to   activate   Cre.   (A)   CD4   T   cells  were   isolated   and  Glut1  
expression   was   examined   by   immunoblot.      (B)   H&E   stained   colon   sections   were  
examined   by   microscopy   and   assessed   for   colitis   severity;   a   score   above   22   indicates  
moderate  to  severe  colitis.    (C)  H&E  histology  of  proximal  colon  from  mice  that  received  
(i)   naïve   control   T   cells,   (ii)   naïve  CreERGlut1fl/fl   T   cells,   (iii)   naïve   control   T   cells   plus  
control  Treg,  or  (iv)  naïve  control  T  cells  plus  CreERGlut1fl/fl  Treg.  Bar  indicates  100µμm;  
arrow   indicates  cryptic  abssess  and  arrowhead   indicates  a  granuloma.     Data   (A-­‐‑C)  are  
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3.2.6 Glut1 is required in vivo for Teff but not Treg expansion in 
colitis 
UbiCreERT2Glut1fl/fl  T  cells  failed  to  induce  inflammation  and  were  resistant  to  
severe  colitis  (Fig.  3.7).    Importantly,  total  numbers  of  Glut1-­‐‑deficient  CD4  T  cells  in  the  
spleen  and  mesenteric  lymph  nodes  were  significantly  reduced  relative  to  control  T  cells  
4  weeks  after  tamoxifen  treatment  (Fig.  3.8A).  Glut1-­‐‑deletion  also  reduced  cytokine  
production  by  CD4  Teff,  as  fewer  IFNγ  and  IL-­‐‑17-­‐‑producing  cells  were  present  in  mice  
receiving  Glut1-­‐‑deficient  T  cells  (Fig.  3.8B,  C).  
Importantly,  Glut1-­‐‑deficient  Treg  remained  functional  in  vivo  and  capable  of  
inhibiting  Teff  in  IBD.  Glut1-­‐‑deficient  nTreg  suppressed  Teff  expansion  similar  to  wild  
type  nTreg,  as  total  CD4+  cell  numbers  in  the  spleen  and  mesenteric  lymph  nodes  and  
gut  pathology  were  identical  when  control  or  Glut1-­‐‑deficient  nTreg  were  transferred  
together  with  control  Teff  cells  (Fig.  3.7C  panels  iii  and  iv,  8D).  Thus,  while  Teff  
populations  require  Glut1  expression  to  drive  inflammatory  colitis,  Treg  can  suppress  
Teff-­‐‑mediated  inflammatory  Teff  expansion  irrespective  of  Glut1  expression.  
Dependence  of  activated  T  cells  and  Teff  on  Glut1  may,  therefore,  allow  selective  
targeting  of  T  cell  glucose  metabolism  to  suppress  inflammatory  responses  and  promote  
tolerance  and  immune  suppression.  
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Figure  3.8:    Glut1  is  acutely  required  for  Teff,  but  not  Treg,  expansion  and  
function  in  colitis  
Rag1-­‐‑/-­‐‑  mice  were   injected  with   control   (CreERGlut1+/+,  Glut1fl/fl)   or  CreERGlut1fl/fl   naïve  
Teff.  Colitis  was  triggered  by  piroxicam  exposure  2  weeks  after  T  cell  transfer.  Animals  
were  then  treated  with  tamoxifen  to  activate  Cre.    (A)  The  number  of  CD4  or  (B,  C)  IFNγ  
or   IL-­‐‑17   producing   T   cells   in   the   spleen   and   mesenteric   (mes)   lymph   nodes   was  
determined  after  4  weeks  by  flow  cytometry.  (D)  Rag1-­‐‑/-­‐‑  mice  were  co-­‐‑injected  with  wild  
type  naïve  Teff  and  either  control  (CreERGlut1+/+,  Glut1fl/fl)  or  CreERGlut1fl/fl  nTreg.  Mice  
were  treated  after  2  weeks  with  piroxicam  and  tamoxifen  to  trigger  IBD  and  activate  Cre  
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3.3 Discussion 
The  in  vivo  metabolic  demands  of  T  cell  activation,  proliferation,  and  
differentiation  and  the  programs  that  T  cells  initiate  to  support  these  needs  may  provide  
new  targets  to  modulate  the  immune  response  (MacIver  et  al.,  2013).    In  vivo,  T  cells  
require  mitochondrial  ROS  (Sena  et  al.,  2013),  lipid  synthesis  (Kidani  et  al.,  2013),  and  
amino  acid  uptake  (Sinclair  et  al.,  2013).    The  mechanism  and  role  of  glucose  uptake  in  T  
cell  homeostasis,  activation,  and  differentiation  have  not  been  directly  tested  in  vivo.    
Here,  our  approach  that  directly  targeted  the  first  step  of  glucose  metabolism  by  genetic  
deletion  of  Glut1  identified  a  selective  reliance  on  this  glucose  transporter  in  T  cell  
proliferation  and  CD4  Teff  expansion  to  induce  GvHD  and  colitis,  while  Treg  are  Glut1-­‐‑
independent.  
In  addition  to  the  cMyc  (Wang  et  al.,  2011)  and  Estrogen  Related  Receptor  α  
(ERRα)  (Michalek  et  al.,  2011a)  transcription  factors  that  regulate  T  cell  metabolism,  
mTOR  and  the  PI3K-­‐‑Akt-­‐‑mTOR  complex  1  (mTORC1)  signaling  pathway  can  promote  
Glut1  cell  surface  trafficking,  glycolysis,  and  lipid  synthesis  (Duvel  et  al.,  2010;  Wieman  
et  al.,  2007)  and  Teff  (Waickman  and  Powell,  2012).    T  cell-­‐‑specific  deletion  of  mTOR  
kinase  to  eliminate  both  mTORC1  and  mTORC2  prevented  generation  of  Teff,  but  
allowed  establishment  of  functional  Treg  (Delgoffe  et  al.,  2009).    Conversely,  specific  
deletion  of  mTORC1  activation  or  components  has  been  shown  in  distinct  settings  to  not    
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affect  (Delgoffe  et  al.,  2011)  or  to  prevent  (Zeng  et  al.,  2013)  Treg  suppressive  function.  
These  data  suggest  that  mTOR-­‐‑driven  glucose  or  lipid  metabolism  may  be  critical  for  
Treg  (Zeng  et  al.,  2013).    However,  decreased  mTORC1  signaling  can  lead  to  exacerbated  
mTORC2  activity  (Zeng  et  al.,  2013)  that  can  also  promote  glycolytic  metabolism  (Gubser  
et  al.,  2013;  Masui  et  al.,  2013)  and  may  thus  suppress  Treg  activity.    Indeed  simultaneous  
deletion  of  essential  mTORC1  and  mTORC2  components  or  mTOR  itself  restored  Treg  
function  (Delgoffe  et  al.,  2009;  Zeng  et  al.,  2013).    This  complex  interplay  between  the  
multiple  mTOR-­‐‑induced  signaling  and  metabolic  events  has  hindered  mechanistic  
interpretation  of  the  specific  role  of  metabolic  regulation  in  T  cell  function  and  fate.    Our  
studies  directly  test  the  role  of  Glut1  upregulation  in  T  cell  activation  and  subsets  to  
show  a  selective  Glut1-­‐‑dependence  of  activated  Teff  and  Glut1-­‐‑independence  of  Treg.  
Glucose  uptake  is  mediated  through  the  fourteen-­‐‑member  Glut  transporter  
family,  of  which  we  show  CD4  T  cells  express  Gluts1,  3,  6,  and  8.    Each  was  regulated  in  
T  cell  activation  and  differentiation,  with  highest  expression  of  Glut1  and  Glut3.    Gluts  6  
and  8  were  expressed  at  relatively  low  levels  and  their  specific  roles  are  unclear  at  this  
time.    The  high  Glut3  expression  and  Glut1-­‐‑independence  of  resting  T  cells  and  CD8  Teff  
suggests  a  role  for  Glut3-­‐‑mediated  glucose  uptake.    While  CD4  Teff  cells  were  reliant  on  
Glut1-­‐‑directed  metabolism,  functional  Treg  could  be  generated  from  naïve  T  cells  
lacking  Glut1,  despite  expressing  only  low  levels  of  Glut3.    These  data  are  consistent  
with  Treg  use  of  mitochondrial  oxidative  pathways  rather  than  glucose  metabolism  
  73  
(Michalek  et  al.,  2011b;  Shi  et  al.,  2011).    In  support  of  an  alternate  metabolic  program,  
Treg  can  be  generated  in  the  absence  of  glucose  (Michalek  et  al.,  2011b)  or  in  the  
presence  of  2DG  (Shi  et  al.,  2011).  
Despite  simultaneous  expression  of  multiple  glucose  transporters,  our  data  
demonstrate  a  specific  requirement  for  Glut1  in  both  activated  mouse  and  human  T  cells  
in  vitro  and  in  vivo.    The  Glut1-­‐‑dependent  molecular  switch  to  elevate  glycolysis  was  
critical  for  rapid  human  T  cell  growth  and  proliferation,  as  Glut1  knockdown  
suppressed  glycolysis  and  slowed  the  transition  of  human  T  cells  from  quiescence  to  
proliferation.    Likewise,  activation  of  murine  cells  led  to  a  dependence  on  Glut1  to  
support  cell  growth,  proliferation,  and  prevention  of  apoptosis.    Thymocytes  in  the  
proliferative  DN3-­‐‑DN4  transition  expressed  Glut1  at  a  high  level  and  were  also  sensitive  
to  Glut1-­‐‑deficiency.    In  the  absence  of  Glut1,  activated  mature  T  cells  failed  to  increase  
glucose  uptake  and  glycolysis  beyond  resting  levels,  had  selectively  reduced  growth  and  
proliferation,  and  many  cells  underwent  apoptosis.    These  broad  inhibitory  effects  of  
Glut1-­‐‑deficiency  were  potentially  due  to  AMPK  activation  and  suppression  of  mTORC1  
in  vitro  and  in  vivo  that  resulted  in  fewer  inflammatory  cytokine-­‐‑producing  cells.  
The  differential  requirements  of  specific  T  cell  populations  for  Glut1  may  reflect  
specific  functional  needs  for  a  highly  glycolytic  metabolism.    Aerobic  glycolysis  is  
closely  linked  with  cell  growth  to  generate  increased  mass  for  cell  proliferation  (Vander  
Heiden  et  al.,  2009)  and  Glut1-­‐‑deficient  T  cells  failed  to  grow  after  stimulation.  
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Proliferation  was  also  suppressed  and  cell  death  increased,  possibly  as  a  consequence  of  
inadequate  nutrients  to  support  biosynthesis  and  prevent  AMPK  suppression  of  
mTORC1.    In  addition,  Glut1-­‐‑deficient  CD4  Teff  cells  also  had  reduced  production  of  
IFNγ.  Glucose-­‐‑deprivation  has  been  shown  to  lead  to  a  specific  reduction  of  IFNγ  
production  in  vitro  (Cham  and  Gajewski,  2005;  Jacobs  et  al.,  2008)  and  glycolytic  flux  has  
been  implicated  in  IFNγ  translation  (Chang  et  al.,  2013).    Indeed,  we  found  both  reduced  
cell  numbers  and  decreased  inflammatory  cytokine  production  by  Glut1-­‐‑deficient  Th1  
and  Th17.    In  contrast  to  Teff,  our  data  show  that  Treg  do  not  require  Glut1  and  appear  
to  utilize  an  alternate  metabolic  program  in  vitro  and  in  vivo.    It  remains  to  be  
determined,  however,  if  Treg  induce  aerobic  glycolysis  using  an  alternate  glucose  
transporter  or  if  they  proliferate  using  a  distinct  metabolic  program.    The  metabolic  
requirements  of  different  T  cell  activation  states  and  subsets  may  also  play  a  broad  role  
in  immune  homeostasis  or  disease,  supporting  specific  T  cell  populations  in  distinct  
tissues  and  immunologic  settings.  
Identifying  biochemical  requirements  for  T  cell  activation  and  the  generation  of  
effector  and  regulatory  T  cells  has  been  a  long  sought  goal  in  efforts  to  treat  
inflammatory  diseases.    Mechanisms  that  control  cell  metabolism  to  support  the  specific  
functional  needs  of  these  cells  have  been  described  only  recently  (MacIver  et  al.,  2013),  
but  have  proven  promising  (Bian  et  al.,  2009;  Eleftheriadis  et  al.,  2013;  Ostroukhova  et  al.,  
2012;  Shi  et  al.,  2011).    To  date,  pharmacologic  approaches  have  provided  limited  
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mechanistic  insight,  and  the  role  of  glucose  uptake  has  been  uncertain.    Data  presented  
here  demonstrate  that  despite  expression  of  multiple  Glut  family  transporters,  Glut1  is  
specifically  required  for  the  cell-­‐‑intrinsic  metabolic  program  of  activated  T  cells  and  CD4  
Teff  in  vitro  and  in  vivo  to  drive  inflammation  in  both  colitis  and  GvHD.    These  data  
show  that  despite  a  potential  requirement  for  lipid  oxidation  (Byersdorfer  et  al.,  2013;  
Gatza  et  al.,  2011),  Glut1  is  central  in  the  metabolism  of  Teff  and  in  GvHD.  Glut1,  
however,  is  not  required  in  all  settings,  as  resting  T  cells,  CD8  Teff,  and  Treg  were  
capable  of  Glut1-­‐‑independent  function.    Collectively,  these  findings  demonstrate  that  
distinct  T  cell  subsets  utilize  selective  metabolic  programs  with  differing  dependence  on  
Glut1.    Understanding  the  roles  and  regulations  of  specific  nutrient  transporters  in  T  cell  
activation  and  subsets  may  now  provide  new  opportunities  to  exploit  metabolic  








4. Intrinsic Metabolic Programming and Pyruvate 
Dehydrogenase Kinase Control CD4 T cell 
Differentiation and Autoimmunity 
  
4.1 Introduction 
CD4  T  Lymphocytes  play  key  roles  to  mediate  or  suppress  immunity  and  
inflammatory  or  autoimmune  diseases.    Antigen  exposure  initially  leads  to  T  cell  
activation  to  induce  rapid  growth  and  proliferation.    Depending  on  the  cytokine  
environment  during  activation,  CD4  T  cells  are  then  stimulated  to  differentiate  into  
effector  (Teff;  Th1,  Th2  and  Th17)  or  regulatory  (Treg)  subsets.    Each  of  these  subsets  
plays  a  unique  role  in  the  adaptive  immune  system,  with  Teff  driving  immunity  and  
inflammation  while  Treg  play  an  opposing  role,  suppressing  Teff  to  limit  excessive  
inflammatory  responses  (Zhu  et  al.,  2010).    The  balance  between  Teff  and  Treg  is  crucial  
to  provide  sufficient  immune  protection  without  promoting  autoimmunity.    Indeed,  
many  autoimmune  diseases,  including  multiple  sclerosis  and  inflammatory  bowel  
disease  (IBD)  involve  an  imbalance  of  Teff  to  Treg  or  decreased  Treg  function  (Buckner,  
2010).  Th17,  in  particular,  play  a  key  pro-­‐‑inflammatory  role  in  many  autoimmune  
diseases  including  experimental  autoimmune  encephalomyelitis  (EAE),  IBD  and  Graft-­‐‑
vs-­‐‑Host  Disease  (Cua  et  al.,  2003;  Yen  et  al.,  2006;  Serody  and  Hill,  2012).    Therefore,  
identifying  characteristics  of  each  T  cell  population  to  allow  the  balance  of  Teff  and  Treg  
to  be  modulated  may  provide  a  way  to  prevent  or  suppress  autoimmunity.  
  77  
   Emerging  evidence  has  suggested  that  CD4  T  cell  metabolism  may  allow  
targeting  of  select  T  cell  populations.    The  transition  from  a  naïve  to  activated  
lymphocyte  requires  rapid  growth  and  proliferation.    With  these  requirements  comes  a  
demand  for  substantial  metabolic  reprogramming  to  provide  the  biosynthetic  precursors  
and  energy  necessary  for  effector  function  (Fox  et  al.,  2005;  Vander  Heiden  et  al.,  2009).    
This  reprogramming  involves  decreased  lipid  oxidation  and  an  increase  in  glucose  
uptake  and  glycolysis  as  well  as  amino  acid  transport  and  glutaminolysis  (Frauwirth  et  
al.,  2002;  Jacobs  et  al.,  2008;  Maciver  et  al.,  2008;  Sinclair  et  al.,  2013;  Wang  et  al.,  2011).    
Importantly,  metabolic  reprogramming  of  Teff  and  Treg  leads  to  distinct  metabolic  
programs  for  each  subset.      
While  Teff  require  large  amounts  of  glucose  and  a  high  rate  of  glycolysis  to  
support  their  energetic  needs,  Treg  are  able  to  expand  and  function  in  the  absence  of  
glucose  (Michalek  et  al.,  2011a;  Shi  et  al.,  2011).    Treatment  of  activated  T  cells  with  the  
glycolytic  inhibitor  2-­‐‑deoxyglucose  (2DG)  leads  to  Treg  accumulation  and  inhibition  of  
IL-­‐‑17  production  (Shi  et  al.,  2011).    In  addition,  we  have  shown  that  exogenous  fatty  
acids  suppress  Teff  generation  while  promoting  Treg  and  that  Treg  have  high  rates  of  
lipid  oxidation  in  vitro  (Michalek  et  al.,  2011a).    The  role  of  specific  metabolic  programs  
and  substrate  usage  for  activation  and  differentiation  of  Teff  and  Treg,  however,  is  
uncertain.  
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   One  bifurcation  point  in  glucose  metabolism  that  may  play  a  central  role  in  the  
glycolytic  or  oxidative  roles  of  Teff  and  Treg  is  determination  of  the  fate  of  glycolytic  
pyruvate  through  Pyruvate  Dehydrogenase  (PDH).    PDH  mediates  the  conversion  of  
cytosolic  pyruvate  into  mitochondrial  acetyl-­‐‑CoA  for  oxidative  metabolism.    PDH  is  
inhibited  by  Pyruvate  Dehydrogenase  Kinase  (PDHK)  to  suppress  pyruvate  oxidation  
and  instead  promote  conversion  to  lactate  and  high  rates  of  glycolysis.    PDHK  has  four  
isoforms  that  are  regulated  by  oncogenic  signaling  and  hypoxia  (Hitosugi  et  al.,  2011;  
Korotchkina  and  Patel,  2001).    Indeed,  cancer  cells  are  also  highly  glycolytic  and  PDHK  
inhibition  with  dichloroacetate  (DCA)  can  suppress  glycolysis  and  lead  to  increased  
oxidative  metabolism  and  reactive  oxygen  species  production  (Michelakis  et  al.,  2010).    
DCA  has  been  shown  to  reduce  pro-­‐‑inflammatory  cytokine  production  and  promote  
FoxP3  expression  in  vitro  and  in  several  in  vivo  inflammatory  models  (Bian  et  al.,  2009;  
Eleftheriadis  et  al.,  2013;  Ostroukhova  et  al.,  2011).    Importantly,  these  studies  examined  
the  effect  of  DCA  in  the  context  of  total  PBMCs  or  mouse  models  and  therefore  the  
direct  effect  on  T  cells  is  unknown.    The  mechanism  of  DCA  action  and  how  Teff  are  
selectively  suppressed  while  Treg  are  promoted  has  not  been  established.  
Here,  we  examine  the  metabolic  programs  underlying  each  T  cell  subset  to  
identify  distinct  metabolic  pathways  that  will  allow  selective  targeting  of  different  T  cell  
populations.    We  show  that  Treg  oxidize  not  only  lipids  at  a  high  rate,  but  also  glycolytic  
pyruvate.    Gene  expression  and  metabolomics  data  suggested  PDHK  isoform  1  
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(PDHK1)  as  a  modulator  of  Th17  and  Treg  differentiation  and  survival.    Indeed,  
PDHK1-­‐‑deficiency  or  inhibition  with  DCA  led  to  ROS  stress  selectively  in  Th17  cells  that  
inhibited  their  survival  and  proliferation.    As  a  consequence,  DCA  was  capable  of  
suppressing  CD4  T  cell  mediated  inflammation  in  both  inflammatory  bowel  disease  
(IBD)  and  experimental  autoimmune  encephalomyelitis  (EAE)  models.    Together,  these  
metabolic  data  have  identified  PDH  as  a  key  regulatory  point  in  CD4  T  cell  subset  fate  
and  show  that  inhibition  of  PDHK1  leads  to  selective  ROS  generation  and  targeting  of  
Th17  cells  in  vivo  in  inflammatory  and  autoimmune  disorders.  
  
4.2 Results 
4.2.1 Teff and Treg utilize different metabolic pathways and have 
distinct fuel capacities 
Previous  studies  have  identified  basic  metabolic  differences  between  effector  T  
cells  (Teff;  Th1,  Th2  and  Th17)  and  regulatory  T  cells  (Treg).  However,  underlying  
distinctions  that  drive  the  CD4  T  cell  subsets  and  may  allow  selective  targeting  of  
inflammatory  subsets  are  poorly  defined.    To  examine  the  metabolic  phenotype  of  the  
CD4  T  cell  subsets,  Teff  and  Treg  were  differentiated  in  vitro  and  oxygen  consumption  
and  lactate  production  were  measured  using  an  extracellular  metabolic  flux  analyzer.    
Cells  were  cultured  in  the  absence  of  glucose  and  the  rate  of  extracellular  acidification  
(ECAR),  a  measurement  of  lactate  production,  was  determined  upon  re-­‐‑addition  of  
glucose  (Fig  4.1a).    All  CD4  T  cell  subsets  increased  ECAR,  although  Th1  and  Treg  
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increased  less  than  Th2  and  Th17  cells.  Oligomycin  was  then  added  to  block  
mitochondrial  ATP  production  and  promote  maximal  rates  of  glycolysis  in  
compensation.    Importantly,  Th1,  Th2,  and  Th17  cells  each  showed  a  robust  increase  in  
ECAR  following  oligomycin  treatment,  but  Treg  were  largely  unchanged.    These  data  
indicate  that  Treg  were  performing  glycolysis  at  maximal  rates  following  glucose  
addition  and  have  limited  capacity  to  increase  this  pathway.    Teff,  in  contrast,  generate  
glycolytic  lactate  at  a  high  rate  and  can  further  elevate  glycolytic  rate  when  required  to  
generate  ATP.  
The  glycolytic  capacity  and  glycolytic  reserve  were  both  severely  impaired  in  
Treg  compared  to  Teff  (Fig  4.1b,  c).    Therefore,  when  glucose  is  the  only  fuel  available,  





Figure  4.1:  Teff  and  Treg  utilize  different  metabolic  pathways  and  have  distinct  fuel  
capacities  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells.    (a-­‐‑c)  The  rate  of  extracellular  acidification  (ECAR)  was  assessed  after  the  addition  
of   10mM  glucose   (gluc)   and   in   response   to   the  metabolic   inhibitors  oligomycin   (oligo)  
and   2-­‐‑deoxyglucose   (2-­‐‑DG).      Shown   are   the   time   course   (a),   and   calculations   of  
glycolytic  capacity  (b)  and  glycolytic  reserve  (c).    (d,  e)  Oxygen  consumption  (OCR)  was  
assessed   basally   and   in   response   to   the   mitochondrial   inhibitors   oligomycin   (oligo),  
FCCP,   rotenone   and   antimycin   A   (Rot/AntiA).      Shown   are   the   time   course   (d),   and  
calculation  of  spare  respiratory  capacity  (e).    (f)  Glucose  oxidation  was  measured  in  the  
T  cell  subsets  and  the  ratio  of  glucose  oxidation  to  glycolysis  is  graphed.    Data  is  shown  
as   mean   ±   SD   (b,   c,   e,   f)   and   all   data   are   representative   of   at   least   3   independent  
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Mitochondrial  and  oxidative  metabolism  can  play  a  key  role  to  support  T  cell  
activation  and  proliferation  (Chang  et  al.,  2013;  Sena  et  al.,  2013).    While  Treg  have  been  
shown  to  have  high  rates  of  lipid  oxidation,  mitochondrial  oxidation  of  glycolysis-­‐‑
derived  pyruvate  had  not  been  examined.    Mitochondrial  oxygen  consumption  rate  
(OCR)  was  therefore  measured  in  each  CD4  subset  in  glucose  containing  media.    Prior  to  
addition  of  metabolic  inhibitors,  Treg  had  an  intermediate  level  of  oxygen  consumption  
relative  to  Teff,  with  Th17  cells  maintaining  the  highest  basal  rate  of  oxygen  
consumption  (Fig  4.1d).    Oligomycin  treatment  to  inhibit  mitochondrial  ATP  production  
suppressed  oxygen  consumption  in  each  subset  to  an  equivalently  low  level,  indicating  
that  oxygen  consumption  was  tightly  coupled  to  ATP  generation  for  all  T  cell  subsets.    
Upon  the  addition  of  the  protonophore  FCCP  to  uncouple  oxidative  phosphorylation  
from  electron  transport  and  allow  maximal  respiration,  Treg  and  Th17  greatly  
upregulated  oxygen  consumption.  When  compared  to  the  basal  rates  of  oxygen  
consumption,  these  data  show  that  Treg  have  the  greatest  spare  respiratory  capacity  
(SRC)  of  the  subsets  (Fig  4.1e).    Thus,  Treg  have  low  glycolytic  production  of  lactate  and  
cannot  further  elevate  this  pathway,  yet  have  the  greatest  capacity  for  mitochondrial  
oxidation  when  given  glucose  as  a  fuel.  
These  data  suggest  that  while  all  CD4  T  cell  subsets  utilize  glucose,  Teff  
preferentially  convert  pyruvate  to  lactate  while  Treg  oxidize  this  fuel  in  the  
mitochondria.    To  directly  measure  the  fate  of  glycolysis-­‐‑derived  pyruvate,  CD4  T  cell  
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subsets  were  provided  radiolabeled  glucose  and  glycolytic  flux  and  glucose  oxidation  
were  measured.  The  ratio  of  glucose  oxidation  to  glycolysis  was  found  to  be  higher  in  
Treg,  supporting  the  conclusion  that  this  subset  preferentially  oxidizes  glucose  rather  
than  converting  pyruvate  to  lactate  (Fig  4.1f).  Overall,  these  data  indicate  that  Treg  
utilize  mitochondrial  oxidative  pathways  using  both  lipids  (Michalek  et  al.,  2011a)  and  
glucose  as  fuels  while  Teff  have  low  levels  of  mitochondrial  oxidative  metabolism  either  
fuel  and  primarily  perform  aerobic  glycolysis  to  lactate.        
  
4.2.2 Inhibition of glycolysis or mitochondrial oxidation selectively 
impacts Teff or Treg survival, proliferation and function 
Although  flux  analysis  revealed  that  Teff  and  Treg  utilize  distinct  glycolytic  or  
mitochondrial  metabolic  programs,  the  reliance  of  these  subsets  on  each  pathway  was  
not  clear.  To  determine  if  each  CD4  subset  required  these  programs,  CD4  T  cell  subsets  
were  labeled  with  the  proliferation  indicator  dye  Cell  Trace  Violet  (CTV)  and  
differentiated  in  vitro  and  treated  with  either  low  dose  2-­‐‑deoxyglucose  (2DG)  or  
rotenone,  to  inhibit  glycolysis  or  electron  transport,  respectively.    2DG  treatment  
inhibited  the  proliferation  of  each  Teff  subset  but  had  a  minimal  effect  on  Treg  (Fig  4.2a).    
Conversely,  rotenone  did  not  affect  Teff,  but  sharply  reduced  Treg  proliferation.      
Differentiation  of  each  CD4  T  cell  subset  is  characterized  by  induction  of  specific  
transcription  factors  as  cells  undergo  DNA  replication  and  division  (Zhu  et  al.,  2010).    
Given  the  reliance  of  Teff  on  glycolysis  and  Treg  on  mitochondrial  metabolism  for    
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Figure  4.2:  Inhibition  of  glycolysis  or  mitochondrial  oxidation  selectively  impacts  
Teff  or  Treg  survival,  proliferation  and  function  
(a,  b)  CD4+CD25-­‐‑  T  cells  were  labeled  with  CellTrace  Violet  (CTV)  and  polarized  in  vitro  
for  3  days   to  generate  Th1,  Th2,  Th17  or  Treg  cells.     Cells  were   treated  with  250µμM  2-­‐‑
deoxyglucose   (2-­‐‑DG)   or   5nM   rotenone   and   (a)   proliferation   or   (b)   transcription   factor  
staining  was   assessed   by  CTV  dilution   after   72   hours.   (c,   d)      CD4+CD25-­‐‑   T   cells  were  
polarized   in   vitro   for   5   days   and   then   incubated   with   (c)   250µμM   2-­‐‑DG   or   (d)   25nM  
rotenone  and  survival  was  determined  by  propidium  iodide  exclusion.     Data   is  shown  
as  mean  ±  SD  (c,  d)  and  all  data  are  representative  of  at  least  3  independent  experiments.      
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proliferation,  it  was  possible  that  the  ability  of  subsets  to  express  these  transcription  
factors  was  also  metabolically  sensitive.    Consistent  with  this  notion,  2DG  treatment  
suppressed  induction  of  T-­‐‑bet  in  cells  cultured  in  Th1  conditions  as  well  as  RORγt  in  T  
cells  cultured  in  Th17  conditions  (Fig  4.2b).    Importantly,  T-­‐‑bet  and  RORγt  expression  
was  inhibited  at  each  equivalent  cell  cycle  division.    Likewise,  expression  of  the  T-­‐‑bet  
and  RORγt  transcriptional  targets,  IFNγ  and  IL-­‐‑17,  respectively,  was  also  suppressed  by  
2DG  at  each  cell  cycle  (Fig  4.3).    Induction  of  the  Treg  transcription  factor  FoxP3,  
however,  was  not  affected  by  2DG.    The  electron  transport  inhibitor,  rotenone,  had  the  
opposite  effect  and  only  minimal  suppressed  on  T-­‐‑bet  and  RORγt  expression  of  Th1  and  





Figure  4.3:  Inhibition  of  metabolic  pathways  selectively  impacts  T  cell  function  
CD4+CD25-­‐‑  T  cells  were  labeled  with  CellTrace  Violet  (CTV)  and  polarized  in  vitro  for  3  
days   to   generate   Th1,   Th2,   Th17   or   Treg   cells.      Cells   were   treated   with   250µμM   2-­‐‑
deoxyglucose  (2-­‐‑DG)  or  5nM  rotenone  and  proliferation  was  assessed  by  CTV  dilution  
and   intracellular   cytokine   staining   staining   for   IFNγ   (Th1)   or   IL-­‐‑17   (Th17)   was  
performed  after  72  hours.    Data  is  representative  of  3  independent  experiments.  
  
  
CD4  subsets  may  rely  on  specific  metabolic  programs  not  only  for  proliferation  
and  differentiation,  but  also  for  survival.    Teff  and  Treg  subsets  were  therefore  
established  in  vitro  and  treated  with  2DG  or  rotenone.  Treg  survived  well  in  the  presence  
of  2DG,  only  slightly  affected  by  the  glycolytic  inhibition  (Fig  4.2c).    In  contrast,  Th1,  Th2  
and  Th17  were  sensitive  to  2DG  treatment  and  showed  increased  cell  death  (Fig  4.2c,  
4.4a).    Teff  were,  however,  relatively  insensitive  to  rotenone,  with  the  Th17  surviving  
better  than  in  the  vehicle  condition  (Fig  4.2d).  Treg  were  extremely  sensitive  to  rotenone  
!
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treatment,  with  less  than  10%  surviving  after  40  hours  of  treatment  (Fig  4.2d,  4.4b).  
Overall,  this  data  suggests  that  metabolism  is  fundamentally  linked  to  CD4  T  cell  




Figure  4.4:  Inhibition  of  glycolytic  or  oxidative  metabolic  pathways  selectively  
impacts  Teff  or  Treg  survival  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  and  then  incubated  with  (a)  250µμM  
2-­‐‑DG  or  (b)  5nM  rotenone  and  survival  was  determined  by  propidium  iodide  exclusion.    
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4.2.3 The CD4 T cell subsets have distinct metabolic phenotypes 
The  metabolic  dependencies  of  CD4  T  cell  subsets  may  allow  targeting  of  specific  
T  cell  populations.    Therefore,  we  examined  metabolite  levels  and  metabolic  gene  
expression  of  Teff  and  Treg  in  detail.    Steady  state  metabolite  levels  were  measured  by  
GC/MS  and  LC/MS  and  unsupervised  clustering  analysis  showed  that  each  CD4  subset  
was  metabolically  distinct  (Fig  4.5).    
Importantly,  Treg  were  the  most  disparate  and  were  distinct  from  each  Teff  
population,  which  were  more  similarly  related.    Pathway  and  principle  component  
analyses  demonstrated  that  glycolytic  and  mitochondrial  metabolic  pathways  in  
particular  were  sharply  different  between  Teff  and  Treg  populations.  Treg  had  lower  
levels  of  many  of  the  glycolytic  metabolites,  including  glucose-­‐‑6-­‐‑phosphate  (G6P)  and  
fructose-­‐‑1,6-­‐‑bisphosphate  (FBP),  with  the  largest  differences  between  Th17  and  Treg  (Fig  
4.6a).    Treg,  however,  had  a  higher  level  of  the  starting  materials  glucose  and  fructose  
compared  to  Teff.    These  data  suggest  that  Treg  are  capable  of  hexose  uptake  but  do  not  
consume  these  fuels  to  the  same  degree  as  Teff.  TCA  cycle  metabolites  were  variable  and  
no  patterns  were  evident  (Fig  4.6b).      
We  next  examined  expression  of  metabolic  genes  and  proteins  in  each  CD4  
subset.    CD4  T  cells  express  several  glucose  transporters,  including  Glut1  and  Glut3.    
The  protein  expression  of  Glut1  protein  was  elevated  in  Teff  compared  to  Treg  and  Treg  
did  not  express  detectable  levels  of  Glut3  (Fig  4.7a).    After  uptake,  glucose  is    
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Figure  4.5:  Metabolomic  profiling  of  Teff  and  Treg  show  diverse  metabolic  pathway  
utilization  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells.     T  cell  subset   lysates  were  extracted  and  GC/MS  and  LC/MS/MS  were  performed  
for   determination   of   cellular   metabolites.      Heat   map   showing   relative   levels   of   each  
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Figure  4.6:  Metabolomic  profiling  of  the  T  cell  subsets  shows  diverse  metabolic  
profiles  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells.      T   cell   subset   lysates   were   extracted   and   split   into   equal   parts   for   analysis   on  
GC/MS   and   LC/MS/MS   platforms   for   determination   of   cellular   metabolites.      Relative  
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phosphorylated  by  hexokinase  (HK),  of  which  there  are  four  isoforms.    Surprisingly,  
Treg  expressed  primarily  HK1  while  the  Teff  subsets  mainly  express  HK2  and  HK3  (Fig  
4.7a).    Glycolytic  metabolic  genes  were  then  examined  and,  interestingly,  CD4  T  cells  
express  a  single  isoform  of  each  glycolytic  gene  (Fig  4.7b).    While  generally  elevated  in  
the  differentiated  cells  compared  to  naïve  T  cells,  Teff  largely  have  higher  levels  of  
expression  of  the  glycolytic  genes  compared  to  Treg,  with  the  comparison  being  most  
striking  between  Th17  and  Treg  (Fig  4.7b).    Of  the  effector  T  cells,  Th17  had  the  highest  
expression  of  glycolytic  genes,  followed  by  Th2  and  finally  Th1.      
Mitochondrial  gene  and  protein  expression  was  then  examined  in  the  CD4  T  cell  
subsets.    Treg  had  slightly  elevated  levels  of  many  of  the  electron  transport  chain  
proteins  as  well  as  higher  levels  of  CPT1A  and  cytochrome  C  compared  to  Teff,  
although  each  subset  was  unique  (Fig  4.7c).    The  expression  of  the  PDH  genes  Pdh1a  
and  Pdhb  were  particularly  interesting  given  their  role  to  direct  pyruvate  to  acetyl-­‐‑CoA  
and  the  TCA  cycle  and  elevated  expression  in  Th17  and  Treg  compared  to  naïve,  Th1  
and  Th2  subsets  (Fig  4.7d,  top  left  panel).    The  expression  of  genes  involved  in  the  TCA  
cycle  and  electron  transport  were  similar  between  all  of  the  CD4  T  cell  subsets,  
suggesting  that  while  Teff  preferentially  use  glycolysis,  both  Teff  and  Treg  can  utilize  
their  mitochondria  for  energy  production  (Fig  4.7d,  Fig  4.8).    
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Figure  4.7:  CD4  T  cell  subsets  have  distinct  metabolic  gene  and  protein  expression  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells  for  (a,  c)  immunoblot  or  (b,  d)  real-­‐‑time  PCR.    (b,  d)    Data  shown  is  mean  ±  SD  of  3  
biological   replicates   and   shown  as   2ΔCT  normalized   to   the  geometric  mean  of  TBP  and  
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Figure  4.8:  CD4  T  cell  subsets  have  distinct  metabolic  gene  expression  profiles  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells   for   real-­‐‑time   PCR   of   mitochondrial   metabolism   and   glucose   metabolism   genes.    
Data  are  representative  of  2  independent  experiments.      
Normalized expression 
Mitochondrial metabolism 
Th1 Treg Th17 Th2 Naïve 
Glucose metabolism 
Naive Treg Th1 Th2 Th17 
Low High 
  94  
Besides  glucose  utilization,  T  cells  can  also  oxidize  amino  acids  and  lipids.    
Therefore,  the  amino  acid  and  acyl  carnitine  profiles  of  the  T  cell  subsets  were  examined  
to  determine  if  subsets  differed  in  fuel  usage.    All  four  of  the  subsets  had  higher  
intracellular  amino  acid  levels  relative  to  naïve  T  cells  (Fig  4.9a).    Within  the  individual  
T  cell  subsets,  levels  of  the  amino  acids  were  variable.    Acyl-­‐‑carnitines,  which  reflect  
mitochondrial  fuels  derived  from  cellular  lipids  and  amino  acids,  were  also  quite  
variable  between  the  CD4  T  cell  subsets.    However,  naive,  Th2  and  Treg  had  increased  
C2  and  C4-­‐‑OH  levels  that  indicate  acetyl  CoA  and  ketone  body  species,  respectively  (Fig  
4.9b,  c).    C4-­‐‑OH  (hydroxybutylcarnitine)  is  elevated  in  cells  undergoing  lipid  oxidation  
(Schooneman  et  al.,  2013)  and  these  findings  suggest  that  Th2  and  Treg  utilize  fatty  acids  
to  a  greater  extent  than  Th1  and  Th17.  Together,  these  metabolic  data  suggest  that  each  
CD4  T  cell  subset  has  a  unique  metabolic  phenotype,  yet  point  to  specific  metabolic  




Figure  4.9:  CD4  T  cell  subsets  have  different  acyl  carnitine  and  amino  acid  profiles  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells.      T   cell   subset   lysates   were   extracted   and   GC/MS   was   performed   to   determine  
relative   levels  of  cellular  metabolites.     Relative   levels  of   (a)  amino  acids  and  (b,  c)  acyl  































































































4.2.4 PDHK is required for Th2 and Th17, but not Treg, function in 
vitro 
The  finding  of  distinct  substrate  utilization  patterns  and  differential  expression  
of  PDH  isoforms  suggested  that  this  bifurcation  point  for  pyruvate  may  be  an  important  
regulatory  node  for  CD4  subsets.    PDH  is  a  highly  regulated  multi-­‐‑subunit  complex  that  
is  difficult  to  target  pharmacologically.    However,  PDH  activity  is  controlled,  in  part,  by  
PDHK,  which  phosphorylates  and  inhibits  PDH  to  direct  pyruvate  to  lactate  rather  than  
to  acetyl  CoA.    Therefore,  the  expression  of  the  four  PDHK  isoforms  was  examined  in  
the  CD  T  cell  subsets.    T  cells  expressed  PDHK1  and  PDHK3,  with  PDHK1  being  the  
prominent  isoform  (Fig  4.10a).    At  both  the  RNA  and  protein  level,  Th2  and  Th17  
expressed  the  highest  levels  of  PDHK1,  followed  by  Treg,  while  Th1  had  little  PDHK1  
expression  (Fig  4.10b).    Therefore,  PDHK1  is  differentially  expressed  in  the  CD4  T  cell  
subsets,  potentially  allowing  for  highly  selective  metabolic  targeting  of  CD4  T  cell  
populations.  
PDHK  is  a  target  of  the  inhibitor  compound  dichloroacetate  (DCA),  which  has  
been  previously  shown  to  differentially  affect  Th17  and  Treg.    The  inhibition  of  PDHK,  
which  in  turn  activates  PDH,  turns  on  the  critical  step  to  convert  pyruvate  to  acetyl  CoA  
and  drive  glucose  into  the  TCA  cycle  to  be  oxidized  (Fig  4.10c).    To  determine  the  effect  
of  PDHK  inhibition  on  CD4  T  cell  fate  and  function,  CD4  T  cells  were  differentiated  in  
vitro  in  the  presence  of  DCA.    
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Figure  4.10:  PDHK  is  required  for  Th2  and  Th17,  but  not  Treg,  function  in  vitro  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells   for   (a)   real-­‐‑time   PCR   or   (b)   immunoblot.      (c)   A   schematic   showing   the   different  
fates   of   pyruvate   and   mechanism   of   DCA   inhibition.   (d,   e)   Cells   were   treated   with  
10mM   dichloroacetate   (DCA)   and   cytokine   production   (d)   and   transcription   factor  
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staining  (e)  was  determined  by  flow  cytometry.    (f)  T  cells  were  polarized,  infected  with  
lentivirus   expressing   PDHK1   shRNA   and   transcription   factor   staining   for   FoxP3   and  
RORγt  was  performed.    Data  is  shown  as  mean  ±  SD  (a)  and  all  data  are  representative  
of  at  least  3  independent  experiments.    PS  Winter  contributed  to  this  data.  
  
DCA  treatment  did  not  affect  Th1  differentiation  or  function,  as  IFNγ  production  and  T-­‐‑
bet  expression  were  similar  regardless  of  treatment  (Fig  4.10d,  e).    This  is  likely  due  to  
the  low  or  absent  expression  of  PDHK  in  Th1.    In  contrast,  DCA  inhibited  the  
production  of  IL-­‐‑4  and  IL-­‐‑17  and  suppressed  expression  of  the  Th2  and  Th17  
transcription  factors  GATA3  and  RORγt.    Surprisingly,  treatment  of  Treg  with  DCA  
increased  the  expression  of  FoxP3  compared  to  the  vehicle  condition.  This  suggests  that  
directing  glucose  to  enter  mitochondrial  metabolism  is  favorable  for  Treg,  yet  has  an  
adverse  effect  on  Th2  and  Th17.    To  confirm  that  the  effects  seen  with  pharmacologic  
inhibition  of  PDHK1  were  not  off-­‐‑target  drug  effects,  we  genetically  targeted  PDHK1  
using  a  lentiviral  construct.    Knockdown  of  PDHK1  using  3  different  lentiviral  
constructs  inhibited  RORγt  expression  in  the  Th17s  and  increased  FoxP3  expression,  
mimicking  the  in  vitro  effects  seen  with  DCA  (Fig  4.10).    Therefore,  PDHK1  plays  a  key  
role  to  promote  Th2  and  Th17  cells  while  suppressing  Treg  generation.  
One  outcome  of  DCA  treatment  to  promote  pyruvate  oxidation  is  a  potential  
increase  in  the  generation  of  reactive  oxygen  species  (ROS).    Indeed,  DCA  can  suppress  
aerobic  glycolysis  of  cancer  cells  and  stimulate  ROS  production  that  can  lead  to  cancer  
cell  senescence  (Michelakis  et  al.,  2010).    Previous  literature  also  suggests  that  Teff  may  
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be  more  sensitive  to  ROS  stress  than  Treg  (Mougiakakos  et  al.,  2009;  Won  et  al.,  2013).    
ROS  levels  were  therefore  examined  in  the  T  cell  subsets.    The  ROS  indicator  dye,  
DCFDA,  showed  that  Treg  had  higher  levels  of  ROS  than  Teff  (Fig.  4.11a).    Consistent  
with  ROS  stress,  Treg  also  had  a  large  reserve  pool  of  reduced  glutathione  (GSH),  as  
well  as  high  levels  of  oxidized  glutathione  (GSSG)  (Fig.  4.11b).    This  suggests  that  Treg  
have  a  greater  capacity  to  handle  ROS  and  utilize  this  GSH  pool  to  a  greater  extent  than  
Teff.    Treg  have  also  been  shown  to  have  higher  levels  of  the  antioxidant  thioredoxin-­‐‑1,  
also  contributing  to  Treg  redox  regulation  (Mougiakakos  et  al.,  2011).      
To  determine  if  DCA  acted  in  part  through  ROS  generation,  established  Th17  
and  Treg  cultures  were  treated  acutely  with  DCA.    In  both  cases,  DCA  increased  
DCFDA  staining  to  indicate  generation  of  ROS  (Fig.  4.11c).    We  next  tested  the  effects  of  
DCA-­‐‑induced  ROS  by  co-­‐‑treatment  of  Th17  and  Treg  with  DCA  and  the  antioxidant  N-­‐‑
acetyl  cysteine  (NAC)  to  prevent  ROS  accumulation.    DCA  treatment  alone  inhibited  IL-­‐‑
17  production,  however  co-­‐‑treatment  with  NAC  prevented  the  decrease  in  IL-­‐‑17  (Fig.  
4.11d).    In  contrast,  while  DCA  promoted  Treg,  co-­‐‑treatment  with  NAC  prevented  the  
increase.    These  data  suggest  that  DCA  drives  glucose  oxidation,  generating  ROS  that  




Figure  4.11:  DCA  treatment  generates  ROS  that  negatively  impacts  Th17  without  
affecting  Treg  
CD4+CD25-­‐‑  T  cells  were  polarized  in  vitro  for  5  days  to  generate  Th1,  Th2,  Th17  or  Treg  
cells.   (a)   ROS   production   was   measured   using   the   indicator   dye   DCFDA.      (b)  
Glutathione   levels  were  measured   in   the   T   cell   subsets   using  mass   spectrometry.      (c)  
ROS  production   in  vehicle   and  DCA   treated  Th17  and  Treg   cells  was  measured  using  
DCFDA.      (d,   e)   Treg   and   Th17   cells   were   treated   with   10mM   DCA,   1mM   N-­‐‑acetyl  
cysteine   (NAC)   or   both   in   combination   and   (d)   FoxP3   and   IL-­‐‑17   production   were  
examined  after  3  days.    Data  is  shown  as  mean  ±  SD  (b,  e)  and  all  data  are  representative  








































































4.2.5 Inhibition of PDHK in vivo differentially affects Th17 and Treg to 
inhibit the progression of colitis and EAE 
In  vitro,  PDHK  inhibition  by  DCA  treatment  has  a  deleterious  and  selective  effect  
on  Th17  function  while  favoring  Treg  differentiation.    While  DCA  has  been  previously  
shown  to  suppress  inflammation  in  arthritis,  asthma,  and  alloreactivity  (Bian  et  al.,  2009;  
Ostroukhova  et  al.,  2011;  Eleftheriadis  et  al.,  2013),  the  selective  effect  on  Th17  and  Treg,  
but  not  Th1,  subsets  has  not  been  examined.    We,  therefore,  tested  the  ability  of  DCA  to  
suppress  the  Th17-­‐‑mediated  inflammatory  diseases.    IBD  is  driven  by  both  Th1  and  
Th17  and  alleviated  by  Treg  to  allow  examination  of  each  subset  in  vivo  (Hale  et  al.,  
2005).  Naïve  T  cells  were  adoptively  transferred  into  immunodeficient  recipients  in  the  
absence  of  Treg  and  were  then  given  normal  or  DCA-­‐‑containing  drinking  water.    IBD  is  
initiated  upon  generation  of  Teff  by  encounter  with  gut  microbiota.    Because  mice  were  
negative  for  enteropathic  bacterial  species,  the  animals  were  given  the  clinically-­‐‑relevant  
NSAID  piroxicam  two  weeks  after  the  T  cell  transfer  to  initiate  gut  damage  and  IBD.  
Significantly  fewer  CD4+  cells  were  found  in  the  mesenteric  lymph  nodes  and  infiltrating  
into  the  gut  tissue  of  mice  treated  with  DCA  relative  to  those  receiving  vehicle  water  
(Fig  4.12a).  Importantly,  DCA  treatment  did  not  lead  to  a  reduction  of  Th1  cells,  as  
measured  by  IFNγ  production  (Fig  4.12b).    However,  IL-­‐‑17  production  was  significantly  
reduced  with  DCA  treatment  (Fig  4.12c).    These  data  suggest  that  PDHK  inhibition  
selectively  affects  Th17  but  not  Th1  proliferation  and  function  in  vivo.    
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Figure  4.12:  PDHK  is  selectively  required  for  Th17  but  not  Th1  expansion  and  
function  in  vivo  
(a-­‐‑c)   Rag1-­‐‑/-­‐‑   mice   were   injected   with   naïve   effector   (CD4+CD25−CD45RBhi)   T   cells   and  
colitis  was   induced.     Mice  were   given   2g/L  of  dichloroacetate   (DCA)  or   vehicle   in   the  
drinking  water  for  the  duration  of  the  experiment.  (a)  The  percentage  of  CD4  T  cells  or  
(b,   c)   IL-­‐‑17   or   IFNγ   producing   cells   in   the   spleen   and   mesenteric   lymph   nodes   was  
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DCA  treatment  did  not  prevent  intestinal  inflammation  or  disease  progression,  likely  
due  to  the  functional  Th1  response  (data  not  shown).      
To  independently  test  the  role  of  PDHK  on  Th17  and  Treg  populations,  we  next  
examined  the  effects  of  DCA  in  EAE.    While  Th1  cells  can  contribute  to  EAE,  this  model  
is  Th17-­‐‑dependent,  as  RORγt  knockout  mice  are  disease-­‐‑resistant.    EAE  was  induced  in  
wild  type  mice  by  MOG  injection  with  pertussis  toxin  administered  on  days  0  and  2.    
DCA  was  again  given  in  the  drinking  water  throughout  the  course  of  the  experiment.    
Clinical  signs  of  EAE  were  assessed  at  regular  intervals.    PDHK  inhibition  by  DCA  
treatment  significantly  alleviated  EAE  symptoms  throughout  the  course  of  disease  
progression  (Fig  4.13a).    Importantly,  DCA  treatment  inhibited  CD44hi  cells  while  
increasing  FoxP3+  Treg  (Fig  4.13b).    Therefore,  PDHK  inhibition  in  vivo  selectively  
modulates  the  balance  between  Th17  and  Treg  and  suppresses  autoimmunity  in  two  
mouse  models.    These  data  suggest  that  the  distinct  metabolic  programs  of  CD4  subsets  
are  both  essential  for  each  subset  and  can  be  exploited  to  target  specific  T  cell  
populations  in  inflammatory  diseases  such  as  through  DCA-­‐‑mediated  selective  
inhibition  of  Th17  cells.  
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Figure  4.13:  PDHK  is  selectively  required  for  Teff  but  not  Treg  expansion  and  
function  in  vivo  
(a,  b)  EAE  was  induced  in  wildtype  mice  with  or  without  DCA  treatment  and  (a)  time  
course   of   clinical   score   and   (b)   percentages   of  CD4+CD44hi   and  CD4+FoxP3+   cells  were  
determined   using   flow   cytometry.      Data   is   shown   as  mean   ±   SD   (e)   and   all   data   are  
representative  of  2  independent  experiments.  AN  Macintyre  and  M  Inoue  contributed  to  
this  data.  






















































It  is  becoming  increasingly  evident  that  metabolic  reprogramming  plays  a  crucial  
role  in  T  cell  activation,  differentiation  and  function.    Activated  CD4  T  cells  require  high  
rates  of  glucose  uptake  and  glycolysis,  glutaminolysis  and  lipid  synthesis  to  support  
proliferation  and  function  (Jacobs  et  al.,  2008;  Kidani  et  al.,  2013;  Sinclair  et  al.,  2013;  
Wang  et  al.,  2011).    We  show  for  the  first  time  a  detailed  analysis  of  the  metabolic  
programs  underlying  each  CD4  T  cell  subset  (Th1,  Th2,  Th17  and  Treg).    These  data  
show  that  Teff  are  reliant  on  glucose  while  Treg  have  fuel  flexibility  and  oxidize  glucose  
in  addition  to  lipids.    However,  while  Th1,  Th2  and  Th17  have  a  similar  need  for  
glucose,  each  T  cell  subset  has  a  distinct  metabolic  profile  that  may  allow  for  selective  
targeting  of  different  T  cell  populations.    Here,  we  identify  pyruvate  dehydrogenase  
kinase  (PDHK)  as  a  selective  regulator  of  CD4  T  cell  differentiation  and  inflammation.      
Previous  studies  have  identified  broad  metabolic  differences  between  Teff  and  
Treg,  however  the  detailed  metabolic  profile  of  each  cell  type  has  not  been  previously  
examined.    We  show  here  that  Treg  are  less  efficient  at  the  conversion  of  glucose  to  
lactate  compared  to  effector  T  cells.    However,  Treg  have  a  higher  spare  respiratory  
capacity  and  preferentially  oxidize  fuels  in  the  mitochondria.    Importantly,  this  
increased  oxygen  consumption  was  not  due  to  lipid  oxidation,  as  lipids  were  not  present  
in  the  media.    This  suggested  for  the  first  time  that  Treg  not  only  oxidize  lipids,  but  also  
glucose.    This  fuel  flexibility  may  be  important  in  vivo  during  T  cell  suppression  and  
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there  is  increasing  evidence  that  Treg  utilize  metabolic  strategies  to  suppress  Teff  (33).    
This  includes  degrading  ATP  through  upregulating  the  expression  of  CD39,  as  well  as  
directly  competing  with  Teff  for  cysteine  uptake  (34).    Treg  can  also  induce  dendritic  
cells  to  consume  essential  amino  acids,  which  inhibits  T  cell  proliferation  (35).    Taken  
together,  these  data  argue  that  it  would  be  advantageous  for  Treg  to  have  a  distinct  
metabolic  profile  from  Teff.    If  Teff  and  Treg  had  similar  signaling  pathways  and  
metabolism,  it  may  be  difficult  for  Treg  to  functionally  inhibit  Teff  when  faced  with  the  
same  environmental  cues.    Therefore,  the  metabolic  differences  between  Teff  and  Treg  
may  be  necessary  for  the  ability  of  Treg  to  function  and  suppress  inflammation.  
In  vitro  2-­‐‑deoxyglucose  (2DG)  treatment  to  inhibit  glycolysis  prevented  Teff  pro-­‐‑
inflammatory  cytokine  production  as  well  as  Teff,  but  not  Treg,  survival  and  
proliferation.    Previous  literature  has  described  a  role  for  glycolytic  intermediates  in  the  
translation  of  IFNγ,  as  GAPDH  can  bind  to  IFNγ  mRNA  and  inhibit  translation  (Chang  
et  al.,  2013).    This  suggests  that  metabolic  enzymes  directly  regulate  inflammatory  
cytokine  production.    However,  2DG  treatment  also  inhibited  the  expression  of  the  
effector  transcription  factors  T-­‐‑bet  and  RORγt.    This  suggests  that  glycolytic  inhibition  
suppressed  T  cell  differentiation  as  well  as  cytokine  production.    Therefore,  T  cell  
metabolism  is  tightly  linked  to  cell  fate  as  well  as  function.    Treg,  on  the  other  hand,  
were  unaffected  by  glycolytic  inhibition.    This  is  likely  due  to  the  ability  of  Treg  to  
oxidize  alternative  fuels,  such  as  lipids.    In  contrast,  low  doses  of  rotenone  to  inhibit  
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mitochondrial  respiration  only  modestly  affected  Teff  and  yet  strongly  inhibited  the  
survival  and  proliferation  of  Treg.    Rotenone  inhibits  complex  I  of  electron  transport  and  
prevents  the  transfer  of  electrons  from  NADH  to  the  electron  transport  chain,  inhibiting  
mitochondrial  ATP  generation.    As  Treg  cannot  upregulate  aerobic  glycolysis  after  
mitochondrial  inhibition,  rotenone  treatment  likely  inhibited  Treg  energy  production  
and  prevented  cell  growth  and  survival.    Teff  were  less  affected  by  rotenone,  suggesting  
that  they  are  able  to  generate  sufficient  ATP  through  the  conversion  of  pyruvate  to  
lactate  in  aerobic  glycolysis.    Rotenone  has  also  been  shown  to  increase  reactive  oxygen  
species  (ROS)  due  to  the  inhibition  of  Complex  I,  however  Treg  are  able  to  withstand  
high  levels  of  ROS  (Mougiakakos  et  al.,  2009;  Won  et  al.,  2013)  and  while  we  cannot  
exclude  the  possibility  that  this  may  be  negatively  affecting  Treg,  our  data  suggest  that  it  
is  likely  an  issue  of  energy  production  and  not  ROS  stress.    
Given  that  Treg  utilize  mitochondrial  oxidation  while  Teff  convert  glucose  to  
lactate,  we  then  identified  the  branch  point  between  glycolysis  and  glucose  oxidation  as  
a  potential  target  to  modulate  the  balance  between  Teff  and  Treg.    One  of  the  primary  
regulators  of  this  branch  point  is  pyruvate  dehydrogenase  kinase  (PDHK).    PDHK  
inhibits  pyruvate  dehydrogenase  (PDH)  to  suppress  glucose  oxidation  and  instead  
promote  lactate  production  and  glycolysis.    Interestingly,  PDHK1  was  differentially  
expressed  in  the  effector  T  cell  subsets,  expressed  in  Th2  and  Th17  but  little  expression  
in  Th1.    This  provided  an  opportunity  to  selectively  target  specific  CD4  T  cell  subtypes.    
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The  compound  dichloroacetate  (DCA)  inhibits  PDHK  and  is  currently  under  
investigation  in  several  different  types  of  cancer  (Sutendra  et  al.,  2013).    DCA  is  thought  
to  be  effective  in  cancer  cells  because  it  inhibits  aerobic  glycolysis  and  instead  directs  
glucose  to  be  oxidized  in  the  mitochondria.    There  is  also  evidence  that  DCA  promotes  
reactive  oxygen  species  (ROS)  in  several  cancer  models  (Gong  et  al.,  2013;  Stockwin  et  al.,  
2010).    DCA  has  also  been  studied  in  an  immune  context.    Treatment  of  human  PBMCs  
with  DCA  inhibited  pro-­‐‑inflammatory  cytokine  production  and  promoted  FoxP3  
expression  in  the  setting  of  asthma  and  alloreactivity  (Ostroukhova  et  al.,  2012;  
Eleftheriadis  et  al.,  2013).    Additional  literature  has  shown  a  role  for  DCA  in  the  
treatment  of  airway  inflammation  and  collagen-­‐‑induced  arthritis  in  mice  (Bian  et  al.,  
2009;  Ostroukhova  et  al.,  2012).    However,  these  studies  do  not  address  directly  examine  
the  role  of  PDHK  or  DCA  in  T  cells  and  the  mechanism  of  inflammatory  cytokine  
production  inhibition  is  unclear.    
Our  data  shows  that  DCA  inhibits  Teff  differentiation  and  cytokine  production  
and  does  so  by  inhibition  of  PDHK1  and  subsequent  alteration  of  glucose  utilization.    
Promoting  glucose  oxidation  through  PDHK1  inhibition  suppresses  Th17  generation,  in  
part  through  the  generation  of  ROS.    Several  recent  reports  suggest  that  Teff  are  more  
sensitive  to  ROS  stress  than  Treg.    Deletion  of  the  antioxidant  molecule  peroxiredoxin  II  
in  T  cells  increased  Treg  and  prevented  dextran  sulfate  sodium  induced  colitis  (Won  et  
al.,  2013).    Here,  Treg  were  found  to  have  high  levels  of  the  antioxidant  glutathione  (Fig  
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4.11b).    While  Treg  also  have  high  levels  of  ROS  compared  to  Teff,  Treg  likely  produce  
ROS  during  mitochondrial  oxidation  and  are  equipped  with  antioxidant  molecules  to  
handle  this  ROS  generation.    Our  data  suggest  that  the  Th17  are  less  able  to  handle  ROS  
stress  generated  by  the  activation  of  PDH  and  subsequent  glucose  oxidation,  as  DCA  
inhibited  IL-­‐‑17  production.    However,  neutralization  of  ROS  with  the  antioxidant  N-­‐‑
acetyl  cysteine  normalized  IL-­‐‑17  production.    Therefore,  PDHK  selectively  modulates  
the  balance  between  Th17  and  Treg,  in  part  through  ROS  generation.      
Previous  studies  have  described  potential  therapeutic  strategies  to  modulate  the  
balance  between  Teff  and  Treg.    Rapamycin  is  used  clinically  to  treat  inflammatory  
disease  and  has  been  shown  to  suppress  CD4+CD25-­‐‑  T  cells  while  preserving  Treg  (Shin  
et  al.,  2011).    However,  it  is  not  always  desired  to  suppress  all  of  the  CD4  effector  T  cell  
subsets.    Each  subset  plays  a  different  role  in  immunity  and  it  may  be  therapeutically  
useful  to  inhibit  one  of  the  subtypes  without  affecting  the  others.    The  finding  that  Th1  
have  little  expression  of  PDHK1  presents  a  unique  opportunity  to  fine  tune  CD4  T  cell  
differentiation  and  the  immune  response.    Inhibition  of  PDHK1  did  not  affect  T-­‐‑bet  
expression  or  IFNγ  production  in  Th1  cells  but  suppressed  RORγt  and  IL-­‐‑17  production  
in  vitro.    In  addition,  treatment  of  mice  with  DCA  in  the  context  of  inflammatory  bowel  
disease  suppressed  IL-­‐‑17  but  preserved  IFNγ  production.    Our  data  therefore  suggests  
that  targeting  PDHK1  inhibits  Th17  differentiation  and  cytokine  production  while  
leaving  Th1  unaffected.    This  may  be  important  in  the  context  of  Th17  driven  
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autoimmune  disorders,  where  it  would  be  favorable  to  suppress  the  Th17  lineage  
without  affecting  Th1  immunity.    PDHK1  inhibition  also  suppressed  Th2  differentiation  
and  function,  and  our  data  would  suggest  that  DCA  therefore  may  also  be  beneficial  in  
an  allergic  asthma  setting.    Overall,  this  work  identified  key  metabolic  differences  
between  the  CD4  T  cell  subsets  and  established  PDHK1  as  a  selective  regulator  of  the  















5. FoxP3 directs an oxidative metabolic program that 
contributes to Treg function 
  
5.1 Introduction 
CD4  T  cells  are  an  essential  component  of  the  adaptive  immune  system.    The  
ability  of  T  cells  to  rapidly  proliferate  upon  TCR  engagement  is  critical  to  provide  
protection  against  foreign  pathogens.    T  cell  activation  and  subsequent  expansion  
creates  a  significant  metabolic  demand,  as  the  activated  T  cell  needs  sufficient  ATP  
energy  and  biosynthetic  precursors  to  clonally  expand  and  initiate  the  immune  response  
(Fox  et  al.,  2005;  Vander  Heiden  et  al.,  2009).    It  has  recently  become  clear  that  T  cell  
metabolism  can  have  an  enormous  impact  on  both  T  cell  activation  and  differentiation  
(Michalek  et  al.,  2011;  Pearce  et  al.,  2009;  Shi  et  al.,  2011;  Wang  et  al.,  2011;  Zheng  et  al.,  
2009).    In  particular,  CD4  effector  and  regulatory  T  cells  have  distinct  metabolic  
requirements,  likely  to  support  cellular  functions  specific  to  each  cell  type.       
Effector  T  cells  (Teff),  including  Th1,  Th2  and  Th17  drive  the  immune  response  
and  are  increased  in  an  inflammatory  setting  (Zhu  et  al.,  2010).    In  contrast,  regulatory  T  
cells  (Treg)  function  to  suppress  inflammation  and  are  important  to  control  
autoimmunity  (Sakaguchi  et  al.,  2008).    Along  with  these  distinct  functional  roles,  Teff  
and  Treg  utilize  different  metabolic  programs  (Michalek  et  al.,  2011).    Like  activated  T  
cells,  Teff  rely  on  glucose  and  have  high  rates  of  glucose  uptake  and  glycolysis.    This  is  
in  part  due  to  the  upregulation  of  the  glucose  transporter  Glut1.    In  contrast,  Treg  
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express  low  levels  of  Glut1  and  a  low  rate  of  glycolysis,  instead  utilizing  lipid  or  glucose  
oxidation  for  energy.    Importantly,  targeting  glucose  metabolism  has  been  shown  to  be  
effective  to  inhibit  Teff  number  or  function,  while  maintaining  Treg  (Michalek  et  al.,  
2011;  Shi  et  al.,  2011).      
Inhibition  of  glycolysis  with  the  hexokinase  inhibitor  2-­‐‑deoxyglucose  (2DG)  has  
been  shown  to  prevent  Th17  differentiation  in  vitro  (Shi  et  al.,  2011).    Additionally,  
treatment  of  mice  with  2DG  suppressed  experimental  autoimmune  encephalomyelitis  
(EAE).    2DG  treatment  also  promotes  Treg,  supporting  the  idea  that  Treg  do  not  rely  on  
glucose.    The  pyruvate  dehydrogenase  kinase  (PDHK)  inhibitor  dichloroacetate  (DCA)  
can  also  promote  Treg  and  inhibit  Teff  proliferation  and  cytokine  production.    
Treatment  of  mice  with  DCA  inhibited  airway  inflammation  in  an  asthma  model  as  well  
as  collagen-­‐‑induced  arthritis  in  vivo  (Bian  et  al.,  2009;  Ostroukhova  et  al.,  2011).    DCA  
inhibits  PDHK  thereby  driving  glucose  oxidation  in  the  mitochondria.    These  and  other  
studies  suggest  that  Teff  rely  on  glucose  while  Treg  have  fuel  flexibility  but  importantly  
require  mitochondrial  oxidation  to  generate  ATP  energy.  
One  important  question  that  arises  from  these  studies  is  what  drives  the  Treg  
oxidative  program.    In  mice,  the  Treg  lineage  is  defined  by  the  expression  of  the  
transcription  factor  FoxP3.    FoxP3  is  known  to  regulate  a  variety  of  genes  including  
CTLA-­‐‑4  and  CD25,  as  well  as  inhibit  the  expression  of  IL-­‐‑2,  IFNγ  and  other  effector  
molecules  (Sakaguchi  et  al.,  2008).    However,  the  role  of  FoxP3  is  more  complex  in  
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human  T  cells.    FoxP3  is  transiently  expressed  by  all  human  T  cells  upon  TCR  activation  
(Morgan  et  al.,  2005).    This  transient  expression  of  FoxP3  in  non-­‐‑Treg  does  not  appear  to  
inhibit  cytokine  production,  nor  does  it  confer  suppressive  capacity  (Tran  et  al.,  2007).    
Recent  literature  described  a  role  for  FoxP3  as  a  negative  regulator  of  T  cell  proliferation  
in  non-­‐‑Treg  human  T  cells.    FoxP3-­‐‑deficient  non-­‐‑Treg  CD4  T  cells  proliferate  more  and  
produce  more  cytokines  than  wildtype  cells  (McMurchy  et  al.,  2012).    As  proliferation  
and  metabolic  status  are  closely  linked,  this  suggests  that  FoxP3  may  be  restraining  T  
cell  metabolism  to  inhibit  proliferation.        
Given  that  Teff  and  Treg  have  distinct  metabolic  profiles,  we  hypothesized  that  
FoxP3  may  drive  the  Treg  oxidative  program.    Here,  we  examine  the  role  of  FoxP3  in  
metabolism  and  determine  that  FoxP3  promotes  glucose  and  lipid  oxidation  and  
suppresses  glycolytic  metabolism.    Additionally,  FoxP3  restrains  glycolytic  metabolism  
in  human  T  cells  upon  activation.    Importantly,  we  show  promoting  glycolysis  by  
transgenic  expression  of  Glut1  inhibits  the  ability  of  Treg  to  suppress.    Therefore,  the  
FoxP3-­‐‑driven  oxidative  metabolic  program  is  critical  to  Treg  function.              
  
5.2 Results 
5.2.1 FoxP3 expression in human T cells restrains glycolytic 
phenotype 
Previous  studies  have  demonstrated  that  FoxP3  is  transiently  expressed  in  all  
human  T  cells  upon  activation  (Wang  et  al.,  2007).    Deletion  of  FoxP3  leads  to  enhanced  
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T  cell  proliferation  and  cytokine  production  after  TCR  engagement  (McMurchy  et  al.,  
2012).    These  studies  suggest  that  FoxP3  is  a  negative  regulator  of  T  cell  proliferation.    
Because  the  metabolic  status  of  a  T  cell  can  modulate  proliferation,  the  metabolic  effect  
of  FoxP3  knockdown  was  examined  in  human  T  cells.    Knockdown  of  FoxP3  increased  
glucose  uptake  and  glycolysis  in  activated  T  cells  (Fig.  5.1A,  B).    Metabolic  protein  
expression  was  also  examined  after  FoxP3  knockdown.    In  the  majority  of  donors,  the  
expression  of  the  glucose  transporter  Glut1,  as  well  as  hexokinase  2  (Hk2)  and  the  mTor  
target  phospho-­‐‑S6  were  upregulated  upon  FoxP3  deletion  (Fig  5.1C,  donors  1  and  2).    
This  suggests  that  FoxP3  inhibits  glycolytic  metabolism  in  human  T  cell  activation  and  
this  may  contribute  to  its  role  as  a  negative  regulator  of  proliferation.              
  
  
Figure  5.1:  FoxP3  restrains  glycolysis  in  human  T  cell  activation  
Peripheral  blood  T  cells  from  healthy  donors  were  transfected  with  scramble  siRNA  or  
FoxP3  siRNA  and  stimulated  with  anti-­‐‑CD3  and  anti-­‐‑CD28  for  48  hours.    Data  show  (A)  
glucose  uptake  and   (B)  glycolytic   rate  after  48  hours.      (C)   Immunoblotting  on  samples  
collected   after   scramble   or   FoxP3   siRNA   from   3   different   healthy   donors.      Data   is  
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Figure  5.2:  FoxP3  expression  suppresses  glycolytic  metabolism  and  growth  
FL5.12  pro-­‐‑lymphocyte  cells  were   lentivirally   infected  with  FoxP3-­‐‑ER-­‐‑NGFR  or  control  
NGFR  vector.    3  FoxP3-­‐‑ER  and  3  control  lines  were  treated  with  4-­‐‑OHT  for  36  hours  and  
then  examined  for  (A)  glucose  uptake,  (B)  glycolysis,  (C)  extracellular  acidification  rate  
(ECAR),  (D)  pentose  phosphate  pathway  (PPP)  and  (E)  cell  growth  over  the  course  of  4  
days.    Data  is  representative  of  3  independent  experiments.    (A-­‐‑E)  show  the  mean  ±  SD.    




















































































































5.2.2 Expression of FoxP3 drives an oxidative metabolic program 
Our  data  suggests  that  FoxP3  inhibit  glycolytic  metabolism  in  human  T  cells.    
This  is  significant  given  the  emerging  data  about  differences  between  Teff  and  Treg  
metabolism.    While  Teff  utilize  a  glycolytic  program,  Treg  are  not  reliant  on  glucose  and  
we  have  previously  showed  that  Treg  have  high  levels  of  fatty  acid  oxidation  (Michalek  
et  al.,  2011).    We  therefore  examined  the  role  of  FoxP3  in  metabolism  using  an  inducible  
FoxP3  construct.    In  this  model,  FoxP3  is  conjugated  to  a  fragment  of  the  estrogen  
receptor  and  remains  in  the  cytoplasm  until  4-­‐‑hydroxytamoxifen  (4-­‐‑OHT)  is  added  to  
translocate  the  FoxP3-­‐‑ER  to  the  nucleus  where  FoxP3  can  initiate  its  transcriptional  
activity  (Allan  et  al.,  2008).    The  FoxP3-­‐‑ER  cell  lines  were  generated  using  the  FL5.12  pro-­‐‑
lymphocyte  cell  line,  which  has  been  used  previously  to  model  T  cell  metabolism  
(Wofford  et  al.,  2008;  Rathmell  et  al.,  2000).    After  36  hours  of  4-­‐‑OHT  treatment,  the  
metabolic  profile  of  three  FoxP3-­‐‑ER  clones  and  three  control  clones  were  examined.    The  
cells  expressing  FoxP3  had  suppressed  glycolytic  measurements,  including  glucose  
uptake,  glycolysis  and  extracellular  acidification  rate  (ECAR)  which  is  a  measurement  of  
lactate  production  (Fig.  5.2A-­‐‑C).    FoxP3-­‐‑expressing  cells  also  had  decreased  flux  through  
the  pentose  phosphate  pathway  (PPP),  which  contributes  to  nucleotide  and  lipid  
synthesis  (Fig.  5.2D).    These  cells  also  had  a  striking  growth  defect,  likely  due  to  the  
inhibition  of  glycolytic  metabolism  and  PPP  (Fig.  5.2E).    Taken  together,  these  data  
suggest  that  FoxP3  expression  inhibits  glycolytic  metabolism  and  slows  cell  growth.  
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Figure  5.3:  FoxP3  expression  promotes  glucose  and  lipid  oxidation  
FL5.12  pro-­‐‑lymphocyte  cells  were   lentivirally   infected  with  FoxP3-­‐‑ER-­‐‑NGFR  or  control  
NGFR  vector.    3  FoxP3-­‐‑ER  and  3  control  lines  were  treated  with  4-­‐‑OHT  for  36  hours  and  
then   examined   for   (A)   oxygen   consumption   rate,   (B)   the   ratio   of   OCR   to   ECAR,   (C)  
glucose   oxidation,   (D)   fatty   acid   oxidation   and   (E)   glutamine   oxidation.   Data   is  
representative  of  3   independent  experiments.      (A-­‐‑E)   show   the  mean  ±  SD.     RJ  Kishton  
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These  cells,  however,  were  not  metabolically  inactive.    While  glycolytic  
metabolism  was  suppressed,  oxidative  metabolism  was  increased.    FoxP3-­‐‑expressing  
cells  had  higher  oxygen  consumption  (OCR)  and  an  increased  ratio  of  OCR  to  ECAR  
(Fig.  5.3A,  B).    This  was  likely  due  to  an  increase  in  glucose  and  lipid  oxidation  (Fig.  
5.3C,  D).    In  contrast,  glutamine  oxidation  was  unchanged  (Fig  5.3E).    Therefore,  
expression  of  FoxP3  promotes  an  oxidative  metabolic  program  and  inhibits  glycolysis  
and  PPP,  mirroring  the  Treg  metabolic  phenotype.      
Because  this  work  was  done  in  a  lymphocyte  cell  line,  FoxP3  was  also  
retrovirally  expressed  in  primary  CD4+CD25-­‐‑  T  cells  to  examine  the  effect  on  
metabolism.    Similarly  to  the  cell  line,  FoxP3  expression  in  primary  T  cells  inhibited  
glucose  uptake  (Fig  5.4A).    Although  glycolysis  was  decreased  upon  FoxP3  expression  
(Fig.  5.4B),  this  measures  flux  through  the  enolase  step  of  glycolysis  and  may  represent  
increased  glucose  oxidation.    Indeed,  OCR  and  the  ratio  of  OCR  to  ECAR  were  increased  
in  primary  T  cells  expressing  FoxP3  (Fig.  5.4C,  D).    Overall,  this  data  suggests  that  the  
Treg-­‐‑specific  transcription  factor  FoxP3  promotes  an  oxidative  metabolic  phenotype  in  T  
cells  (Fig  5.5).      
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Figure  5.4:  Retroviral  expression  of  FoxP3  in  primary  T  cells  drives  an  oxidative  
metabolic  program  
CD4+CD25-­‐‑   primary   mouse   T   cells   were   retrovirally   infected   with   FoxP3-­‐‑NGFR   or  
control  NGFR.     T  cells  were  activated   for  72  hours  and   then  examined   for   (A)  glucose  
uptake  (Gluc  uptake),  (B)  glycolysis,  (C)  oxygen  consumption  (OCR)  and  (D)  the  ratio  of  
oxygen   consumption   to   extracellular   acidification   rate   (OCR/ECAR   ratio).   Data   is  
representative  of  3  independent  experiments.    (A-­‐‑D)  show  the  mean  ±  SD.    AG  Nichols  
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Figure  5.5:  Overview  of  metabolic  changes  driven  by  FoxP3  
FoxP3   expression   leads   to   metabolic   changes   including   reduced   glucose   uptake,  
glycolysis,   pentose   phosphate   pathway   (PPP)   and   decreased   lactate   as   measured   by  
extracellular   acidification   rate.      Additionally,   FoxP3   promotes   glucose   oxidation,   lipid  















5.2.3 Expression of FoxP3 alters metabolic gene expression 
FoxP3  is  a  transcription  factor  that  is  known  to  interact  with  NFAT,  NFκB  and  
other  transcriptional  regulators  to  promote  or  suppress  gene  transcription  and  drive  the  
Treg  lineage  (Wu  et  al.,  2006).    Many  studies  have  examined  FoxP3  target  genes,  
however  these  were  focused  on  the  immune  aspects  of  FoxP3’s  regulatory  network  
(Zheng  et  al.,  2007).    Our  data  suggest  that  FoxP3  drives  an  oxidative  metabolic  program  
but  this  may  be  due  to  additional  transcription  factors  or  secondary  effects.    We  
therefore  wanted  to  examine  the  role  of  FoxP3  on  metabolic  gene  expression.    FoxP3  was  
retrovirally  expressed  in  primary  CD4+CD25-­‐‑  T  cells  and  gene  expression  was  examined.    
Pathway  analysis  of  affymetrix  data  showed  that  lipid  metabolic  genes  were  
upregulated  by  FoxP3  while  glucose  and  nucleotide  metabolic  genes  were  
downregulated  (Fig.  5.6).    These  genes  appear  to  be  both  direct  and  indirect  FoxP3  
targets.    Therefore,  FoxP3  regulates  a  metabolic  network  both  by  directly  targeting  
metabolic  gene  transcription  and  inducing  secondary  pathways  that  are  regulated  by  
FoxP3  and  other  transcription  factors.                    
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Figure  5.6:    Schematic  of  pathways  regulated  by  FoxP3  expression  
CD4+CD25-­‐‑  primary  mouse  T  cells  were  retrovirally  infected  with  FoxP3-­‐‑NGFR  and  gene  
expression  changes  were  examined.     Pathways  that  are  up  or  downregulated  by  FoxP3  
expression  are  shown.    Data  contributed  by  AD  Wells.          
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5.2.4 Promoting glycolysis inhibits Treg suppressive capacity 
There  is  increasing  evidence  that  the  metabolic  profiles  of  Teff  and  Treg  support  
T  cell  differentiation  and  function.    Our  previous  data  shows  that  metabolic  inhibition  
can  alter  T  cell  cytokine  production,  proliferation  and  survival  (Fig.  4.1,  4.2).    Treg  utilize  
an  oxidative  metabolic  program  and  inhibition  of  electron  transport  with  rotenone  limits  
Treg  differentiation  and  survival.    In  contrast,  promoting  glucose  oxidation  by  activating  
pyruvate  dehydrogenase  (PDH)  activity  promoted  Treg  differentiation  and  function  in  
vitro  and  in  vivo  (Fig.  4.11,  4.13).    This  suggests  that  Treg  function  is  intimately  linked  to  
an  oxidative  metabolic  status.    Therefore,  we  examined  the  effect  of  a  glycolytic  
metabolism  on  Treg  function.      
We  have  previously  described  mice  that  transgenically  express  the  glucose  
transporter  Glut1  specifically  in  the  T  cells  (Jacobs  et  al.,  2008;  Michalek  et  al.,  2011).    T  
cells  in  which  Glut1  is  overexpressed  show  increased  glucose  uptake,  glycolysis  and  
cytokine  production.    T  cells  from  aged  Glut1  transgenic  mice  (Glut1  tg)  have  elevated  
levels  of  activation  markers  including  CD25,  CD44  and  CD69  and  develop  a  mild  
inflammatory  disorder.    T  cells  from  Glut1  transgenic  mice  were  therefore  in  vitro  
differentiated  into  Treg  and  assessed  for  suppressive  capacity.    Surprisingly,  Glut1  tg  
Treg  differentiation  was  normal,  even  enhanced,  compared  to  control  Treg  (Fig.  5.7A).    
However,  despite  increased  Treg  numbers,  Glut1  tg  Treg  had  decreased  suppressive  
capacity  at  every  ratio  of  effector  T  cells  (Fig.  5.7B).    While  the  functional  defect  is  not  
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severe,  this  data  suggests  that  promoting  glycolysis  in  Treg  is  unfavorable  and  inhibits  
Treg  function.                  
  
Figure  5.7:  Glut1  transgenic  Treg  have  decreased  suppressive  function  
CD4+CD25-­‐‑   T   cells   from  Glut1   transgenic   or   littermate   control  mice  were   polarized   in  
vitro   for   5   days   to   generate  Treg   cells.   (a)   FoxP3   expression  was   examined  using   flow  
cytometry.      (b)   Treg   function   was   tested   in   an   in   vitro   suppression   assay.      Data   is  
representative  of  2  independent  experiments.      
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   CD4  T  cell  activation  leads  to  rapid  growth,  proliferation  and  differentiation  into  
effector  (Teff)  or  regulatory  (Treg)  cells,  each  with  specific  immune  functions.    Treg,  in  
particular,  are  essential  to  maintain  self–tolerance  and  actively  suppress  autoimmunity.    
It  has  recently  become  clear  that  Teff  and  Treg  utilize  distinct  metabolic  programs  and  
these  programs  are  required  for  the  survival,  proliferation  and  function  of  each  subset.    
While  Teff  rely  on  high  rates  of  glycolysis,  Treg  instead  require  mitochondrial  oxidation  
and  can  utilize  both  glucose  and  lipids  as  fuel.    However,  the  regulation  of  these  
metabolic  programs  is  unknown.    Here,  we  identify  FoxP3  as  the  key  regulator  of  Treg  
metabolism.    Inducible  expression  of  FoxP3  in  a  lymphocyte  cell  line  or  in  CD4+CD25-­‐‑  
primary  T  cells  suppresses  glycolytic  metabolism  and  promotes  glucose  and  lipid  
oxidation.    Chromatin  immunoprecipitation  experiments  suggest  that  FoxP3  binds  to  
and  directly  regulates  the  expression  of  many  metabolic  genes.    Importantly,  this  
oxidative  program  is  required  for  Treg  function,  as  overexpression  of  the  glucose  
transporter  Glut1  to  promote  glycolytic  metabolism  inhibits  Treg  function  in  vitro.    
Overall,  this  data  suggests  that  FoxP3  drives  an  oxidative  metabolic  program  that  is  
critical  to  Treg  function.      
   The  transcription  factor  FoxP3  is  considered  to  be  the  master  regulator  of  Treg  
and  is  critical  to  Treg  development  and  function  (Fontenot  et  al.,  2003;  Hori  et  al.,  2003).  
FoxP3-­‐‑deficient  mice  lack  Treg  and  develop  a  fatal  multiorgan  autoimmune  disease  
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(Fontenot  et  al.,  2003).    While  FoxP3  appears  to  be  the  key  regulator  of  mouse  Treg,  the  
role  of  FoxP3  in  human  T  cells  is  less  clear.    FoxP3  is  not  sufficient  to  confer  the  human  
Treg  phenotype  and  human  Treg  are  now  defined  by  multiple  transcription  factors,  
including  FoxP3,  Helios,  Eos  and  others  (Thornton  et  al.,  2010;  Sharma  et  al.,  2013).    
Additionally,  FoxP3  is  transiently  expressed  by  a  majority  of  CD4  and  CD8  conventional  
T  cells  immediately  following  T  cell  activation  (Walker  et  al.,  2003).    This  expression  of  
FoxP3  does  not  necessarily  lead  to  a  suppressive  phenotype,  as  many  FoxP3+  human  T  
cells  still  produce  IL-­‐‑2  and  IFNγ  and  cannot  suppress  (Allan  et  al.,  2007;  Gavin  et  al.,  
2006).  Together,  these  data  suggest  that  FoxP3  may  have  functions  beyond  Treg  
suppression.      
A  recent  study  showed  that  FoxP3  knockdown  increased  proliferation  and  
cytokine  production  in  conventional  T  cells  (McMurchy  et  al.,  2013).    Here,  we  show  that  
FoxP3-­‐‑null  human  T  cells  have  increased  glycolytic  metabolism  and  glycolytic  protein  
expression.    As  metabolism  and  proliferation  are  tightly  linked  (Fox  et  al.,  2005;  Vander  
Heiden  et  al.,  2009),  our  data  suggests  that  FoxP3  restricts  glycolytic  metabolism  and  
thereby  prevents  proliferation  in  conventional  human  T  cells.    Interestingly,  FoxP3  may  
be  differentially  localized  in  Treg  and  conventional  T  cells.    Magg  et  al.  showed  that  
FoxP3  can  shuttle  between  the  nucleus  and  cytoplasm  and  is  largely  located  in  the  
cytoplasm  in  conventional  T  cells  (Magg  et  al.,  2012).    Whether  FoxP3  is  directly  
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regulating  metabolic  changes  through  gene  expression  or  through  another  mechanism  is  
still  under  active  investigation.    
We  and  others  have  shown  that  Teff  and  Treg  utilize  distinct  metabolic  pathways  
and  these  pathways  are  critical  for  the  survival,  proliferation  and  function  of  each  
subtype  (Michalek  et  al.,  2011b;  Shi  et  al.,  2011).    The  regulation  of  these  metabolic  
programs,  however,  is  unknown.    Here,  we  examined  the  role  of  FoxP3  in  Treg  
metabolism  and  found  that  FoxP3  drives  an  oxidative  metabolic  program  that  is  critical  
to  Treg  function.    While  our  gene  expression  data  suggests  that  FoxP3  directly  regulates  
metabolic  gene  expression,  it  is  likely  that  FoxP3  functions  to  drive  these  metabolic  
changes  through  both  direct  and  indirect  methods  and  will  be  examined  in  further  
studies.      
Several  other  signaling  pathways  have  been  shown  to  modulate  the  balance  
between  Teff  and  Treg  and  may  interact  with  FoxP3  to  contribute  to  the  Treg  metabolic  
phenotype.    Delgoffe  et  al.  showed  that  mTOR  knockout  T  cells  fail  to  become  Teff  even  
when  differentiated  in  vitro  with  the  appropriate  cytokines  and  instead  default  to  the  
Treg  lineage  (Delgoffe  et  al.,  2009).    The  mTOR  pathway  affects  a  variety  of  signaling  
pathways,  including  metabolic  pathways,  and  may  be  an  important  contributor  towards  
Teff  and  Treg  metabolic  profiles  (Chi,  2012).    Future  work  is  needed  to  determine  if  
FoxP3  and  mTor  interact  to  contribute  to  the  Treg  metabolic  phenotype.    Additionally,  
there  is  increasing  evidence  that  Treg  may  use  metabolic  strategies  to  suppress  Teff  
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(Shevach,  2009).    Treg  can  trigger  a  signaling  pathway  in  dendritic  cells  that  inhibits  
glutathione  (GSH)  synthesis  to  inhibit  Teff  (Yan  et  al.,  2010).    Treg  can  also  induce  
dendritic  cells  to  consume  essential  amino  acids  (EAA),  which  inhibits  T  cell  
proliferation  (Cobbold  et  al.,  2009).    Taken  together,  these  data  argue  that  it  would  be  
beneficial  for  Treg  to  utilize  a  different  metabolic  program  than  Teff.                
While  previous  studies  showed  that  Treg  utilize  mitochondrial  oxidation  for  
energy  production,  this  is  the  first  to  show  that  promoting  glycolytic  metabolism  
suppresses  Treg  function.    Glut1  transgenic  T  cells  have  been  previously  shown  to  have  
increased  glucose  uptake  as  well  as  increased  cytokine  production  in  aged  mice  (Jacobs  
et  al.,  2008).    While  in  vitro  differentiation  into  FoxP3+  Treg  was  normal  or  even  enhanced  
in  Glut1  transgenic  T  cells  compared  to  vehicle,  these  cells  were  less  suppressive  in  an  in  
vitro  suppression  assay.    Interestingly,  Zeng  et  al.  showed  that  Treg  can  also  be  
generated  from  Raptor-­‐‑deficient  (mTORC1-­‐‑deficient)  T  cells  but  they  are  not  functional  
(Zeng  et  al.,  2013).    mTORC1  deletion  was  also  shown  to  suppress  lipid  metabolism  and  
the  rate  of  oxygen  consumption.    Overall,  these  data  suggest  that  FoxP3  drives  an  
oxidative  metabolic  program  in  Treg  that  is  distinct  from  Teff  metabolism.    These  
metabolic  differences  between  Teff  and  Treg  may  be  necessary  for  the  ability  of  Treg  to  
function  and  suppress  inflammation  during  an  active  immune  response.  
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6.  Conclusion and Future Directions 
The  work  described  here  outlines  four  major  points.    1)  Inhibition  of  glucose  
metabolism  through  a  T  cell-­‐‑specific  genetic  deletion  of  Glut1  suppresses  effector  T  cell  
(Teff)  but  not  regulatory  T  cell  (Treg)  differentiation  and  function.    2)  While  Teff  
generally  rely  on  glucose  and  Treg  are  glucose  independent,  the  four  T  cell  subsets;  Th1,  
Th2,  Th17  and  Treg  all  have  distinct  metabolic  profiles.    This  allows  for  the  exciting  
possibility  to  target  a  specific  T  cell  subtype  in  a  pathological  setting.    3)  Inhibition  of  
PDHK1  selectively  suppresses  Th2  and  Th17  function,  and  promotes  Treg  
differentiation.    This  suggests  that  promoting  glucose  oxidation  is  unfavorable  for  Th2  
and  Th17,  while  it  is  advantageous  for  Treg.    4)  The  Treg-­‐‑specific  transcription  factor  
FoxP3  is  important  to  direct  an  oxidative  metabolic  program  that  contributes  to  Treg  
function.      
  
6.1 Glucose metabolism is required for Teff, but not Treg 
While  the  metabolic  reprogramming  that  occurs  upon  T  cell  activation  is  well  
described,  less  is  understood  about  the  metabolic  phenotype  of  differentiated  CD4  T  
cells  (Teff:  Th1,  Th2,  Th17;  and  Treg).    Furthermore,  the  studies  that  suggest  metabolic  
differences  between  Teff  and  Treg  are  largely  in  vitro  experiments  or  use  
pharmacological  agents  in  vivo,  which  affect  all  cell  types,  including  antigen-­‐‑presenting  
cells,  and  may  have  indirect  effects  on  T  cell  differentiation.    Here,  a  mechanistic,  cell-­‐‑
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intrinsic  approach  was  taken  to  determine  the  direct  effect  of  glucose  metabolism  on  T  
cell  differentiation.      
To  determine  the  role  of  glucose  metabolism  on  T  cell  differentiation,  the  glucose  
transporter  Glut1  was  genetically  deleted  specifically  in  T  cells.    Glut1  is  one  of  the  major  
transporters  in  T  cells  (Fig.  3.1B)  and  is  upregulated  and  trafficked  to  the  cell  surface  
during  T  cell  activation  (Jacobs  et  al.,  2008;  Wofford  et  al.,  2008).    Importantly,  Glut1  
represents  one  major  entry  point  of  glucose  into  the  cell  and  therefore  deletion  of  Glut1  
suppresses  global  cellular  glucose  metabolism.    By  deleting  Glut1  specifically  in  T  cells  
using  a  T  cell  specific  Cre  (LckCre  or  CD4Cre),  we  were  able  to  determine  the  cell-­‐‑
intrinsic  role  of  glucose  metabolism.    Indeed,  deletion  of  Glut1  in  T  cells  led  to  decreased  
glucose  uptake,  glycolysis  and  lactate  production  and  proliferation  upon  T  cell  
activation  (Figs.  3.2  and  3.3).    Deletion  of  Glut1  in  the  T  cell  compartment  led  to  a  drastic  
increase  in  the  percentage  of  T  cells  that  were  FoxP3+  (Fig.  3.4A).    As  the  number  of  
FoxP3+  Treg  was  unchanged,  this  increased  percentage  was  due  to  a  decrease  in  the  non-­‐‑
Treg  T  cells  (Fig.  3.4B).    In  an  in  vivo  model  of  colitis,  Glut1  knockout  Teff  were  less  able  
to  expand  or  function  compared  to  control  Teff,  however  Glut1  knockout  Treg  had  a  
similar  suppressive  capacity  as  wildtype  Treg.      
While  this  work  demonstrates  the  role  of  Glut1  in  Teff,  but  not  Treg,  function,  
many  questions  remain  to  be  addressed.    We  chose  to  delete  Glut1  because  it  is  at  the  
top  of  the  glucose  metabolic  pathway  and  will  therefore  globally  suppress  glucose  
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metabolism.    However,  Glut1  has  many  functions  and  may  be  affecting  other  aspects  of  
T  cell  biology  and  signaling  pathways  besides  glucose  metabolic  pathways.    For  
example,  Glut1  has  been  shown  to  transport  ascorbic  acid  (vitamin  C)  in  addition  to  
glucose  (KC  et  al.,  2005).    It  is  possible  that  the  lack  of  this  important  antioxidant  affects  
Teff  but  not  Treg  function.    Additionally,  Glut1  has  been  shown  to  transport  
glucosamine,  a  precursor  for  O-­‐‑linked  glycosylation  of  proteins  (Uldry  et  al.,  2002)  and  
this  cannot  be  ruled  out  as  a  mechanism  for  the  effect  of  Glut1  on  Teff  with  the  current  
study.    
Therefore,  it  will  be  important  to  examine  other  glucose  transporters  as  well  as  
metabolic  enzymes  further  downstream  of  glucose  transporters.    Glut3  is  expressed  in  
naïve  T  cells  and  then  similarly  to  Glut1,  it  is  highly  upregulated  in  Teff  (Fig.  3.1B).    
However,  it  has  a  low  expression  level  in  activated  T  cells  and  Treg.    This  is  in  contrast  
to  Glut1,  which  is  upregulated  during  T  cell  activation  and  remains  high  in  Teff.    It  
remains  to  be  seen  whether  Glut3  protein  levels  decrease  upon  initial  T  cell  activation  
and  later  increase,  or  alternatively  the  cytokines  present  during  in  vitro  T  cell  
differentiation  may  promote  the  continued  expression  of  Glut3.    Regardless,  it  will  be  
important  to  examine  Glut3  deletion  as  an  alternative  strategy  to  inhibit  glucose  uptake,  
as  it  does  not  transport  ascorbic  acid  and  therefore  any  differences  between  Glut3  and  
Glut1  deletion  will  indicate  Glut1-­‐‑specific  effects.    This  could  be  done  using  
Glut3fl/flCD4Cre  mice  in  which  Glut3  is  deleted  specifically  in  the  T  cell  compartment.    
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One  caveat  will  be  the  potential  loss  of  naïve  T  cells,  as  they  may  rely  on  Glut3  for  
glucose  import  and  low  T  cells  numbers  would  make  these  studies  more  difficult.    As  an  
alternative  strategy,  Glut3fl/flUbiCreER  mice  could  be  generated  and  therefore  Glut3  
could  be  deleted  after  T  cell  activation  and  the  role  of  Glut3  could  be  assessed  in  
activated  and  differentiated  T  cells.      
In  addition  to  studying  the  effect  of  deleting  other  glucose  transporters,  it  is  
critical  to  examine  the  role  of  metabolic  enzymes  further  down  the  glycolytic  pathway.    
One  potentially  exciting  target  is  immediately  downstream  of  glucose  import:  
Hexokinase  (Hk).    Hexokinase  phosphorylates  glucose  to  glucose-­‐‑6-­‐‑phosphate  and  
analysis  of  Hk  inhibition  either  pharmacologically  or  genetically  will  be  important  to  
determine  if  the  effects  on  Teff  function  seen  with  Glut1  knockout  T  cells  is  specific  to  
glucose  transporter  inhibition  or  general  glycolytic  inhibition.      
Additionally,  there  are  four  isoforms  that  have  distinct  tissue  specificity  and  
enzyme  kinetics.    In  T  cells,  Hk1  is  expressed  in  naïve  T  cells  and  Treg  while  Hk2  is  
expressed  in  activated  T  cells  and  Teff  (Fig.  4.4;  Wang  et  al.,  2012).  While  Hk1  is  
expressed  in  many  tissue  types,  Hk2  is  more  selectively  expressed.    Hk2  has  also  been  
associated  with  an  aerobic  glycolysis  phenotype  and  is  typically  expressed  by  highly  
proliferative  tissues,  including  many  types  of  cancer  (Mathupala  et  al.,  2006).    Indeed,  
recent  literature  suggests  that  Hk2  may  be  a  therapeutic  target  for  cancer,  as  Hk2  
ablation  inhibited  tumor  initiation  and  maintenance  in  mouse  models  of  lung  and  breast  
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cancer  (Patra  et  al.,  2013).    Further,  mice  heterozygous  for  Hk2  do  not  have  changes  in  
glucose  levels  when  fed  a  normal  diet,  suggesting  that  Hk2  inhibition  may  be  possible  
therapeutically  (Heikkinen  et  al.,  1999).    The  differential  expression  of  Hk  isoforms  in  T  
cells  therefore  makes  it  a  potential  target  for  modulating  the  Teff:Treg  balance.    The  lack  
of  Hk2  expression  in  naïve  T  cells  and  Treg  suggests  that  Hk2  knockout  T  cells  may  have  
a  similar  phenotype  to  Glut1  knockout  T  cells.    If  there  are  differences  seen  between  
Glut1  and  Hk2  knockout  T  cells,  it  suggests  that  there  may  be  Glut1-­‐‑  or  Hk2-­‐‑specific  
effects  on  T  cell  signaling  that  could  then  be  examined  in  greater  detail.      If  Hk2  looks  
like  a  promising  target,  there  are  pharmacological  strategies  that  can  also  be  employed.    
There  are  several  drugs  that  target  Hk  including  lonidamine,  which  is  in  clinical  trials  
(Floridi  et  al.,  1998;  Pelicano  et  al.,  2006).    Although  Hk1  and  Hk2  are  structurally  similar,  
they  differ  in  the  response  to  inorganic  phosphate  and  this  may  lead  to  a  specific  
inhibition  strategy  (Wilson  et  al.,  2003).    Therefore,  inhibition  of  alternate  glucose  
transporters  or  other  metabolic  enzymes  such  as  hexokinase  will  provide  additional  
evidence  for  the  role  of  glucose  metabolism  on  T  cell  differentiation.      
Another  important  area  of  study  will  be  to  extend  this  work  to  human  T  cells.    
Although  human  and  mouse  T  cells  show  a  similar  metabolic  reprogramming  upon  
activation,  Teff  and  Treg  metabolism  in  human  T  cells  is  unknown.    To  proceed  forward  
with  therapeutic  strategies  for  human  disease,  it  is  critical  to  determine  whether  the  
metabolic  programs  we  have  described  in  mouse  T  cells  are  similar  in  human  T  cells.    A  
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few  studies  have  examined  the  role  of  DCA  in  human  T  cells  and  it  appears  to  have  a  
similar  effect  to  mouse  T  cells  (Ostroukhova  et  al.,  2012;  Eleftheriadis  et  al.,  2013).    
However,  there  are  currently  no  studies  that  look  at  the  metabolic  profile  of  human  T  
cells  or  the  effect  of  metabolic  inhibition  on  Teff  or  Treg  function.    There  are  several  
difficulties  with  working  with  human  T  cells.    Whereas  mouse  studies  use  very  
genetically  similar  animals  and  therefore  have  less  biological  variability,  humans  are  
much  more  genetically  diverse  and  there  may  be  vast  differences  between  the  T  cells  of  
different  humans.    This  will  likely  require  a  high  number  of  human  donors  to  analyze  
when  looking  at  the  T  cell  metabolic  profiles.    
Additionally,  and  unlike  mouse  Treg  cells  that  are  simply  defined  by  the  
transcription  factor  FoxP3,  human  Treg  are  described  by  multiple  transcription  factors,  
including  FoxP3,  Helios,  Eos  and  others  (Thornton  et  al.,  2010;  Sharma  et  al.,  2013).    In  
addition,  some  groups  define  natural  human  Treg  as  Helios+  but  others  argue  that  there  
are  both  Helios+  and  Helios-­‐‑  natural  human  Treg  (Himmel  et  al.,  2013).    Therefore,  the  
role  of  metabolism  in  human  T  cells  is  complicated  but  it  is  important  to  extend  these  
studies  to  human  T  cells  as  the  next  step  towards  an  application  to  human  autoimmune  
disease.            
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6.2 Distinct metabolic profiles and requirements in Teff and Treg 
      An  important  question  that  arises  from  this  work  is  why  Teff  and  Treg  would  
require  distinct  metabolic  programs.    Our  work  and  the  work  of  other  groups  suggest  
that  Treg  can  function  in  the  absence  of  glucose  and  can  utilize  fatty  acids  to  support  
their  functions  (Michalek  et  al.,  2011a;  Shi  et  al.,  2011).    Importantly,  studies  with  DCA  
indicate  that  Treg  can  utilize  glucose  through  glucose  oxidation  pathways.    Overall,  this  
suggests  that  Treg  have  metabolic  fuel  flexibility  and  are  able  to  utilize  either  glucose  or  
fatty  acids.    Treg  function  to  suppress  Teff  proliferation  as  a  means  to  restrain  Teff  
inflammatory  function  and  prevent  excessive  inflammation  or  autoimmunity.    This  fuel  
flexibility  may  be  important  in  vivo  during  T  cell  suppression.    
Recently,  there  is  increasing  evidence  that  Treg  utilize  metabolic  strategies  to  
suppress  Teff  (Shevach  2009).    Treg  upregulate  the  expression  of  CD39,  which  converts  
ATP  into  AMP,  thereby  degrading  ATP  in  the  microenvironment  and  leading  to  Teff  
suppression  (Deaglio  et  al.,  2007).    Treg  also  directly  compete  with  Teff  for  cysteine  
uptake  as  well  as  trigger  a  signaling  pathway  in  dendritic  cells  that  inhibits  GSH  
synthesis  to  inhibit  Teff  (Yan  et  al.,  2010).      Additionally,  Treg  can  induce  dendritic  cells  
to  consume  essential  amino  acids  (EAA),  which  inhibits  T  cell  proliferation  (Cobbold  et  
al.,  2009).    In  this  study,  Cobbold  et  al.  showed  that  amino  acid  starvation  also  inhibits  
the  mTOR/PI3K  pathway  and  induces  Treg  in  a  feed-­‐‑forward  loop.    Taken  together,  
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these  data  argue  that  it  would  be  advantageous  for  Treg  to  have  a  distinct  metabolic  
profile  from  Teff.    If  Teff  and  Treg  had  similar  signaling  pathways  and  metabolism,  it  
would  be  difficult  for  Treg  to  migrate  to  a  hostile,  inflammatory  environment  and  
functionally  inhibit  Teff.    For  Treg  to  suppress  Teff  by  inhibiting  GSH  synthesis,  it  
suggests  that  Treg  do  not  rely  as  heavily  on  GSH  synthesis.    For  Treg  to  suppress  by  
inhibiting  EAA,  it  suggests  that  Treg  have  a  different  amino  acid  requirement  than  Teff.    
Therefore,  the  metabolic  differences  between  Teff  and  Treg  may  be  necessary  for  the  
ability  of  Treg  to  function  and  suppress  inflammation.  
Given  our  data  that  Treg  do  not  rely  on  glucose,  this  suggests  the  exciting  
possibility  that  Treg  inhibit  glucose  metabolism  as  another  mechanism  of  Teff  
suppression.    It  is  conceivable  that  Treg  inhibit  glucose  metabolism  in  Teff  through  the  
downregulation  of  Glut1  surface  protein.    Because  there  are  not  Glut1-­‐‑specific  surface  
antibodies  available  for  sensitive  flow  cytometry,  this  could  be  tested  with  Glut1-­‐‑myc  
mice.    These  mice  express  Glut1  protein  with  a  tandem  Myc  epitope  tag  that  is  expressed  
under  the  endogenous  promoter  and  therefore  transporters  and  traffics  glucose  
normally  (Michalek  et  al.,  2011a).    To  test  the  hypothesis  that  Treg  inhibit  glucose  
metabolism  as  a  means  of  suppression,  Treg  can  be  co-­‐‑cultured  with  Glut1-­‐‑myc  Teff  in  a  
in  vitro  suppression  assay  and  Glut1  surface  expression  can  be  tracked  by  flow  
cytometry  to  see  if  Glut1  gets  downregulated  upon  Treg  suppression.      
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Additionally,  Treg  suppression  assays  can  be  performed  using  Glut1  knockout  or  
Glut1  transgenic  Teff.    Our  data  would  suggest  that  Treg  suppression  would  be  less  
effective  in  Glut1  transgenic  Teff  in  which  Glut1  is  overexpressed  and  glucose  uptake  is  
highly  increased.    This  could  then  be  taken  into  an  inflammatory  model,  such  as  colitis,  
to  test  this  hypothesis  in  vivo.    In  this  setting,  Glut1  transgenic  Teff  would  be  co-­‐‑injected  
with  wildtype  Treg  into  Rag1-­‐‑/-­‐‑  mice  to  initiate  colitis.    If  Treg  are  less  able  to  suppress  
Glut1  transgenic  Teff,  we  would  predict  the  colitis  disease  progression  to  be  more  severe  
than  with  wildtype  Teff.    Similarly,  we  could  examine  Glut1-­‐‑myc  T  cells  in  vivo  to  
determine  the  time  course  of  Glut1  up-­‐‑  or  down-­‐‑regulation  during  colitis  disease  
progression  with  or  without  the  presence  of  Treg.    This  could  be  done  both  with  co-­‐‑
injection  of  Treg  or  alternatively,  using  a  colitis  model  where  colitis  is  initiated  with  Teff  
and  then  21  days  later,  Treg  are  injected  and  are  able  to  suppress  colitis  at  this  later  time  
point  (Chunder  et  al.,  2012).    Both  models  would  provide  valuable  information  about  the  
necessity  of  Glut1  to  both  disease  progression  and  resistance  or  sensitivity  to  Treg  
suppressive  abilities.      
While  this  work  focused  on  differences  in  glucose  metabolism,  there  is  little  
understanding  of  Treg  lipid  and  glutamine  utilization.    In  previous  studies,  our  lab  
showed  that  Treg  have  high  levels  of  lipid  oxidation  and  are  sensitive  to  etomoxir  
treatment  (Michalek  et  al.,  2011a).      However,  etomoxir  can  have  off-­‐‑target  effects  and  
therefore  a  better  approach  would  be  to  genetically  delete  a  component  of  fatty  acid  
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oxidation,  such  as  CPT1α,  in  T  cells.    An  alternative  strategy  is  to  either  overexpress  
CPT1α  or  a  CPT1α  shRNA  lentiviral  construct  in  primary  T  cells.    Using  these  
techniques,  the  requirement  of  Treg  for  lipid  oxidation  could  be  directly  tested.    It  
remains  to  be  seen  whether  Treg  primarily  use  lipids  as  a  fuel  or  if  they  are  simply  able  
to  use  them  but  prefer  glucose  or  another  fuel.    Additionally,  our  previous  studies  also  
suggest  that  lipids  have  a  negative  effect  on  Teff  (Michalek  et  al.,  2011b).    This  could  also  
be  tested  with  the  above  strategies  and  examine  if  CPT1α  induction  in  Teff  has  a  
negative  impact  on  effector  proliferation  or  function.    It  is  possible  to  imagine  that  the  
induction  of  lipid  oxidation  would  be  unfavorable  for  Teff,  given  that  DCA  or  PDHK1  
shRNA  to  drive  glucose  oxidation  inhibits  Th2  and  Th17  differentiation  and  function.  
In  contrast  to  glucose  and  lipid  metabolism,  glutamine  metabolism  in  the  context  
of  T  cell  differentiation  is  not  well  understood.    However,  there  are  a  few  studies  looking  
at  glutamine  metabolism  during  T  cell  activation.    Wang  et  al.  showed  that  Myc-­‐‑driven  
glutaminolysis  is  critical  for  T  cell  activation  (Wang  et  al.,  2011)  and  Sinclair  et  al.  
demonstrated  that  T  cell  activation  leads  to  the  upregulation  of  a  particular  amino  acid  
transporter  subunit,  Slc7a5,  and  was  required  for  the  activation  of  mTORC1  and  the  
expression  of  Myc  (Sinclair  et  al.,  2013).      This  suggests  that  glutamine  and  other  amino  
acid  metabolism  is  important  for  T  cell  metabolic  reprogramming  and  so  it  will  be  
important  to  examine  in  the  context  of  T  cell  differentiation.      
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Given  that  some  of  the  Treg  suppression  mechanisms  involve  amino  acid  
utilization  or  starvation,  it  is  likely  that  Teff  and  Treg  have  different  glutamine  or  other  
amino  acid  requirements.    Therefore,  examining  glutamine  metabolism  in  the  context  of  
T  cell  differentiation  will  also  be  important  to  gain  a  more  complete  understanding  of  
Teff  and  Treg  fuel  utilization.    Ultimately,  these  differences  in  fuel  utilization  could  be  
exploited  in  targeting  specific  T  cell  subsets.    Glutamine  starvation  in  vitro  or  inhibition  
using  glutaminase  inhibitors  such  as  6-­‐‑diazo-­‐‑5-­‐‑oxo-­‐‑L-­‐‑norleucine  (DON)  will  provide  
preliminary  data  on  the  requirement  of  differentiated  T  cells  on  glutamine  metabolism  
(Willis  et  al.,  1977).    While  Wang  et  al.  used  Myc  knockout  T  cells  for  this  purpose;  a  
more  direct  approach  would  be  to  use  glutaminase  (GLS)  knockout  T  cells.    Glutaminase  
is  an  enzyme  that  converts  glutamine  to  glutamate  and  is  an  important  part  of  glutamine  
utilization  in  the  cell.    Using  GLS  knockout  T  cells  it  will  be  possible  to  study  the  in  vivo  
glutamine  requirements  of  T  cells  in  the  context  of  colitis  or  other  inflammatory  
disorder.            
 
6.3 Regulation of glucose metabolism in T cell differentiation 
Another  important  question  that  arises  from  this  work  is  how  the  metabolic  
differences  between  the  T  cell  subsets  are  regulated.    In  Th17,  there  is  evidence  that  
RORγt  can  directly  interact  with  HIF1α  and  drive  a  glycolytic  program  (Dang  et  al.,  
2011).    Dang  et  al.  showed  that  HIF1α  activates  RORγt  via  a  complex  with  p300  and  
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regulates  Th17-­‐‑specific  genes  including  IL-­‐‑17.    In  our  study,  we  examined  the  role  of  
FoxP3  in  Treg  metabolism.    Given  that  FoxP3  is  the  major  transcriptional  regulator  in  
Treg,  we  hypothesized  that  FoxP3  may  influence  Treg  metabolism,  either  directly  or  
indirectly.      
Several  approaches  were  taken  to  examine  this  hypothesis.    Knocking  out  FoxP3  
in  Treg  is  not  useful  because  FoxP3-­‐‑  T  cells  are  no  longer  suppressive  and  thus  no  longer  
defined  as  Treg.    Therefore,  we  generated  a  cell  line  where  FoxP3  can  be  inducibly  
activated  and  metabolism  could  therefore  be  examined  pre-­‐‑  and  post-­‐‑FoxP3  activation.    
We  used  a  FoxP3-­‐‑ER  construct  where  FoxP3  is  conjugated  to  a  fragment  of  the  estrogen  
receptor  and  remains  in  the  cytoplasm  until  tamoxifen  (in  vitro:  4-­‐‑hydroxytamoxifen)  is  
added  to  translocate  the  FoxP3-­‐‑ER  to  the  nucleus  where  FoxP3  can  initiate  its  
transcriptional  activity.    The  FoxP3-­‐‑ER  cell  lines  were  generated  using  the  FL5.12  pro-­‐‑
lymphocyte  cell  line  because  it  does  not  normally  express  FoxP3  but  is  a  lymphocyte  
precursor  line  that  has  been  used  to  model  T  cell  metabolism  previously  (Wofford  et  al.,  
2008;  Rathmell  et  al.,  2000).      Using  this  model,  the  role  of  FoxP3  on  metabolism  was  
examined.  
    In  our  study,  we  examined  the  effect  of  FoxP3  on  metabolism  through  both  
retroviral  expression  in  primary  CD4+CD25-­‐‑  T  cells  or  in  the  inducible  FoxP3-­‐‑ER  lines.    
Through  these  studies  we  found  that  FoxP3  drives  an  oxidative  metabolic  program  that  
promotes  both  glucose  and  lipid  oxidation  while  suppressing  glucose  uptake  and  lactate  
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production.    These  metabolic  changes  may  be  due  to  both  direct  and  indirect  gene  
transcription  and  further  work  is  needed  to  determine  the  mechanism  of  these  metabolic  
changes.    FoxP3  does  have  direct  target  genes  that  are  metabolic  in  nature  and  further  
work  will  examine  these  direct  target  genes  in  greater  detail  by  knockdown  
experiments.    It  is  likely  that  in  addition  to  direct  metabolic  target  genes,  FoxP3  drives  
the  expression  of  other  transcription  factors  that  lead  to  metabolic  changes.      
For  example,  the  transcription  factor  Foxo1  has  recently  been  found  to  control  
Treg  development  and  function.    Mice  that  have  Foxo1-­‐‑deficient  T  cells  have  multiorgan  
lymphocyte  infiltration  (Kerdiles  et  al.,  2010).    Additionally,  Foxo1  knockout  T  cells  
differentiated  into  Th1  cells  even  in  the  presence  of  TGFβ  (Kerdiles  et  al.,  2010).    In  the  
context  of  skeletal  muscle  and  adipocytes,  Foxo1  plays  a  metabolic  role,  maintaining  
glucose  homeostasis  and  promoting  lipid  oxidation  during  fasting  conditions  (Bastie  et  
al.,  2005).    This  suggests  that  Foxo1  may  be  playing  a  metabolic  role  in  Treg,  either  to  
promote  Treg  function  through  metabolic  changes  or  as  an  additional  role.    Therefore,  it  
would  be  interesting  to  examine  the  metabolic  profile  of  Foxo1-­‐‑null  Treg  to  see  if  they  
have  altered  metabolism  in  addition  to  their  lack  of  function.  
Another  important  transcription  factor  that  regulates  oxidative  metabolism  is  
peroxisome  proliferator-­‐‑activated  receptor  gamma  coactivator  1-­‐‑alpha/beta  (PGC1α/β).    
This  family  of  transcription  factors  is  involved  in  the  control  of  energy  metabolic  
pathways,  primarily  mitochondrial  pathways.    Together  with  downstream  transcription  
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factors  including  ERRα  and  the  peroxisome  proliferator-­‐‑activated  receptor  (PPAR)  
family,  PGC1  promotes  electron  transport,  oxidative  phosphorylation  and  fatty  acid  
oxidation  (reviewed  in  Finck  et  al.,  2006).    Interestingly,  PGC1  has  been  shown  to  
directly  associate  with  and  activate  Foxo1  in  the  context  of  liver  metabolism  (Puigserver  
et  al.,  2003).    FoxP3  may  promote  the  expression  of  Foxo1,  PGC1  or  both  as  a  mechanism  
to  promote  oxidative  metabolism  in  Treg.  
Another  important  signaling  pathway  in  T  cells  is  the  Akt/PI3K/mTOR  pathway.    
Previous  studies  have  pointed  towards  a  role  of  mTORC1/2  in  T  cell  differentiation,  
although  the  role  of  mTOR  in  T  cells  appears  to  be  complex.    Delgoffe  et  al.  showed  that  
mTOR  knockout  T  cells  fail  to  become  Teff  even  when  differentiated  in  vitro  with  the  
appropriate  cytokines  and  instead  default  to  the  Treg  phenotype  (Delgoffe  et  al.,  2009).    
In  a  later  paper,  Delgoffe  et  al.  showed  that  T  cells  lacking  mTORC1  activity  
preferentially  differentiate  into  Th2  but  not  Th1/17,  and  alternatively  T  cells  lacking  
mTORC2  activity  can  differentiate  into  Th1  and  Th17  but  not  Th2  (Delgoffe  et  al.,  2011).    
Additional  data  from  Zeng  et  al.  shows  that  Treg  can  be  generated  from  Raptor-­‐‑deficient  
(mTORC1-­‐‑deficient)  T  cells  but  they  are  not  functional,  however  when  mTORC2  is  also  
deficient,  the  Treg  phenotype  is  rescued  (Zeng  et  al.,  2013).    Therefore,  the  literature  on  
mTOR  signaling  in  T  cell  differentiation  is  both  complex  and  controversial;  however  this  
pathway  plays  an  important  in  Teff  and  Treg  differentiation.    The  mTOR  pathway  
affects  a  variety  of  signaling  pathways,  including  metabolic  pathways,  and  may  be  an  
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important  contributor  towards  Teff  and  Treg  metabolic  profiles  (Chi,  2012).    It  may  be  
that  fine-­‐‑tuning  of  mTORC1/2  complexes  promotes  a  particular  metabolic  program.    
Indeed,  Zeng  et  al.  demonstrated  that  Raptor-­‐‑deficient  Treg  had  reduced  lipid  and  
cholesterol  synthesis  (Zeng  et  al.,  2013).    In  our  studies,  we  took  a  metabolic  approach  to  
examine  the  role  of  glucose  metabolism  in  the  T  cell  subsets  and  showed  that  Glut1  
plays  an  important  role  in  Teff,  but  not  Treg  differentiation  and  function.    It  is  possible  
that  the  mTOR  signaling  pathway  influences  Glut1  and  other  metabolic  proteins  as  a  
mechanism  for  the  effect  of  mTOR  on  T  cell  differentiation.      
In  addition  to  further  studies  on  the  role  of  FoxP3  or  other  transcription  factors  
on  Treg  metabolism,  very  little  is  known  about  the  transcriptional  programs  underlying  
Th1  and  Th2  metabolism.    Therefore,  a  similar  approach  that  was  taken  with  FoxP3  
should  be  taken  with  T-­‐‑bet  and  GATA3  to  examine  the  role  of  these  important  
transcription  factors  on  Th1  and  Th2  metabolism.    It  may  be  that  each  transcription  
factor  activates  a  unique  set  of  metabolic  genes,  either  directly  or  by  influencing  one  of  
the  above  mentioned  transcription  factor  or  signaling  pathway.    Understanding  the  
transcriptional  programs  underlying  the  T  cell  subset  metabolic  profiles  is  crucial  to  
determine  mechanisms  of  modulating  T  cell  differentiation  in  the  context  of  
autoimmunity.    
While  many  transcription  factors  including  Myc,  ERRα  and  HIF1α  are  known  to  
contribute  to  T  cell  metabolism,  it  is  intriguing  to  consider  the  possibility  that  T  cell  
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metabolism  influences  gene  expression.    There  is  now  an  appreciation  for  metabolic  
regulation  of  epigenetics.    Epigenetics  involves  modifications  to  DNA  and  associated  
proteins,  including  acetylation,  methylation  and  SUMOylation,  that  influences  gene  
expression.    DNA  acetylation  is  initiated  by  histone  acetyltransferases  (HATs),  which  
transfer  an  acetyl  CoA  group  to  the  lysine  residue  of  a  DNA  histone,  typically  
promoting  gene  expression.    Therefore,  the  availability  of  acetyl-­‐‑CoA  would  be  a  
determining  factor  in  histone  acetylation  (reviewed  in  Lu  et  al.,  2012).    Additionally,  
there  is  evidence  that  histones  can  also  be  O-­‐‑linked  N-­‐‑acetylglucosamine  (GlcNAc)  
modified  using  glucose  as  a  starting  product  (Fujiki  et  al.,  2011).    Therefore,  the  
metabolic  profile  of  each  T  cell  subset  may  in  turn  contribute  to  epigenetic  changes  that  
affect  gene  transcription  and  T  cell  function.    This  could  be  tested  by  treating  T  cells  with  
2-­‐‑deoxyglucose  to  inhibit  glucose  metabolism  and  examine  the  transcription  of  key  
genes  including  cytokines  and  transcription  factors  associated  with  each  subset.    
Additionally,  acetate  can  be  directly  added  to  cultured  cells  in  vitro  to  provide  
acetylation  substrate  and  see  how  this  affects  T  cell  gene  expression  (Wellen  et  al.,  2009).    
It  is  likely  that  signaling  pathways  in  each  T  cell  subset  contributes  to  T  cell  metabolism,  
and  the  metabolic  profile  in  turn  affects  T  cell  gene  expression  and  both  contribute  to  the  
overall  T  cell  subset  phenotype.                    
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6.4 T cell metabolism and inflammatory disease 
The  objective  of  this  work  is  to  establish  the  role  of  glucose  metabolism  in  T  cell  
differentiation  and  ultimately,  a  metabolic  strategy  to  target  effector  T  cells  in  
autoimmune  and  inflammatory  disease.    Currently,  therapies  for  autoimmune  disease  
involve  broad  immunosuppression  using  glucocorticoids  or  cytostatic  agents  (Brogan  et  
al.,  2000).    These  therapies  non-­‐‑selectively  inhibit  all  immune  cells  and  therefore  have  a  
lot  of  side  effects  including  immunodeficiency,  hyperglycemia  and  others.    More  
recently,  biologic  therapies  have  been  developed  with  some  success,  mainly  in  the  area  
of  rheumatoid  arthritis  (RA).    These  include  monoclonal  antibodies  that  bind  to  
cytokines  or  components  of  lymphocytes,  mainly  B  cells.    While  the  newer  biologic  
therapies  are  more  specific,  they  still  cause  immunosuppression  and  may  lead  to  
adverse  side  effects  like  infections  and  drug-­‐‑induced  SLE  (Rosman  et  al.,  2013).    
Therefore,  there  is  a  need  to  find  strategies  to  inhibit  specific  effector  T  cell  subsets  and  
promote  Treg  in  the  context  of  inflammatory  and  autoimmune  disease.    
Inflammatory  disorders  encompass  a  category  of  diseases  with  an  excessive  and  
inappropriate  immune  response  against  healthy  body  tissue  and  are  widely  prevalent  in  
developed  countries  (El-­‐‑Gabalawy  et  al.,  2010).    In  particular,  inflammatory  bowel  
diseases  (IBD)  such  as  ulcerative  colitis  and  Crohn’s  disease  arise  from  inappropriate  T  
cell  responses  against  the  gut  microbiota  and  lead  to  chronic  inflammation  and  intestinal  
damage  (Zenewicz  et  al.,  2009).    In  the  healthy  gut,  barrier  functions  of  the  colon  
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epithelial  cells,  as  well  as  immunosuppression  by  the  gut  commensal  bacteria,  help  to  
maintain  homeostasis  despite  constant  immune  stimulation  from  food  and  bacterial  
antigens  (Hooper  et  al.,  2001).    IBD  is  therefore  caused  by  both  a  disruption  of  the  
mucosal  barrier,  as  well  as  an  excessive  Teff  response  or  deficient  Treg  response  causing  
intestinal  inflammation.    Indeed,  Treg  are  extremely  important  to  prevent  inflammation,  
and  when  mice  are  depleted  of  Treg  the  major  site  of  inflammation  is  in  the  intestinal  
tract  (Powrie  et  al.,  1994).      
Although  there  is  a  clear  role  of  the  Th1  cytokine  IFNγ  in  IBD  pathogenesis,  
recent  data  suggests  an  important  role  for  Th17  in  IBD  (Powrie  et  al.,  1994).    Th17-­‐‑related  
cytokines  are  upregulated  in  patients  with  IBD  and  IL-­‐‑23  has  been  found  to  play  a  
significant  inflammatory  role  (Yen  et  al.,  2006).    Work  from  Izcue  et  al.  suggests  that  IL-­‐‑23  
controls  the  frequency  of  Treg  in  the  gut  and  in  the  presence  of  IL-­‐‑23,  there  is  a  decrease  
in  Treg  and  this  promotes  colitis  (Izcue  et  al.,  2008).    Therefore,  therapeutic  strategies  to  
inhibit  Th17  while  preserving  or  increasing  Treg  will  be  important  in  the  treatment  of  
IBD.      
   In  the  present  study,  we  show  that  Glut1  deficiency  in  Teff  decreases  T  cell  
proliferation  and  function  and  therefore  IBD  severity.    In  contrast,  Glut1  deficiency  does  
not  affect  Treg,  as  Glut1  knockout  Treg  are  still  able  to  control  Teff  function  and  prevent  
IBD.    Additionally,  mice  treated  with  the  PDHK1  inhibitor  DCA  develop  less  severe  IBD  
and  this  is  associated  with  a  decrease  in  IL-­‐‑17  producing  cells.    Importantly,  IFNγ  
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production  was  unaffected.    This  suggests  that  the  inhibition  of  Th17  through  DCA  
treatment  is  sufficient  to  inhibit  IBD  progression  without  affecting  Th1.    In  vitro,  DCA  
treatment  increases  Treg  however  this  did  not  reach  statistical  significance  in  the  IBD  
model.    One  reason  for  this  is  that  the  mice  were  injected  with  CD4+CD25-­‐‑CD45RBhi  
naïve  effector  T  cells,  which  were  depleted  of  natural  Treg.    Therefore,  it  will  be  
important  to  examine  Treg  in  IBD  upon  DCA  treatment.    This  could  be  done  by  co-­‐‑
injecting  low  doses  of  Treg  along  with  the  naïve  Teff  cells,  followed  by  DCA  treatment,  
to  see  if  DCA  increases  Treg  in  the  context  of  IBD.    In  the  setting  of  EAE,  DCA  did  
increase  the  Treg  percentage  in  vivo.    Overall,  our  studies  suggest  that  the  modulation  of  
T  cell  metabolism  may  allow  for  the  targeting  of  specific  Teff  subsets  to  modulate  the  
immune  response.    DCA  itself  is  an  intriguing  prospect,  as  it  has  been  used  in  humans  
and  was  well  tolerated  in  both  children  and  adults  during  clinical  trials  for  lactic  
acidosis  (Stacpoole  et  al.,  1992).    DCA  is  currently  in  clinical  trials  for  glioblastoma  and  
recurrent  brain  tumors.    It  will  be  important  to  focus  future  studies  on  how  DCA  affects  
the  T  cell  metabolic  profile.    This  can  be  done  with  metabolomics  or  C13-­‐‑glucose  labeling  
to  look  at  metabolite  changes.    It  will  also  be  critical  to  examine  the  effect  of  DCA  on  
other  immune  cell  types,  including  CD8,  B  cells  and  antigen  presenting  cells.    Finally,  
DCA  treatment  could  be  tested  in  other  animal  models  of  autoimmunity  including  
allergic  asthma,  where  both  Th2  and  Th17  cells  play  a  major  role.                
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   IBD  is  an  excellent  model  for  examining  Treg  function,  as  disease  spontaneously  
forms  in  the  absence  of  Treg  and  alternatively  can  be  rescued  by  the  addition  of  Treg,  
either  concurrently  or  after  disease  progression  (Chunder  et  al.,  2012).    However,  an  
important  consideration  is  the  possibility  that  different  tissues  have  distinct  metabolic  
profiles  that  can  contribute  to  T  cell  biology.    As  the  GI  tract  is  the  site  of  food  
adsorption,  it  brings  up  the  possibility  that  nutrient  availability  may  affect  the  gut  
microbiota  and/or  immune  cell  function  in  the  intestinal  tract.    Indeed,  several  recent  
studies  have  examined  the  relationship  between  nutritional  status,  gut  microbiota  and  
the  immune  response  (reviewed  in  Kau  et  al.,  2011).    One  study  found  that  short-­‐‑chain  
fatty  acids  (SCFAs),  which  are  provided  by  the  gut  bacteria,  could  promote  the  integrity  
of  the  epithelial  barrier  and  also  regulate  the  size  of  the  Treg  pool  in  the  colon  (Smith  et  
al.,  2013).    Mice  that  had  been  injected  with  T  cells  to  induce  IBD  were  treated  with  
SCFAs  and  this  was  able  to  prevent  IBD  progression  in  a  Treg-­‐‑dependent  manner.      
The  microbiota  also  affects  the  absorption  of  vitamins  and  minerals.    Vitamin  A  
(retinoic  acid)  deficiency  can  lead  to  a  loss  of  Th17  cells  and  affects  the  balance  between  
Th17  and  Treg  (Cha  et  al.,  2010).    Further,  iron  deficiency  protects  mice  against  EAE  and  
iron  supplementation  altered  the  composition  of  the  gut  microbiota  and  exacerbated  
Crohn’s  disease  in  a  mouse  model  (Grant  et  al.,  2003;  Werner  et  al.,  2011).    These  studies  
suggest  that  there  is  an  important  interaction  between  nutritional  status,  the  gut  
microbiome  and  T  cells.    This  is  a  significant  area  of  study  and  could  be  expanded  to  
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examine  IBD  and  T  cell  dysregulation  in  the  context  of  different  nutrient  diets.    For  
example,  putting  mice  on  a  ketogenic  diet  may  prevent  T  cell  glucose  metabolism  and  
thereby  inhibit  Teff  and  IBD  progression.    
There  is  also  a  link  between  obesity  and  the  immune  system.    Obesity  is  
associated  with  the  expression  of  many  inflammatory  cytokines  including  IL-­‐‑6,  IL-­‐‑17  
and  TNFα.    There  is  even  evidence  for  a  unique  Treg  population  found  in  visceral  
adipose  tissue  (VAT)  of  obese  animals  (Cipolletta  et  al.,  2012).    This  was  associated  with  
an  increased  PPARγ  expression  in  this  Treg  population,  and  the  finding  that  VAT  Treg  
contribute  to  the  ability  of  pioglitazone  to  regulate  insulin  sensitivity.    Additionally,  the  
adipokine  leptin  functions  as  a  T  cell  cytokine  and  has  a  variety  of  direct  T  cell  effects  
(Procaccini  et  al.,  2012;  Saucillo  et  al.,  2013).    Overall,  it  remains  to  be  seen  whether  
changes  in  whole  body  nutritional  status  affect  T  cell  function  or  differentiation  but  is  an  
important  area  of  investigation.  
The  finding  that  a  unique  Treg  population  exists  in  VAT  brings  up  the  
interesting  possibility  that  the  T  cell  subsets  have  tissue-­‐‑specific  metabolic  profiles  that  
may  affect  their  function.    Differences  in  nutrient  availability,  or  even  oxygen  status  and  
hypoxia,  may  alter  T  cell  signaling  pathways  and  influence  their  functional  properties.    
It  will  be  important  to  examine  the  metabolic  profile  of  T  cells  in  different  tissues  to  
determine  whether  the  metabolic  profiles  we  have  described  are  illustrative  of  all  T  cells  
of  a  particular  population  or  if  there  is  variability  based  on  tissue  distribution.                                                              
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6.5 Concluding Remarks  
The  work  presented  here  examines  the  metabolic  phenotypes  and  regulation  of  
effector  and  regulatory  CD4  T  cells  and  potential  metabolic  targets  that  could  be  used  to  
treat  autoimmune  disease.    While  cellular  metabolism  has  always  been  appreciated  as  a  
mechanism  of  energy  production,  it  is  often  thought  that  metabolism  is  controlled  by  
allosteric  regulation  and  feedback  product  inhibition  of  metabolic  enzymes.    In  contrast,  
the  work  presented  here  argues  that  the  same  signals  that  drive  T  cell  activation  and  
differentiation  may  set  up  a  metabolic  program  that  is  appropriate  and  required  for  each  
specific  cell  type.    Instead  of  upregulating  glycolysis  as  a  byproduct  of  glucose  
limitation,  effector  T  cell  metabolism  is  linked  to  differentiation  and  glucose  metabolic  
pathways  may  be  upregulated  in  anticipation  of  metabolic  and  functional  needs.    
Similarly,  the  Treg-­‐‑specific  transcription  factor  FoxP3  drives  an  oxidative  metabolic  
program  that  is  required  for  optimal  Treg  suppressive  function.    Therefore,  T  cell  
metabolism  is  intimately  linked  to  CD4  T  cell  survival,  differentiation  and  function.  
These  data  also  suggest  that  targeting  cell  metabolism  may  provide  a  new  
opportunity  for  immune  therapy.    Each  of  the  effector  T  cell  subtypes  and  regulatory  T  
cells  play  a  unique  role  in  the  immune  system,  and  with  those  roles  have  a  distinct  
metabolic  need  to  provide  the  proper  fuels  and  biosynthetic  precursors  necessary  for  
function.    These  metabolic  differences  may  provide  an  opportunity  to  modulate  the  
immune  response  by  selectively  targeting  a  particular  cell  type.    This  work  describes  
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several  strategies  of  metabolic  inhibition,  with  Glut1  deficiency  suppressing  Teff  but  not  
Treg  function,  as  well  as  PDHK  inhibition  as  a  mechanism  to  specifically  inhibit  Th17  
and  promote  Treg.    Future  studies  are  needed  to  examine  the  immunometabolism  of  
other  cell  types,  as  well  as  in  the  context  of  autoimmunity  or  inflammatory  disease.    
Ultimately,  a  complete  understanding  of  T  cell  metabolism  and  its  regulation  may  lead  
to  targeted  immune  therapies  and  improve  the  treatment  of  human  autoimmune  
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